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In the continuous research for more targeted therapies, a full comprehension of molecular 
biorecognition phenomena, involving small molecules and biological targets, is pivotal to clarify 
pathophysiological mechanisms and rationally develop new and more effective drugs. The 
investigation of such interactions requires the development and application of advanced analytical 
approaches to profile the binding partners. Several analytical techniques have been applied over the 
years to elucidate different aspects of biomolecular phenomena, both in solution or involving target 
immobilization. The selection of the most suitable and informative approach depends on the issue to 
be addressed and, usually, the combination of several techniques may help better elucidating the 
phenomenon. 
In the current dissertation, approaches based on mass spectrometry (MS), circular dichroism (CD) 
spectroscopy and surface plasmon resonance (SPR) biosensing have been used, both individually or 
in combination, to investigate two targets of pharmaceutical interest, namely human serum albumin 
(HSA) and human cholinesterases (ChEs). HSA, the most abundant plasma protein, plays a key role 
in a broad range of biological functions. Furthermore, HSA is used in clinical practice to treat 
different diseases, such as hypovolemia, hypoalbuminemia and sepsis and its integrity (or alteration 
of) also reflects the health status of the subject. Indeed, in circulatory system, it could undergo 
structural modifications which, from one side, may be studied as biomarker or prognostic features 
and, on the other hand, may trigger pathological paths. For this reason, the elucidation of the 
connection between HSA modifications, biological functions and the pathogenic role of altered 
HSA is crucial to be investigated. In this scenario, the binding capacity of pharmaceutical-grade 
HSA for intravenous infusion was studied implementing and employing a CD spectroscopy-based 
assay. The work focused on the investigation of the impairment of the binding capacity caused by 
commonly added stabilizers, i.e., N-acetyltryptophan and sodium octanoate, in the formulation. 
Results showed an altered binding capacity at site II caused by the presence of octanoate. The work 
also highlighted that, because of the high affinity binding of octanoate, its removal cannot be 
achieved by simple ultrafiltration or simple dialysis. Furthermore, SPR- and affinity 
chromatography-MS-based assays enabled an initial characterization of the interaction between an 
altered form of the protein, i.e. glycated HSA, and the receptor for advanced glycation end products 
(RAGE). The multimethodological approach provided further insights into such interaction, laying 
the groundwork for subsequent studies on the interaction between RAGE and circulating early and 
end glycation products formed under diabetic conditions.  
Concerning ChEs, these enzymes have been widely studied as molecular targets in drug discovery 
for Alzheimer’s disease. In particular, according to cholinergic hypothesis, the inhibition of ChEs 
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has represented and still represents the main strategy to temporally counteract cognitive 
impairment. In this context, both in solution functional assays and a tailored SPR-based assay were 
used for the identification of new potential inhibitors and for the affinity and kinetic studies on 
known ligands, respectively. The new developed SPR-based assay nicely complemented classic 
inhibition studies, providing further key elements for ranking new inhibitors, which can be 
classified not only on the basis of their potency but also on the basis of their kinetic parameters 
including residence time.  
Overall, the tailored analytical strategies developed and applied in the projects reported in the 
current dissertation have contributed to elucidating biorecognition events and/or uncover alterations 
of such mechanisms which may result in pathological mechanisms. The final goal of elucidating 
some biorecognition events, indeed, is to provide pivotal information which can help the 





Outline of the thesis 
 
The current thesis includes the collection of studies carried out during the PhD program, aimed at 
investigating biorecognition events involving two pharmaceutically relevant targets, namely HSA 
and ChEs. The dissertation is divided in three main parts. 
Part I briefly outlines the complex correlation between in vitro and in vivo activity. The opening 
chapter I focuses on the study of biorecognition phenomena. In particular, recent ligand–receptor 
theories, which better explain in vivo activity, are discussed. These novel approaches, which 
consider biological systems as open-systems characterized by a fluctuation of ligands, may give a 
better picture of the conditions encountered in the human body. In this context, in vitro on- and off-
rate constants proved to correlate better than the affinity data with in vivo activities [1]. Therefore, 
the interest in robust methodologies able to provide kinetic information on drug binding events is 
growing. In this chapter, examples of analytical techniques employed over the years to structurally 
and functionally characterize bioactive molecules have been also discussed with particular focus on 
SPR, CD and MS techniques, which are the main analytical approaches used in the studies carried 
out during my PhD. Chapter 2 reports the aims of the thesis.  
Following the introductory part, the thesis reports the main studies carried out during the PhD 
program, most of which has been published in peer-reviewed journals. Each original article has 
been reprinted without modification with publishers’ permission, when I am the first author, while 
it has been adapted, when my contribution to the work concerned only a part of the treated aspects. 
The readers, who would like to obtain further information about the studies, are invited to directly 
refer to published articles.  
More in detail, the reports on the experimental work have been divided into two parts according to 
the two target macromolecules investigated, i.e. HSA and ChEs. 
Part II collects HSA studies. Chapter 3 provides a brief overview of this target with a particular 
focus on the biological functions relevant for the reported studies. The structural modifications that 
circulating HSA could undergo as a result of pathological conditions, such as high level of 
oxidative stress and inflammation (e.g. cysteinylation, glycation, oxidation) and the analytical 
strategies developed over the years to identify these modifications are discussed. The last part of 
this chapter also comments the connection between structural changes and pathological processes. 
Chapter 4 contains the results from the study focused on the impairment of binding capacity of a 
pharmaceutical-grade HSA, which is triggered by stabilizers added when it is formulated for 
intravenous infusion, by means of a CD spectroscopy-based assay. Stabilizers clearance by two 
different purification methods, namely ultrafiltration and dialysis, is also discussed in the light of 
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the assessment of the availability of HSA binding sites obtained by the method proposed. Chapter 
5 reports the investigation of the binding between a form of glycated HSA, recently released on the 
market, and the extracellular region (VC1) of the human RAGE. The study has been carried out by 
SPR and affinity chromatography coupled to MS with a tailored multimethodological approach 
aiming at investigating such interaction and shedding light on complex interacting ligands. 
Part III focuses on cholinesterase enzymes. Chapter 6 provides a brief overview of AChE and 
BuChE enzymes (enzyme structure, biological function and their role as therapeutic targets for the 
treatment of neurodegenerative disorders, such as Alzheimer’s disease) as well as of the marketed 
cholinesterase inhibitors, since most of the drugs released on the market for treating AD symptoms 
belongs to this class of compounds. Moreover, the new rational strategy, namely multi-target-
directed ligands, developed for countering the multifactorial etiology of AD, is also presented. 
Chapter 7 presents the development of a new SPR sensing surface to study binding affinity and 
kinetic parameters for the interaction of human AChE and known inhibitors. The suitability of the 
developed hAChE-based surface to obtain additional elements (kon, koff, residence time) which may 
aid the selection of favorite chemical scaffolds, is discussed. Chapter 8 and 9 deal with the results 
achieved in the screening of two new classes of MTDL compounds, namely donepezil-lipoic acid 
hybrids and tacripyrimidines hybrids, by using the classic in solution Ellman’s method [2]. These 
compounds have been designed to exert multiple functions including ChEs inhibition. In particular, 
the design of the former class aims at achieving anticholinesterase and antioxidant activities in a 
single molecule, while the second class of derivatives aims at achieving cholinesterase inhibition 
and calcium channels modulation. To assess whether the rational design was successful, the 
investigation of the inhibitory potency toward cholinesterase enzymes and the definition of SARs 
are key steps along the characterization of the biological profile of these new classes of derivatives 
as well as for the selection of the most promising hybrids. Results of such studies are discussed 
together with those achieved by other research groups on the other designed properties. 
At the end of the third part, a brief conclusion is reported aimed at summing up all the findings and 



























Analytical strategies for monitoring biorecognition phenomena 
 
1.1 From in vitro studies to in vivo efficacy of drugs 
Biorecognition phenomena between complementary chemical species underpin all physiological 
and pathological processes. The study of the different interactions which occur in biological 
systems, such as proteinprotein, RNAribosome, DNAprotein, enzymesubstrate, 
antigenantibody, enables the comprehension of the complex mechanisms underlining living 
systems [3].  
Corpora non agunt nisi fixate. This iconic sentence, which transposes in a more contemporary 
expression means ‘‘a substance will not exert its physiological activity unless it is bound to the 
target’’, was coined at the end of the 20
th
 century by Paul Ehrlich and is a cornerstone of modern 
molecular medicine and pharmacology [4]. This concept points out the importance of studying the 
interactions in terms formation/disruption events since the biological effect modulated by a ligand 
to its target depends on the formation of the binary complexes. Similarly, a drug exerts a 
pharmacological effect as long as it is bound to its target, making the information on drug–target 
interaction important to help the prediction of in vivo drug action. As a result, during the early 
stages of drug discovery, many efforts are focused on the optimization of the selectivity and the 
affinity of drugs candidates toward their targets. Target affinity is usually assessed performing 
either a direct measurement of the binding or, indirectly, measuring the modulation of the target 
activity as a result of the binding (e.g. enzymatic activity assays). 
Typically, these in vitro studies are carried out in closed system-based conditions (Fig. 1a) in which, 
throughout the experiment, the concentration of binding partners is treated as invariant [1]. In this 
scenario, assays can only partially mimic what happens in real systems, in which the interaction 
process is dynamic and the exposure time of the ligand to its target is limited in time and floating 
over time. In such static systems, drug–target binary complex is commonly quantified in terms of 
equilibrium dissociation constant (KD). KD is defined as the concentration of a substance necessary 
to bind 50% of macromolecular target population. This parameter is not up to the nature of 
interactants (ligandreceptor, ligandenzyme, ligandion channel) and it is measured at the steady 
state, in which the concentration of both molecules is kept constant over the period of analysis. 
Similarly, for inhibitor–target studies, the inhibitory constant (Ki), measured in equilibrium 
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conditions, represents the concentration of inhibitor capable to inhibit of 50% the biological activity 
of an enzyme. 
Besides these parameters act as guides during drug discovery route to predict the in vivo behavior of 
drugs, they can only provide a clue of the in vivo effectiveness. Indeed, the closed system-based 
conditions can only partially reflect the dynamic process to which drugs are subjected in the human 
body, where their concentration fluctuates over time both locally and globally [1]. In vivo, 
compounds undergo different interactions besides the primary target, such as binding to serum 
proteins. Similarly, several steps such as absorption, distribution metabolism and excretion 
(ADME) rule the drug fate, thus influencing the concentration of compound that reaches the 
primary target-harboring tissue and, as a consequence, the rate of the interaction. In this scenario, 
the human body is better described as an open system (Fig. 1a) in which the local concentration of 
the ligand as well as the time window in which it is available for the interaction with the target 
change over time.  
 
 
Figure 1 Kinetic aspects of ligandtarget binary interactions. (a) Representative picture of a closed and an open 
system. The former is characterized by constant concentrations of reactants enabling the formation of a real equilibrium 
between free and bound drug. The latter, more representative of the real conditions in the human body, is characterized 
by a fluctuation of the ligand as a result of multiple factors including absorption, distribution, metabolism and excretion. 
(b) Schematic simple 1:1 interaction for the receptor (R) and its ligand (L) characterized by a one-step mechanism with 
the corresponding formation/disruption kinetic constants. (c) Schematic 1:1 ligandreceptor interaction characterized by 
a two-step mechanism with the corresponding formation/disruption kinetic constants. In this case, the binding between 
the two interactants induces the isomerization of the receptor. The k3 and k4 constants represent further association and 
dissociation rate parameters respectively, which account for the reversible conformational transition of the complex. 
Reprinted with permission from [5]. 
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From this perspective, the time-dependent variation of the ligand concentration is an important 
parameter that should be considered for better mimicking in vivo biomolecular interactions. In this 
context, the possibility of assessing the steady state affinity constant on the basis of individual 
kinetic rate constants (KD = koff/kon) can provide further insights into the affinity–activity 
relationship. Kinetic rate constants, namely association (kon) and dissociation (koff) rate constants, 
seems to better correlate with in vivo activities [5]. Therefore, in addition to affinity and inhibitory 
potency, kinetic binding data are increasingly recognized as key parameters to be considered in the 
optimization of a lead compound [6,7]. As examples of hit compounds selected on the basis of their 
target binding kinetic properties, the fast off-rate dopamine D2 antagonist JNJ-37822681 (treatment 
of schizophrenia and bipolar disorder) [8] and inhibitors of the colony-stimulating factor 1 receptor 
(target in oncology and rheumatoid arthritis) [9] can be mentioned. The importance of considering 
kinetic parameters is exemplified by the experimental proof that chemical entities with the same 
affinity but different on- and off-rates may display different biological activities. This is exemplified 
by some muscarinic M3 antagonists, used in therapy as bronchodilators, which display similar 
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[10]. Notably, quantification of koff for ligand–target complexes grants easy access to residence time 
(τ = 1/koff), which corresponds to the reciprocal of the dissociation rate constant and represents the 
time that a drug ‘resides’ in the target. Indeed, τ parameter results a more critical tool when 
structure–kinetic relationship (SKR) studies are performed [11]. Therefore, we are witnessing 
growing interest in robust methodology able to provide kinetic information on drug binding events 
already at early steps in the drug discovery process. Among these methodologies, surface plasmon 
resonance (SPR) based assays, radioligand binding/competition assays, biolayer interferometry and 
kinetic probe competition assays (kPCA) based on the time-resolved fluorescence energy transfer 
(TR-FRET) are worth to be mentioned [10,12,13].  
The access to kinetic parameters (and to residence time) acquires even more importance when 
interactions involve more than a single reaction step such as in the case of target isomerization 
induced by the binding. Taking the example of the most common 1:1 interaction between a ligand 
and its target (Fig. 1b-c), in pharmacology two situations are usually observed. In the simplest case 
(Fig.1b) the interaction is characterized by association and dissociation both in one single step (Fig. 
1b). Herein, on- and off- rates (in the figure labeled k1 and k2, respectively) directly refer to 
formation and disruption events. In the second case (Fig. 1c), the interactions between the two 
binders (RL complex) envisages a rearrangement into a conformation, in the figure named R*L, 
characterized by a greater stability and higher affinity [14]. The additional isomerization reaction 
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implies that these two interactants cannot directly decouple. In this case, also known as two-state 
reaction, the koff is made from all microscopic rate constants involved in the reaction, also 
accounting for forward and reverse isomerization steps (in the figure k3 and k4, respectively) (Eq. 
1).  
𝑘𝑜𝑓𝑓 =  
𝑘2 𝑘4
(𝑘2 + 𝑘3 + 𝑘4)
                                                                                                                                   (1) 
In medicinal chemistry, efforts to obtain the majority of details regarding a selective interaction 
increase the success rate of better performing drug candidates. Of course, the in vivo duration of 
drug action as well as its pharmacodynamic efficacy depend on multiple variables in addition to 
molecular drug–target interactions. However, the combination of primary measurements of potency 
and drug–target affinity (IC50 or KD values) with metrics such as residence time and kinetic data, 
provides additional information during SAR studies, enhancing the connection of in vitro 
measurements and in vivo effect. In this scenario, the development and application of advanced 
analytical strategies enabling monitoring, directly or indirectly, biomolecular interactions are key 
aspects to elucidate specific features which underpin biomolecular phenomena and to favor the 
rational development of new and more efficient drugs. 
 
1.2 Analytical methods for rationalizing binding events 
The employment of analytical techniques and the development of experimental methods to 
rationalize binding events constitute a connection bridge between pharmacological hypothesis and 
the comprehension of specific network of communication, eventually resulting in the discovery of 
new drugs with better therapeutic properties. The investigation of biological systems to clarify the 
role of biological targets and their behavior upon interaction with ligands requires the development 
and application of advanced analytical approaches to profile the binding partners. Indeed, an in-
depth characterization of structural and functional features of biological targets is pivotal to define 
the relationship between the tridimensional conformation of a macromolecule and its function. In 
drug discovery, the characterization of the ligand-target interaction may highlight the key amino 
acids involved in the binding and help the rational design of new ligands. Moreover, investigation 
of biorecognition phenomena using a set of different binders may facilitate the definition of the 
chemical space to be further investigated along the lead optimization phase. In this context, the 
determination of thermodynamic and kinetic data using in vitro systems mimicking physiological 
setting enables to better predict the ligand behavior at the target in vivo. 
Over the years, different analytical techniques have been employed to characterize ligandtarget 
interactions, both in solution or upon target immobilization. Each of these may enable the 
investigation of different aspects of biomolecular phenomena. The selection of the most suited 
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approach depends on the specific aspect to be investigated and requires an in-depth knowledge of 
the specific features of each method. Moreover, the use of orthogonal analytical techniques within a 
multimethodological approach ensures complementary information which may facilitate the 
understanding of the phenomenon.  
Among the multitude of techniques, for their wide use in drug discovery we can quote X-ray 
crystallography [15,16], nuclear magnetic resonance (NMR) [17,18], mass spectrometry (MS) [19–
25] circular dichroism spectroscopy (CD) [26–29], equilibrium dialysis [30,31], ultrafiltration [32] 
and ultracentrifugation [33,34], fluorescence spectroscopy [35,36], affinity separation approaches 
such as high-performance affinity chromatography (HPALC) [37–40] and affinity capillary 
electrophoresis (ACE) [41–44], quartz crystal microbalance (QCM) [45,46], microscale 
thermophoresis (MST) [47–49], isothermal titration calorimetry (ITC) [50–52] and biosensors 
based on different technologies such as surface acoustic wave (SAW) [53,54] or surface plasmon 
resonance (SPR) [55–60]. In structural field, in recent years cryo-electronic microscopy (cryo-EM) 
[61,62] has become a valid label-free method to obtain details of macromolecule structures. This in 
solution technique is based on the rapid cooling of biomolecules to cryogenic temperatures. The 
formation of amorphous solids by means of a vitrification process enables the retention of native 
structures. Biomolecules are then screened by electron diffraction patterns (particles distribution, 
orientation and concentration) obtaining highly-informative 3D models.  
MS is a powerful technique employed at different stages of the drug discovery path. For instance, it 
is used to qualitatively and quantitatively identify known and unknown chemical entities, to 
investigate the purity of synthesized compounds and to elucidate structural and functional 
properties of biomolecules [19,21]. Besides providing specific sequence and exact mass of 
molecules, MS is a robust and reliable tool for studies on macromolecular systems. Non-covalent 
biomolecular assemblies, from small molecule–protein/nucleic acid interactions to macromolecular 
complexes, can be investigated as well as affinity values (KD), stoichiometry and target specificity 
of the binding can be assessed. Moreover, MS enables the localization of the binding site by epitope 
mapping approaches or allows to evaluate structural modifications of macromolecules. In some 
cases, e.g. using ion mobility, MS can also provide details regarding binding-induced 
conformational changes [20,21]. The versatility of the technique, the possibility of identifying and 
separately quantifying several compounds in a single scan as well as the high automation granted by 
the modern MS platforms confer to MS a great potential for rapid, sensitive and high throughput 
analyses.  
Toward the characterization process, CD spectroscopy is undoubtedly the technique of choice when 
conformational details of free or bound molecules are required (Fig. 2), granting the determination 
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of the absolute configuration of chiral chemical entities or achiral molecules in a chiral environment 
[63]. Intrinsic chirality of compounds, or the asymmetric arrangement of atoms upon binding can be 
used to obtain details on the interaction, also when crystal structures or data from in silico studies 
are lacking. Secondary structure studies (Fig. 2) are usually employed as ‘‘quality control’’ for 
elucidating batch-to-batch the correct protein folding. Besides this application, secondary structure 
analysis is also employed to investigate biological processes, such as the relationship between 
protein conformational changes and pathological conditions. Indeed, changes in the secondary 
structure of proteins or peptides may influence their functionality and, in some cases, play a role in 
the pathogenesis of different disorders such as neurodegenerative diseases like Alzheimer’s and 
Parkinson’s diseases or amyotrophic lateral sclerosis. In AD, for instance, analyses carried out in 
aqueous solution confirmed that amyloid beta protein shifts from mainly -helix conformation to -
sheet conformation, responsible for amyloid plaques aggregation and disease progression [64–66]. 
 
 
Figure 2 Typical CD spectra of proteins secondary structures. Typical -helical (red), random coil (green), -
sheet (light blue) secondary structures. Reprinted with permission from [67]. 
 
CD technique also enables the assessment of thermodynamic parameters [26]. In particular, the 
induced CD (ICD) phenomenon, which arises when the interaction between a guest and its host 
perturbs the symmetry of the system (as a consequence of conformational changes), can be 
exploited to this purpose. ICD can be a valid tool to investigate ligand–target binding events, 
providing the assessment of the binding mode(s) as well as the determination of the binding 
parameters. Since ICD signal arises as a consequence of the complex formation, ICD monitoring 
allows to extrapolate specific information on the absolute configuration of chiral molecules along 
with how the two interactants involved in the binding are mutually oriented. Furthermore, ICD 
 14 
studies can provide affinity constants, accounting for possible simultaneous competitors. Moreover, 
the technique ensures monitoring the formation of the ligandtarget complex without interfering 
with the in solution equilibrium process. 
Among analytical techniques enabling kinetic evaluation, SPR- or SAW-based biosensors as well as 
QCM are extensively used. Indeed, these techniques share the potential to monitor formation and 
disruption events in real-time, extrapolating kinetic parameters (kon, koff) besides thermodynamic 
data (KD). Despite each method possesses its own specific physical transducer, they all feature 
anchorage of the ligand (usually the macromolecule) on a surface and flowing of the analytes (such 
as drugs) on the immobilized ligand. In detail, SPR detects shifts in the refractive index of the 
sensing medium near the surface layer (Fig. 3), SAW monitors changes in acoustic waves 
characteristics, i.e. frequency and amplitude, and QCM recognizes changes in frequency and 
dissipation of a quartz crystal resonator. Among these, SPR has assumed a central role over the last 
decades for monitoring biomolecular interactions.  
 
 
Figure 3 SPR biosensing. At a specific angle of incident, a portion of the light energy couples with the electron of the 
metal surface layer. The defined SPR angle at which resonance takes place is dependent on the refractive index of the 
material near the metal surface. After biomolecular interaction, shift in the reflected light can be detected and the 
magnitude is directly related to the amount of ligandanalyte complex. 
 
SPR biosensing allows retrieving information about the complex formation without the need of any 
labeling, providing qualitative information (yes/no binding) as well as quantitative thermodynamic 
and kinetic data. SPR phenomenon (Fig. 3) takes place when a beam of incident light hits a metal 
surface (typically a gold surface), located at the interface between two materials characterized by 
diverse refractive indices. At a specific angle of incidence, a portion of the light energy couples 
with the electrons of the metal surface layer. The defined SPR angle at which resonance takes place 
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depends on the refractive index of the material near the metal surface. Since changes in the 
refractive index are directly related to the mass of the sensing medium near the surface, changes in 
the reflected light, resulting from the biomolecular interactions, can be detected and the 
formation/disruption events easily assessed. Moreover, dissociation rate constant of a drug–target 
complex grants easy access to residence time (), which is a useful tool in combination with 
functional data for a better prediction of the in vivo activity of a drug toward a specific target. SPR 
biosensing approaches are also developed to achieve preliminary information on the ADME 
behavior for new chemical entities. In this context, different experimental set-ups have been 
developed over the years to investigate the binding to two of the major abundant proteins in plasma, 
namely human serum albumin (HSA) and 1-acid glycoprotein (AGP) [59]. The versatility of the 
methodology grants the investigation of either simple protein/protein or protein/small molecule (< 
200 Da) binding as well as monitoring interactants in physiological environments (i.e. human 
plasma/serum). The low amount of sample required for screening makes SPR a suitable choice 
when a low amount of one/both interactants is available. Furthermore, the highly automated and 
integrated instrumentation minimizes operator procedures, thus improving the throughput and 
facilitating the screening of series of compounds during drug selection phase.  
Recently, the integration of in silico approaches with structural and functional studies has reduced  
time-consuming steps/studies in drug discovery programs [68,69]. Computational methods can be 
used at different stages: from target recruitment, to hit-to-lead process up to optimization of 
compounds. The possibility of calculating free energy of reactions or simulating molecular 
dynamics of macromolecules assists the prioritization process. In the fragment-based lead discovery 
and design, the virtual screening favors and speeds up the rational design of new therapeutic 





Scope of the thesis 
 
Biorecognition phenomena between complementary chemical species underpin all physiological 
and pathological processes. The investigation of such phenomena requires the development and 
application of advanced analytical approaches to profile the binding partners. Within the variety of 
analytical methods developed and employed over the years to elucidate different aspects of 
biomolecular phenomena, a case-by-case selection must be done on the basis of the specific system 
under study and the information to be retrieved. Moreover, it is worth taking into consideration that 
the combination of different techniques may promote a better comprehension of a studied 
biomolecular system [71]. Keeping in mind these considerations, the main purpose of the here 
presented work was the development and application of tailored methodologies to investigate 
biorecognition phenomena involving two pharmaceutically relevant targets, namely human serum 
albumin (HSA) and human cholinesterases (ChEs). 
HSA is the most abundant protein in plasma, playing a significant role in several biological 
functions. In particular, the ability of binding many endogenous and exogenous compounds has 
been widely studied since it strongly influences the bioavailability and pharmacokinetics of drugs 
[59]. Furthermore, HSA is used in clinical practice to treat different diseases, such as hypovolemia, 
hypoalbuminemia and sepsis and its integrity (or alteration of) also reflects the health status of the 
subject. Indeed, HSA could undergo several structural modifications in bloodstream. For instance, 
oxidation and glycation (promoted by high levels of oxidative stress and inflammation) not only 
may affect its biological functions but also might lead to activation of pathological events. For this 
reason, the comprehension of the connection between HSA modifications, biological functions and 
pathogenic role of altered HSA is crucial to be studied. 
In this context, impairment of binding capacity upon structural modification as well as the possible 
role of such forms as mediators of pathological events is worth to be investigated. Concerning the 
former aspect, since quality of HSA administered as biological drug might have health implications, 
the impairment of the binding capacity of a pharmaceutical-grade HSA, clinically administered by 
infusion, will be investigated. A CD spectroscopy-based assay will be employed in the attempt of 
elucidating the effect of stabilizers, which are required for HSA pasteurization, on HSA binding 
capacity, also offering a useful analytical method to monitor their clearance. On the other hand, 
concerning the pathological implications of HSA alteration, HSA glycation will be considered with 
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particular focus of its interaction with RAGE, due to the important pathological path in which this 
receptor seems to be involved.  
Concerning the second selected target, inhibition of cholinesterase enzymes, namely 
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has been one of the most 
investigated strategies pursued in the field of drug discovery for Alzheimer’s disease (AD). 
Notwithstanding a number of alternative and potentially more effective strategies are under 
investigation, inhibition of cholinesterases is still a valid therapeutic way to enhance, although 
temporally, patient’s quality of life. According to the so-called multi-target-directed ligand (MTDL) 
strategy, anticholinesterase activity is combined with other activities at other identified key targets 
for AD in order to achieve a single compound with multiple actions. Thus, in the context of drug 
discovery for AD, analytical strategies based on in solution assays will be employed to investigate 
new MTDLs designed to act as ChE inhibitors. 
In parallel, strategies involving target immobilization will be developed to complement classic in 
solution assay. In particular, a SPR-based assay will be developed to help the prioritization of 
favorite chemical scaffolds by complementing inhibitory data with affinity and kinetic parameters. 
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3.1 General remarks 
Human serum albumin (HSA) is the most abundant plasma protein in humans, representing more 
than 50% of the total protein content in bloodstream. Its high concentration (~ 600 M) and net 
negative charge modulate fluid distribution between compartments, accounting for ~70% to colloid 
osmotic pressure [1]. Beside oncotic properties, HSA exerts a broad range of biological functions 
including antioxidant activity, inflammatory and immunological modulation, stabilization of 
hemostatic and endothelial functions and the carrier role for a vast variety of ligands [2]. Recent 
surveys have highlighted that almost half of all developing new drugs are withdrawn before 
marketing, because of absorption, distribution, metabolism, excretion, toxicity (ADMET) issues [3]. 
Since, ADMET profile and the therapeutic activity of drugs depend on the circulating free fraction, 
binding to serum proteins, including binding to HSA, is a crucial parameter in the drug discovery 
process [4]. Moreover, because of the ability of HSA to bind a variety of structurally different 
endogenous and exogenous compounds, competition of new drug candidates for the same binding 
site of marketed drugs is also a key aspect to be evaluated during drug development.  
Due to its biological functions, pharmaceutical-grade HSA for infusion is widely used in clinical 
practice to treat different diseases, such as hypovolemia, hypoalbuminemia, shock, acute respiratory 
distress syndrome, burns, hemorrhage and hemodialysis [5,6]. Moreover, it is usually part of the 
therapy for the treatment of acute liver failure and chronic liver diseases, which are characterized by 
a strong impairment of albumin metabolism [7,8]. HSA is proposed as biomarker for several 
diseases [9], namely rheumatoid arthritis, cancer, obesity related to post-menopause, ischemia or 
altered glycemic values-based diseases. Indeed, HSA could undergo structural modifications in the 
bloodstream, including cysteinylation, oxidation, glycation and truncation both at the N- and C- 
terminal. For instance, pathological conditions characterized by high levels of oxidative stress and 
inflammation, e.g. cirrhosis and diabetes mellitus, are known to induce structural changes, which, in 
some cases, affect HSA non-oncotic functions [10]. Some of these altered forms of HSA seem 
playing a role in the progression and/or complication of some important diseases, making the 
elucidation of the relationship between HSA modifications, biological functions and pathogenic 
role of altered HSA, crucial to be understood [2,11]. For instance, some chronic complications of 
diabetes have been related to the increased levels of protein glycation which occurs as a 
consequence of the higher levels of glucose in the blood of these patients. In this context, 
 24 
monitoring variations in glycation has been proposed as possible biomarker in patients suffering 
from diabetes [12–14]. In this scenario, analytical methods to investigate structural features and 
functional properties, which are strictly connected with protein integrity, e.g. binding capacity, are 
of relevance in clinical research and in the early stages of drug discovery. 
The huge amount of biological functions exerted by HSA in many physiological and pathological 
setting makes albumin one of the most investigated proteins. Nevertheless, its role in the 
modulation of many processes has not been completely clarified. For this reason, HSA still remains 
an intriguing object of research.  
 
3.2 Albumin structure 
HSA biosynthesis starts in the hepatocytes with the production of pre-pro-albumin. This form is 
subsequently modified into pro-albumin and cleaved of the N-terminal oligopeptide in endoplasmic 
reticulum and in Golgi apparatus, respectively. HSA is released with a daily rate of 1015 g/day 
into the bloodstream, where it remains with a relatively long half-life time (~20 days) [1]. The 
mature plasma protein is composed by 585 residues and has a molecular weight of 66438 Da. 
Protein high solubility is granted by the presence of several ionizable amino acid residues, e.g. 
lysines, arginines and glutamic acids, with a net negative charge. Furthermore HSA structure is 
characterized by the presence of a single tryptophan residue (Trp214) which ensures fluorescence 
studies [9]. The protein is composed by 17 cysteines-based disulfide bonds, which increase protein 
stability and flexibility. Cysteine at position 34 is the only cysteine residue not involved in disulfide 
bridges, constituting the larger reservoir of thiols in plasma [15]. This residue acts as radical 
scavenging in circulatory system and can bind different endogenous ligands, e.g. nitric oxide (NO) 
and metal ions. Moreover, free Cys34 may interact with different circulating molecules and, in a 
limited extent, with other circulating HSA molecules, forming protein dimers [16]. 
HSA secondary structure displays the typical features of -helix-rich proteins (~68 % helices 
content) [17]. HSA consists of three homologous domains (I, II, III), which are divided into two 
sub-domains, labeled A and B which contain 6 and 4-helices, respectively. In solution, the six 
subdomains, namely IA (residues 1–112), IB (residues 113–195), IIA (residues 196–303), IIB 
(residues 304–383), IIIA (residues 384–499) and IIIB (residues 500–585) assemble asymmetrically, 
in the so-called heart-sharp conformation [18,19] (Fig. 4). Nevertheless, the huge flexibility of this 





Figure 4 Three-dimensional structure of albumin. Heart-sharp conformation of HSA caused by subdomains 
disposition: IA (red), IB (brown), IIA (light green), IIB (dark green), IIIA (blue), IIIB (cyan).  
 
3.3 Structural modifications of circulating HSA 
HSA undergoes several changes which may affect protein structure and conformation. Among 
them, the most common and investigated are cysteinylation, truncation at the N- and C- terminal, 
oxidation and glycation. 
Oxidation of HSA, which is promoted by reactive oxygen species (ROS), chemical products 
derived from lipid peroxidation, ascorbic acid and hydroxyl radicals formed via Fenton reaction, 
can affect protein integrity and functionality [20]. Oxidation of Cys34 represents the major 
alteration of circulating HSA and despite this process occurs in physiological conditions, it is 
enhanced by increased oxidative stress and age. In about 20–30 % of the circulating protein, this 
residue is involved in mixed disulfide bonds with another cysteine residue or glutathione residue. 
These modifications, i.e., cysteinylation or glutathionylation, lead to the formation of a reversibly 
oxidized form of HSA which is also known as non-mercaptoalbumin 1 (HNA1). Almost 5 % of the 
total content of HSA in plasma undergoes irreversible oxidation into sulfinic or sulfonic acid, 
forming the so-called non-mercaptoalbumin 2 (HNA2). Cys34 acts as antioxidant compound 
towards NO and other radicals as well as it displays binding capacity for different ligands (metal 
ions, NO, drugs). For this reason, its alterations may cause an impairment of HSA redox potential 
and functionality [9,21]. Moreover, oxidation of Cys34 by other cysteines promotes N-
homocysteinylation of Lys525, which has been related to the onset of pathological states such as 
thrombogenesis or production of antibodies against the modified albumin form [22–24]. Less 
frequently, oxidative modifications may involve lysine, arginine or methionine residues. Oxidation 
of these amino acids, such as arginine at position 410, has been shown to possibly increase the rate 
of HSA clearance [25,26]. 
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The truncations at the N- and C- terminal are other common modifications. Since the N-terminal 
domain of HSA is able to bind circulating free metal ions, the removal of asparagine–alanine 
residues impairs HSA scavenging activity towards circulating metal ions [15,27]. On the other 
hand, the truncation at C- terminal decreases protein half-life time, from 20 days to less than 80 h 
[28].  
Circulating glycated HSA is the result of physiological non-enzymatic glycation of the native 
protein by reducing sugars. This modification, which accounts for almost 10 % of the total HSA 
content in healthy people, increases 2 or 3 times in case of diabetes mellitus. Indeed, despite this 
process is physiological and increases in aging, it results much faster under diabetic conditions 
defined by chronic hyperglycemia. Moreover, because of HSA long half-life and high 
concentration, as compared to other proteins, glycated HSA is proposed as a possible biomarker for 
diabetes control [29]. Initially chemically reversible Schiff bases and Amadori adducts are formed. 
The formation of the early glycation adducts involves several lysines, such as Lys525 (as prevalent 
site of glycation), Lys199, Lys281, Lys489, and arginine residues (e.g. Arg410) [20,30]. Overtime, 
these products slowly undergo further rearrangements, e.g. oxidation, degradation and dehydration, 
resulting in the irreversible formation of the so-called advanced glycation end products (AGEs) 
[31]. Glycation process modifies the structure of the protein. Moreover, since this process may 
involve aminoacid residues located in or near HSA binding sites, it also may compromise HSA 
binding capacity for endogenous and exogenous compounds [32].  
Besides these common modifications, it is worth mentioning also dimerization, nitration and 
nitrosylation [2]. 
 
3.4 HSA biological functions 
Albumin displays important biologic functions, which can be divided into oncotic and non-oncotic. 
Indeed, HSA plays an important role as fluid modulator through body compartments and regulates 
~70–80 % of the oncotic pressure in plasma. This function is granted for two-thirds by the osmotic 
effect, which is related to its molecular weight, while for one-third by Gibbs-Donnan effect. Indeed, 
in physiological conditions the net negative charge of HSA recalls positively charged ions (e.g. 
sodium and water) inside intravascular compartments. As a result of its osmotic effect, HSA is 
widely used in clinical practice as plasma expander, e.g. in case of hypovolemic shock [33].  
HSA also owns different non-oncotic properties which, in most of the cases, are strictly connected 
to its peculiar structure (Fig. 5) [9,10].  
HSA remarkable binding capacity reflects its organization in multidomains. Under physiological 
conditions, the protein binds a huge variety of endogenous ligands, such as fatty acids, ions, 
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hormones as well as exogenous compounds, i.e. drugs and their metabolites [10]. Moreover, HSA is 
also responsible for bilirubin binding, favoring its clearance [1]. Over the years, albumin binding 
sites have been widely investigated. According to the classification proposed by Sudlow, HSA has 
two major binding sites for drugs (sites I and II) located in sub-domains IIA and IIIA, respectively. 
 
 
Figure 5 HSA biological functions and binding properties. On the right column, HSA oncotic and non-oncotic 
biological functions are listed while the left panel lists the most common classes of endogenous and exogenous ligands. 
Reprinted with permission from [34]. 
 
Site I, which is larger and more flexible than site II, enables the binding of heterocyclic compounds, 
e.g. warfarin or phenylbutazone [35]. Site II, smaller and less adaptable, is called indole-
benzodiazepine binding site and hosts aromatic or indole-compounds, like diazepam or L-
tryptophan. Recently, a third binding site (site III), allosterically coupled with the other two, has 
been identified in sub-domain IB [36]. Site III is considered a promiscuous pocket, on the basis of 
its different ligand recognition capacity: among its binders, biliverdin, bilirubin and several 
anticancer agents are included. HSA binding capacity promotes drugs solubility, thus enabling their 
transport to the sites of action. Moreover, the great capacity of the main binding sites to 
discriminate stereoisomers makes binding of drugs highly influenced by stereochemistry [37].  
Another important function of HSA is its antioxidant activity. Cys34 represents the major reservoir 
of thiols in plasma (~ 80%), acting as scavenger for ROS. The pronounced antioxidant capacity 
displayed by this residue is related to the low pKa of the corresponding thiol group (about 5.0), in 
contrast to the pKa of the other aminothiols (cysteine and glutathione residues). As consequence, at 
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physiological pH, Cys34 predominantly exists as thiolate anion, which grants the peculiar 
nucleophilic reactivity against metals and oxygen/nitrogen reactive species [38]. HSA scavenger 
activity is also assisted by aminoacidic residues (methionines) and the ability of the N-terminal 
portion to chelate iron and copper ions, inhibiting their involvement in the formation of hydroxyl 
radicals via Fenton reaction [15].  
HSA is also considered an important modulator of prostaglandins bioavailability, resulting in the 
activation of inflammatory response promoted by immune system [39]. Moreover, the ability of 
Cys34 to bind NO seems to prevent its rapid inactivation prolonging its antiplatelet effect and the 
antithrombotic activity [40]. Finally, HSA is involved in immune response to both Gram-positive 
and Gram-negative bacteria due to protein interaction with some components located on the 
bacteria surface. This event promotes the interaction with the Toll-like receptor 4, thus modulating 
albumin anti-inflammatory activity [41]. 
The relationship between HSA structure and physiological properties requires the development of 
different analytical strategies capable of correlating structural and functional features. The 
following section briefly resumes the principal analytical techniques employed over the years in the 
structural characterization of HSA as well as binding capacity and antioxidant activity as main non-
oncotic properties.  
 
3.5 Analytical strategies for HSA characterization 
Structural and functional integrity of HSA have been widely investigated over the years. In 
particular, because of its important physiological role, many efforts have been made to develop 
tailored strategies capable to identify and quantitate altered HSA structures. Among analytical 
methods used to highlighting HSA structural integrity, methods focused on the qualitative and 
quantitative investigation of the most frequent and abundant HSA alterations are particularly 
relevant. Among chromatographic techniques, ion exchange chromatography (IEC), size exclusion 
chromatography (SEC) and reverse-phase chromatography (RP-LC), all coupled with UV or MS 
detection, represent the most commonly used approaches. For instance, IEC strategy is suitable to 
investigate HSA isoforms arising from altered Cys34 oxidative state [43,44]. On the other hand, 
SEC is useful to highlight the formation of dimers and aggregates thanks to its ability to resolve 
different compounds as function of their hydrodynamic volume. For example, a SEC-based method 
has been applied to evaluate the formation of dimeric products in the presence of high levels of 
oxidative stress or as function of temperature [44]. Hyphenation of RP-LC with MS grants analyses 
of HSA modifications by both top-down and bottom-up approaches [46] which allowed the study of 
HSA truncation, cysteinylation and glycation [2]. For instance, many studies have been carried out 
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using RP-LC-MS in order to obtain information concerning HSA glycation extent or preferential 
glycation sites involved in the process [46,47]. Besides chromatographic methods, HSA alterations 
can be investigated using capillary zone electrophoresis (CZE), in which analytes are separated on 
the basis of their charge, shape and size [48]. Moreover, this technique allows performing analyses 
in physiological-like environment (i.e. aqueous solutions). 
HSA conformational changes are usually investigated by means of spectroscopic techniques, 
namely circular dichroism (CD) and fluorescence spectroscopies [2]. CD method has been widely 
used to evaluate HSA secondary structure along with functional features resulting from several 
different conditions: high temperature, pro-oxidant compounds, addition of stabilizers in the 
pharmaceutical-grade HSA or sugar concentration during in-vitro glycation process [49]. Instead, 
HSA fluorescence, which is granted by the presence of a single tryptophan residue (Trp214), has 
been used to assess stability and isomers conformation as well as to investigate conformational 
changes involving domain II, where Trp214 is located [50]. 
Many efforts in the development of analytical strategies have been also made to assess HSA 
binding capacity and antioxidant activity. Over the years, drug binding to HSA has been measured 
by several techniques. Among them, it is worth mentioning equilibrium dialysis, ultrafiltration 
(UF), high performance affinity chromatography (HPAC), Hummel-Dreyer method, affinity 
capillary electrophoresis (ACE), capillary electrophoresis-frontal analysis (CE-FA), ultrafast 
affinity extraction, spectroscopic approaches and surface plasmon resonance (SPR) [2]. In 
particular, HPAC enables the quantitative determination of drug–HSA binding on the basis of 
retention time. Indeed, drugs with stronger affinities towards immobilized HSA will show higher 
retention times compared with drugs characterized by lower affinities. Frontal affinity 
chromatography (FAC) and/or zonal elution chromatography enable the determination of 
association constants, granting precision, low-time consuming and reduced sample handling 
[51,52]. The main drawback of the technique is the huge amount of analyte consumption for 
analyses, representing a limitation when low quantities are extracted from biological samples. 
Conversely, SPR-based technology enables affinity and kinetic estimation of binding events using 
small quantities of materials. The interaction is monitored in real-time and the high automation 
grants time saving [53,54]. Indeed, different compounds can be screened using the same HSA 
sensing surface granting a fast screening process. Moreover, altered HSA isoforms as well as 
albumins from different species can be immobilized onto SPR platforms. In the first case, SPR 
approach may favor the correlation between structural modifications and HSA binding properties. 
In the latter, it may underline the species-dependent binding, pointing out the caution necessary 
before the extrapolation of data for clinical studies [55,56]. Besides conformational analysis, CD 
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spectroscopy has been widely employed to investigate ligand–HSA interactions. The achievement 
of affinity binding constants relies on the onset of induced circular dichroism (ICD): a typical CD 
signal peculiar of the complex. Similarly, well-characterized ICD markers can be exploited for 
competition studies at the main binding sites of HSA, disclosing the binding site as well as the 
binding mode of compounds [37,57]. HSA binding capacity as function of structural modifications 
(e.g. glycation) has been recently questioned by several research groups [58,59]. Moreover, a CD 
spectroscopy-based assay to investigate the impairment of HSA binding properties resulting from 
stabilizers addition, namely sodium octanoate and N-acetyltryptophan, is presented in the chapter 4.  
In addition to HSA binding capacity, HSA antioxidant activity is one of the mostly studied non-
oncotic functions. HSA antioxidant capacity is strictly connected to protein structure, mostly 
depending on the presence of a free thiol group at the Cys34 residue and on the N-terminal binding 
capacity towards free ions. As a consequence, structural changes triggered by pro-oxidant 
microenvironment can deeply affect this function [48]. Analytical approaches used to assess 
antioxidant properties of HSA include Ellman’s assay, albumin cobalt binding assay (ACB), 
oxygen radical absorbance capacity assay (ORAC) and 3,3’,5,5’-tetramethylbenzidine (TMB)-
based assay [2]. ACB assay tests the binding capacity of the N-terminal portion of the protein 
towards cobalt ions (Co) by means of a colorimetric reaction. This approach is employed in clinical 
practice to investigate the level of ischemia modified albumin (IMA) in circulating albumin pool, 
which reflects, in turn, a decrease in HSA antioxidant activity. IMA levels have also been proposed 
as biomarkers for acute coronary syndrome. Newly, ACB-based method has been employed to test 
antioxidant capacity of pharmaceutical-grade HSA [60]. Another colorimetric reaction, based on the 
interaction between free thiol groups and a chromogenic agent, is Ellman’s assay. This method is 
indirectly used to test HSA scavenger activity on the basis of the availability of Cys34 residues to 
form a colorimetric complex with 5,5’-dithiobis-2-nitrobenzoic acid (DTNB) [61]. For instance, 
this approach enables the evaluation of antioxidant activity as function of structural changes 
triggered by in vitro glycation and oxidation processes. Moreover it can be used to compare 
circulating HSA scavenger activity between healthy control subjects and diabetic patients [62,63]. 
Finally, ORAC and TMB assays can evaluate HSA antioxidant capacity towards peroxyl radicals 
and hydroxyl radicals respectively of pharmaceutical formulations and altered proteins [60]. 
 
3.6 Clinical implications of modified circulating HSA  
Circulating HSA could undergo structural modifications in the bloodstream, such as oxidation, 
cysteinylation and glycation, which may affect its physiological functions. Moreover, a significant 
decrease in physiological albumin amount has been related to an increasing hazard of morbidity and 
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mortality in renal and liver diseases, rheumatoid arthritis, ischemia, cancer and hypoalbuminemia 
[9]. In this scenario, modifications of HSA structure may reflect pathological conditions of human 
body, resulting in a possible use of HSA as prognostic biomarker in diseases, such as kidney, liver 
failure and aging (Fig. 6) [2].  
Oxidative stress increases with aging, thus promoting HSA oxidation and, as consequence, a 
decrease of the native isoform. Impairment in the overall redox state directly contributes to elderly-
related complications, such as an increasing risk of cardiovascular pathologies [65]. Oxidative 
stress and oxidized HSA have also been related to renal diseases. For example, a significant 
oxidation of HSA is encountered in primary nephrotic syndrome [66]. 
 
 
Figure 6 Clinical implication of the equilibrium between physiological and modified HSA. HSA alterations as 
prognostic biomarkers in several diseases. Reprinted with permission from [64]. 
 
Circulating levels of HNAs (1 and 2) are considered important biomarkers of the oxidative stress 
status of patients which are submitted to hemodialysis. Moreover, the total fraction of HNA 
(HNA1+ HNA2) is strongly tied to the decrease of creatinine clearance. In the end-stage renal 
disease, an increased level of cysteinylated HSA has been observed. These high levels, in turn, 
promote oxidative stress. Moreover, alteration of the native HSA affects its vasculoprotective 
properties, promoting cardiovascular complications in hemodialysis patients [64]. Impaired HSA 
functions have been reported during end-stages of renal failure, e.g. binding capacity at site II of the 
protein. Moreover, the alterations of the N-terminal portion of the protein, which also occur under 
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these conditions, contribute to increase the levels of IMA which, in turn, enhances the incidence 
percentage of coronary heart disease [12].  
Oxidative stress also plays a key role in the pathogenesis of liver diseases, such as cirrhosis [34]. 
This pathology alters not only the content of albumin as a consequence of a reduced production in 
the liver, but also HSA structural quality. Indeed, increased levels of HNA1 and HNA2 along with 
the carbonylated HSA have been detected in cirrhotic patients. In particular, these modified 
isoforms increase in case of decompensated cirrhosis and in patients which suffer of acute-on-
chronic-liver failure [67]. In case of decompensated cirrhosis and severe alcoholic hepatitis, an 
increase of HSA dimers, C- and N-terminal truncations and cysteinylation have been also reported. 
The quantification of all these altered isoforms favors the estimation of the residual native HSA in 
plasma, which has been shown to be a better predictor of patient survival after 1-year instead of 
albumin content (currently considered in clinical practice) [68]. Cirrhosis also increases IMA ratio 
which, in turn, enhances the severity of cirrhosis itself and leads to many complications. In this 
scenario, the carrier function for fatty acids and site-II ligands as well as the antioxidant activity 
have been shown to be considerably impaired.  
Finally, circulating glycated HSA increases in diabetic conditions and serum levels of glycated 
HSA have been proposed as a better short-term indicator of diabetes than glycated hemoglobin. 
Concerning its involvement in pathological processes, recent evidence suggests that advanced 
glycation end products (AGEs) may play a role in the onset of diabetic complications including 
retinopathy, nephropathy and cardiomyopathy. Similarly, RAGE activation by AGEs seems to be 
involved in the ethiopathogenesis of some chronic diabetes complications. This observation has 
recently increased the interest and the efforts towards the investigation of such interaction [69,70]. 
In this context, a multimethodological strategy to investigate the binding of glycated HSA with 
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Abstract 
The ADMET profile of drugs is strongly affected by human serum albumin (HSA), due to its 
leading role as carrier of poorly soluble compounds in plasma; a critical assessment of the binding 
capacity of HSA and the evaluation of binding competition between drugs are therefore pivotal for 
a reliable pharmacokinetic and pharmacodynamic characterization. In clinical practice, a potential 
source of impairment in the binding properties of HSA is the use of octanoate and N-
acetyltryptophan as stabilizers during the production of pharmaceutical-grade HSA for infusion (i-
HSA), which is currently administered in the treatment of a growing range of pathological 
conditions. The peculiar sensitivity of circular dichroism (CD) spectroscopy towards the 
stereochemical features of high-affinity binding events is herein exploited to achieve a site-specific 
assessment of the effect of stabilizers on the binding properties of i-HSA. The binding affinity and 
capacity of fatty-acid-free HSA towards site-selective induced circular dichroism (ICD) markers for 
the three high-affinity binding sites of HSA was compared to that of i-HSA submitted to 
ultrafiltration and dialysis to remove both stabilizers. Results showed a considerable impairment of 
the binding capacity of i-HSA at site II and a relatively lower influence on the binding properties of 
site I. Ultrafiltration proved to be ineffective in depleting octanoate, while the proposed dialysis 
protocol, which involves a pH-induced reversible unfolding of the protein, resulted in a total 
clearance of both stabilizers, confirmed by the full restoration of the binding properties of HSA at 
all binding sites. The outcomes of this study proved that CD spectroscopy is a suitable technique to 
evaluate the binding properties of i-HSA, ensuring an assessment of the availability of the binding 
sites and the possibility of monitoring the clearance of stabilizers. Eventually, the proposed method 
for their depletion might constitute a connection bridge between albumin in vitro studies and its 
clinical applications.  
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4.1 Introduction 
Human serum albumin (HSA) is the major plasma protein in humans, constituting more than 50% 
of the total protein content in plasma [2]. Due to its high concentration (~ 40 g/L) and its net 
negative charge, HSA contributes to ~ 70 % of the total osmotic pressure, regulating the distribution 
of plasma fluids between compartments. Besides its oncotic properties, HSA owns other important 
biological functions, defined as non-oncotic, related to its unique binding capacity for a huge 
variety of endogenous and exogenous compounds and to its antioxidant activity (both direct and 
mediated by the transport of free radical scavengers), as well as to its role in the inflammatory and 
immunological modulation, stabilization of hemostatic and endothelial functions and control of 
extracellular pH [3,4]. The structure of HSA consists of three homologous domains, each formed by 
two sub-domains (IA-B, IIA-B and IIIA-B) [2,5]. At least three main binding sites for drugs 
(labeled I-III) and seven binding sites for long-chain fatty acids have been identified and thoroughly 
investigated over the years, unveiling the complex network of interactions that regulates the 
properties of HSA as a carrier protein [6–9]. The binding to HSA modulates the solubility of drugs 
in plasma and influences their ADMET profile and therapeutic activity; therefore, the 
characterization of drug–HSA binding is pivotal for a full pharmacokinetic and pharmacodynamic 
evaluation [10]. 
The beneficial effects of the administration of HSA by intravenous infusion have been highlighted 
in several clinical settings, such as hypovolemia, hypoalbuminemia, burns, hemorrhage and 
hemodialysis, as well as liver diseases characterized by an altered albumin metabolism [11]. The 
production of pharmaceutical-grade HSA is based on the isolation and purification of the protein 
from the plasma of donors, a process that includes a pasteurization step to inactivate viruses. The 
denaturation of HSA during the heat treatment (60 °C for 10 hours) is avoided by the addition of 
sodium octanoate and N-acetyltryptophan as thermal and antioxidant stabilizers, respectively [12]. 
A recently published crystal structure of the ternary complex of HSA with octanoate and N-acetyl-
L-methionine shows that octanoate has a different binding pattern compared to long-chain fatty 
acids [13]. Octanoate binds at drug binding sites I and II of HSA, since the limited extension of its 
aliphatic chain prevents a full interaction with the main fatty acid binding sites; its binding modes 
are largely superimposed with those of site I- and site II-selective HSA ligands. Binding assays 

















The presence of stabilizers in pharmaceutical-grade HSA can alter its non-oncotic properties with 
respect to the native protein [15,16]; such effects have also been observed in vivo, with a marked 
increase of the free circulating concentration of naproxen (a site II ligand) in patients treated with 
HSA for infusion [17]. Moreover, the long-term administration of pharmaceutical-grade HSA might 
increase the health risks related to the toxicological profiles of octanoate and N-acetyltryptophan, 
which have been deemed as pathogenic factors in patients with liver diseases and linked to hepatic 
encephalopathy and renal tubular toxicity [18]. Attempts at addressing these concerns are mainly 
devoted to the identification of alternative stabilizers [19] and to the development of depletion 
devices to remove stabilizers before infusion. A recent evaluation of several commercial adsorbents 
for the depletion of octanoate and N-acetyltryptophan from pharmaceutical-grade HSA showed that 
the simultaneous removal of both stabilizers cannot be fully achieved when a single adsorbent is 
employed in depletion devices for the purification of HSA formulations before infusion [16]. 
In the present article, a binding affinity assay based on circular dichroism (CD) spectroscopy was 
employed to gain further insight into the effect of octanoate on the binding properties of HSA at its 
drug binding sites, exploiting the peculiar sensitivity of CD spectroscopy toward the stereochemical 
features of high-affinity binding events; the assay could be applied to monitor the depletion of 
stabilizers from pharmaceutical-grade HSA, whose binding properties after ultrafiltration and 
dialysis were compared to those of fatty-acid-free HSA, used as reference.  
The efficiency in the removal of stabilizers was quantified by HPLC-UV analysis, while the HSA 
binding affinity of selected site-specific markers (warfarin for site I, diazepam for site II and 
biliverdin for site III) was determined by means of induced CD measurements. Moreover, to 
enlarge the comprehension of site-II binding impairment caused by the strong modulation of 
octanoate, ketoprofen, which interacts with site II in a different binding mode as compared with 
diazepam [20], was also considered. The proposed approach should ensure a trustworthy 
monitoring of the binding properties of HSA, offering a deeper insight in the stabilizer cleaning 
process and supporting the selection of the optimal removal strategy.  
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4.2 Experimental section 
4.2.1 Materials 
Essentially fatty-acid-free HSA (f-HSA; product code A1887), biliverdin hydrochloride (BLV), 
rac-warfarin sodium salt (WRF), rac-ketoprofen (KPF), octanoic acid, N-acetyl-DL-tryptophan 
(NAT), formic acid (FA), trifluoroacetic acid (TFA), potassium dihydrogen phosphate (KH2PO4), 
dipotassium hydrogen phosphate trihydrate (K2HPO4 · 3 H2O), disodium hydrogen phosphate 
(Na2HPO4), sodium chloride (NaCl), potassium chloride (KCl) and activated charcoal were 
purchased from Sigma-Aldrich (Milan, Italy). 
Diazepam (DZP) was kindly supplied by Prof. Lucacchini (University of Pisa, Italy). 
Pharmaceutical-grade HSA for infusion (i-HSA) was a 200 g L
−1
 solution form (Albital
®
; Kedrion 




 T4 regenerated cellulose tubular membranes with a 50 kDa molecular weight cut-off 
(MWCO) were supplied by Membrane Filtration Products, Inc. (Seguin, USA). 
Amicon
®
 Ultra 0.5 mL centrifugal filters with a 50 kDa MWCO were purchased from Millipore 
Merck (Darmstadt, Germany). 
HPLC-grade (≥ 99.9%) 1-propanol (1-PrOH), methanol (MeOH) and acetonitrile (ACN) were 
supplied by Honeywell (Milan, Italy). 
Aqueous solutions were obtained using deionized water purified by a Milli-Q purification system 
(Millipore, Milford, MA, USA). 
Buffers were filtered through 0.22 µm membrane filters (Millipore, Milford, MA, USA) before use. 
Spectroscopic measurements were carried out using high-performance quartz (QS) cells purchased 
from Hellma Analytics (Müllheim, Germany). 
HSA samples prepared from f-HSA and i-HSA and used in the study are summarized in Table 1. 
 
Table 1| List of all HSA samples employed in the study. 
HSA sample Description 
Experimental 
section 
i-HSA pharmaceutical-grade HSA for infusion 4.2.1 
i-HSAUF i-HSA after ultrafiltration 4.2.2 
i-HSAdial i-HSA after dialysis 4.2.3 
f-HSA fatty-acid-free HSA 4.2.1 
s-HSA f-HSA with the addition of octanoic acid and NAT 4.2.3 
s-HSAdial s-HSA after dialysis 4.2.3 
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4.2.2 Ultrafiltration 
Ultrafiltration (UF) was performed with a Varifuge 3.0 r centrifuge (Heracus Sepatech, Hanau, 
Germany). 500 µL of i-HSA were ultrafiltered using Amicon Ultra centrifugal filters, which were 
washed with 1 mL Milli-Q water before use to remove glycerol from filter membranes. Each UF 
cycle was performed at room temperature, setting 4000×g for 15 min. After each cycle, 400 μL of 
phosphate buffered saline solution — PBS (pH 7.4) containing Na2HPO4 (10 mM), KH2PO4 (1.8 
mM), KCl (2.7 mM) and NaCl (137 mM) — were added before resubmitting the solution to the 
following UF cycle. The residual content of NAT and octanoate in the ultrafiltered i-HSA samples 
(i-HSAUF; Table 1) was monitored by HPLC-UV analysis on filtrates (see Section 4.2.4). Non-
specific binding (NSB) to filter membranes was evaluated with a blank solution containing NAT  
and octanoate at the same concentrations. The concentration of each stabilizer in the receiver 




 , (2) 




Dialysis was carried out at room temperature on two different freshly prepared samples (Table 1): i-
HSA diluted in deionized water at 500 µM and a solution containing f-HSA dissolved at 500 μM in 
deionized water with octanoic acid (2.7 mM) and NAT (2.7 mM), labeled s-HSA. Aliquots of 3.0 
mL of each solution were transferred into 24-cm Cellu·Sep T4 tubular membranes and submitted to 
the dialysis procedure which consisted of fifteen steps (I–XV) of 2 h each, against 2 L of freshly 
prepared buffer, under gentle stirring. In detail, steps I–III were conducted in PB (pH 7.4; 10 mM); 
steps IV–IX were carried out in PB (pH 3.0; 10 mM):1-PrOH 80:20 (v/v) with 4 g of activated 
charcoal; step X was performed against PB (pH 3.0; 10 mM):1-PrOH 90:10 (v/v) with the addition 
of 4 g of activated charcoal; steps XI–XII were conducted in PB (pH 3.0; 10 mM); step XIII was 
carried out in PB (pH 4.6; 10 mM); steps XIV–XV were performed in PB (pH 7.4; 10 mM). 
At the end of the procedure, dialyzed i-HSA (i-HSAdial, Table 1) and dialyzed s-HSA (s-HSAdial, 
Table 1) were spectrophotometrically quantified by a direct calibration method. For this purpose, a 
stock solution of f-HSA (15 µM) was prepared in PB (pH 7.4; 67 mM) and subsequently diluted in 
a series of two-fold dilutions (from 15 to 0.94 µM). A calibration curve was then derived by linear 
regression (𝑦 = 𝑎 𝑥 + 𝑏; 𝑎 = 31848.0; 𝑏 = 0.00082; 𝑅2  = 0.9993) based on the molar concentration 
of samples and the corresponding maximum absorbance at 280 nm (𝐴280, 1 cm pathlength). 
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To exclude the presence of stabilizers in the i-HSAdial sample, the protein was removed by 
precipitation and the supernatant was analyzed by HPLC-UV (see Section 4.2.4). In detail, 400 µL 
of ice cold ACN were added to 100 µL of i-HSAdial; the sample was vigorously vortexed for 1 min 
and centrifuged at 13000×g for 10 min at 4 °C; the concentration of stabilizers in the supernatant 
was then quantified. 
 
4.2.4 HPLC-UV analysis 
HPLC-UV analyses were carried out using a Zorbax Eclipse XDB-C18 column (150×2.1 mm, 3.5 
µm I.D.; Agilent, Walbronn, Germany) on a Jasco PU-2089 Plus HPLC system (Tokyo, Japan) 
equipped with a CO-2067 Plus column thermostat. Data were processed using the ChromNAV 
software package (Jasco, Tokyo, Japan).  
 
4.2.4.1 Quantitative determination of N-acetyltryptophan 
The quantitative determination of NAT was performed setting the column temperature at 40 °C, the 
flow rate at 0.3 mL min
−1
 and the detection wavelength at 280 nm; an injection volume of 50 μL 
was used. Mobile phases A — H2O:ACN:FA:TFA (99:1:0.1:0.025, v/v/v/v) — and B — 
ACN:H2O:FA:TFA (99:1:0.1:0.025, v/v/v/v) — were employed to develop a gradient: the starting 
condition A–B (80:20, v/v) was kept for 4 min, then the percentage of mobile phase B was linearly 
incremented to 40% (v/v) in 2 min. The column was equilibrated with the mobile phase 
composition of the starting condition for 10 min before the next injection. 
The stock solution of NAT (4.0 mM) was prepared in methanol. Standard solutions were prepared 
by diluting the stock solution in PBS (concentration range: 2.50–254 µM). Each standard solution 
was injected in duplicate; the derived average peak areas (in µV min) were plotted against the 
corresponding NAT concentration (in µM) to obtain the calibration curve by linear regression 
(𝑦 = 𝑎 𝑥 + 𝑏; 𝑎 = 54470; 𝑏 = 127000; 𝑅2 = 0.9999).  
The quantification limit (LOQ, S/N = 10) was determined by performing LC–UV analysis on 




 , (3) 
where 𝑎 is the slope and 𝜎𝑏 is the standard deviation of the y-intercept of the regression curve. The 
LOQ value resulted to be 1.78 µM. 
 
4.2.4.2 Quantitative determination of octanoate 
The quantitative determination of octanoate was performed in isocratic mode using a 
MeOH:H2O:TFA (70:30:0.1, v/v/v) mobile phase at a flow rate of 0.3 mL min
−1
. Analyses were 
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performed setting the column temperature at 40 °C and the detection wavelength at 214 nm; an 
injection volume of 50 μL was used.  
The stock solution of octanoic acid (32 mM) was prepared in DMSO. Standard solutions were 
prepared by diluting the stock solution in PBS (concentration range: 0.0625–8.00 mM). Standard 
solutions were analyzed in duplicate; the derived average peak areas (in µV min) were plotted 
against the corresponding octanoate concentration (in mM) to obtain the calibration curve by linear 
regression (𝑦 = 𝑎 𝑥 + 𝑏; 𝑎 = 478000; 𝑏 = −22980; 𝑅2 = 0.9993). The LOQ value was derived as 
described in Section 4.2.4.1 and resulted to be 42 µM.  
 
4.2.5 CD spectroscopy studies 
All measurements for CD spectroscopy studies were performed on a Jasco J-810 spectropolarimeter 
(Tokyo, Japan) at room temperature. Samples were prepared by dilution from fresh stock solutions 
of HSA and of the selective ICD markers for its three drug binding sites: WRF (site I), DZP (site 
II), KPF (site II) and BLV (site III). The final concentration of organic modifier (1-PrOH or 
DMSO) in the samples never exceeded 0.5% (v/v) and 1% (v/v), respectively. Solutions containing 
BLV were protected from direct exposure to ambient light throughout the experiments. 
Near-UV CD measurements were carried out using a 50 nm min
−1
 scanning speed (20 nm min
−1
 for 
WRF), a 2 nm spectral bandwidth, a 2 s data integration time, a 0.2 nm data pitch and an 
accumulation cycle of 3; spectral ranges were defined to include the peculiar ICD bands of each 
complex: 360–300 nm for WRF–HSA (𝜆max  = 308 nm), 350–250 nm for DZP–HSA (𝜆max  = 316 
nm), 400–250 nm for KPF–HSA (𝜆max  = 340 nm) and 450–250 nm for BLV–HSA (𝜆max  = 385 
nm). Far-UV CD measurements were carried out in the 260–195 nm spectral range using a 20 nm 
min
−1
 scanning speed, a 2 nm spectral bandwidth, a 2 s data integration time, a 0.2 nm data pitch 
and an accumulation cycle of 3. Spectra were processed using the Jasco Spectra Analysis software 
(Tokyo, Japan) and plotted using the Bezier smoothing algorithm provided by the Gnuplot software 
(version 5.2.2, http://gnuplot.sourceforge.net). 
 
4.2.5.1 Affinity studies with ICD markers 
The determination of the affinity constants for the three drug binding sites of HSA was carried out 
by near-UV CD measurements on equimolar (1:1) mixtures of the protein with the corresponding 
ICD marker in PB (pH 7.4; 67 mM). 
Stock solutions of f-HSA, i-HSAUF and i-HSAdial were prepared in PB (pH 7.4; 67 mM) at a final 
concentration of 500 μM. Stock solutions of ICD markers were prepared as follows: WRF (10 mM) 
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in PB (pH 7.4; 67 mM); DZP (5 mM) in PB (pH 7.4; 67 mM)–(1-PrOH) (75:25, v/v); BLV (2 mM) 
in PB (pH 7.4; 67 mM)–DMSO (62:38, v/v). 
Five 1:1 mixtures were analyzed for each marker–HSA complex; the pathlength and the initial 
concentration of analytes were changed simultaneously, while keeping their product constant. QS 
quartz cells with 10, 5, 2, 1 and 0.5 cm pathlengths were used, while concentrations were defined 
based on the binding properties and spectroscopic response of each complex: 5.0, 10, 25, 50 and 
100 μM for WRF–HSA and DZP–(i-HSAUF) complexes; 1.5, 3.0, 7.5, 15 and 30 μM for BLV–HSA 
and other DZP–HSA complexes. All markers were either non-chiral or used as racemic mixtures, so 
the ICD spectra of the marker–HSA complexes were obtained by subtraction of the CD spectrum of 
the protein from the CD spectra of the 1:1 mixtures.  
The chemical equilibrium of the marker–HSA binding interaction was evaluated using a Benesi-
Hildebrand mathematical method [21,22] based on the absolute values of maximum intensity for 
the ICD bands (|∆𝐴ind| at 𝜆max). For interactions exhibiting a 1:1 stoichiometry, the concentrations 




The initial concentration of the protein ([𝑃]0) can then be expressed as a function of the 
concentration of the ligand–protein complex at equilibrium ([𝐿𝑃]): 
[𝑃]0 = [𝐿𝑃] + [𝑃] = [𝐿𝑃] + √
[𝐿𝑃]
𝐾A
 . (4) 
The ICD signal is proportional to the concentration of the marker–protein complex; the combination 







 , (5) 
where ∆𝜀ind is the absolute value of the induced molar differential extinction coefficient for the 




) and 𝑙 is the pathlength (in cm). By setting 𝑥 = √|∆𝐴ind| 𝑙⁄  and 







 , (6) 
where 𝑦 = [𝑃]0 𝑥⁄ . 
The values of ∆𝜀ind and 𝐾A for each marker–HSA complex were calculated from the slope (𝑚 =
1
|∆𝜀ind|
) and intercept (𝑞 = √
1
|∆𝜀ind| ∙ 𝐾A
) of Equation 6, as obtained by linear regression from the 
average 𝑥 and 𝑦 data of two independent assays (𝑛 = 2). The uncertainties of ∆𝜀ind and 𝐾A were 




4.2.5.2 Binding to HSA site II 
The different binding capacities of f-HSA, i-HSAUF, s-HSA, i-HSAdial and s-HSAdial at site II were 
evaluated by near-UV CD measurements on their equimolar mixtures (1:1, 50 µM) in PB (pH 7.4; 
67 mM) with two site II-specific ICD markers, namely DZP and KPF. Spectra were recorded using 
a QS quartz cell with a 1 cm pathlength. The ICD spectra of the marker–HSA complexes were 
obtained by subtraction of the CD spectrum of the protein from the CD spectra of the 1:1 mixtures.  
 
4.2.5.3 Secondary structure analysis 
Far-UV CD measurements for the analysis of the secondary structure of HSA were performed on f-
HSA, i-HSAUF, i-HSAdial and s-HSAdial samples (5 μM) in PB (pH 7.4; 67 mM) using a QS quartz 
cell with a 0.05 cm pathlength. 
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4.3 Results and discussion 
4.3.1 Depletion of N-acetyltryptophan and octanoate by ultrafiltration 
Ultrafiltration (UF) is a common procedure used for protein concentration, buffer exchange and 
desalting. In the current study, UF was employed in the attempt to remove NAT and octanoate 
excess from i-HSA. The process was monitored by quantitating, after each UF cycle, the stabilizers 
concentration in the receiver chamber by means of the HPLC-UV methods described in Section 
4.2.4. The optimized analytical approach allowed a fast determination of NAT and octanoate, 
whose chromatographic retention times were 4.0 (𝑘 = 2.9) and 3.8 min (𝑘 = 2.2), respectively. The 
assessment of UF efficacy was carried out by monitoring the residual concentration of each 
stabilizer in the i-HSA solution over 20 UF cycles (Fig. 7). Each stabilizer was quantified in the 




Figure 7| Progressive depletion followed by HPLC-UV analysis. Progressive depletion of N-acetyltryptophan (solid 
line) and octanoate (dotted line) from i-HSA by ultrafiltration. 
N-acetyltryptophan and octanoate are present at the same declared starting concentration (16 mM), 
but the efficacy of UF was significantly different for the two stabilizers, as expected by their 
different binding affinities to HSA [12,13]. While the residual concentration of NAT fell below 1% 
after 12 cycles and reached 0.4% after 20 cycles, the removal of octanoate was significantly more 
difficult (Fig. 7) in agreement with data presented by Harm et al. [16]. The low removal efficiency 
is consistent with both the high affinity of octanoate for HSA and the high binding capacity of 
HSA. Based on the analysis of the concentration of octanoate in the receiver chamber after the first 
cycle of UF, only 10.7% of the stabilizer results to be free in solution, while the remaining fraction 
is bound to HSA. 
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4.3.2. Site-specific ICD markers as a tool for monitoring the removal of octanoate  
CD spectroscopy can provide valuable information on both the structural features and the affinity of 
binding interactions in near-physiological conditions; the relatively higher information content that 
can be obtained through in solution CD binding assays represents an advantage over other popular 
techniques, such as isothermal titration calorimetry, fluorescence spectroscopy and surface plasmon 
resonance biosensing. Specifically, CD spectroscopy is a powerful technique for the investigation 
of the binding properties of HSA, thanks to the high degree of stereospecificity displayed by its 
main drug binding sites. The eventual onset of an induced circular dichroism (ICD) signal can be 
exploited to evaluate the binding parameters of a ligand–HSA complex and the bound conformation 
of the ligand; conversely, ligands with well-characterized ICD spectra can be used as selective 
markers to investigate the competition for the binding sites of HSA by other small molecules [21]. 
The availability of specific ICD markers for the three drug binding sites of HSA allowed a thorough 
comparison of the binding properties of samples derived from i-HSA with those of f-HSA by means 
of CD affinity studies. The simultaneous determination of 𝐾A and ∆𝜀ind values by the Benesi-
Hildebrand method allows a reliable evaluation of the binding affinity and capacity of HSA at each 
binding site, with the additional advantage of monitoring highly stereoselective binding events; 
nevertheless, it must be noted that the reliability of ICD affinity studies using this approach strongly 
depends on the nature of the binding complex under investigation. Indeed, the analysis must be 
carried out on strictly equimolar marker–protein mixtures in a concentration range where the 
binding complex is not close to saturation and the resulting ICD signal is sufficiently intense to be 
accurately monitored; situations where these requirements are not fulfilled will lead to significant 
errors in the estimation of binding affinities. 
 
Table 2| Affinity constant (𝐾A), induced molar differential extinction coefficients (∆𝜀ind) and linear 
regression parameters of the Benesi-Hildebrand equations for the binding of site-specific ICD 
markers to f-HSA, as obtained by CD spectroscopic analysis (𝑛 = 2). Affinity data available from 
literature are also listed for comparison. 















) for HSA 
WRF I (8.62 ± 0.81) × 104 1.84 ± 0.05 308 (5.44 ± 0.13) × 10−1 (2.51 ± 0.09) × 10−3 0.9982 1.1 × 105 (a) 
DZP II (1.09 ± 0.15) × 106 −7.45 ± 0.14 316 (1.34 ± 0.03) × 10−1 (3.50 ± 0.21) × 10−4 0.9989 6.6 × 105 (b) 
BLV III (1.93 ± 0.45) × 106 62.1 ± 1.5 385 (1.61 ± 0.04) × 10−2 (9.12 ± 0.95) × 10−5 0.9982 1.5 × 106 (c) 
(a) determined by surface plasmon resonance biosensing [23]. 
(b) determined by equilibrium dialysis [24]. 
(c) determined by HSA fluorescence quenching [25]. 
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The calculated 𝐾A values for the marker–(f-HSA) complexes (Table 2) were found to be in good 
agreement with affinity values determined with orthogonal techniques, showing that the ICD 
approach can provide accurate estimates for the affinity of small molecules to HSA. 
The ∆𝜀ind obtained from the slopes of the Benesi-Hildebrand equations highlighted that the 
presence of octanoate in the i-HSAUF samples affects the binding of markers [14]: the binding 
capacity of site II was found to be significantly lower in i-HSAUF than in f-HSA (Table 3). 
 
Table 3| Affinity constant (𝐾A), induced molar differential extinction coefficients (∆𝜀ind) and linear 
regression parameters of the Benesi-Hildebrand equations for the binding of site-specific ICD 
markers to i-HSAUF, as obtained by CD spectroscopic analysis (𝑛 = 2). 𝐾A and ∆𝜀ind values for f-
HSA are also listed for comparison. 











𝒎 𝒒 𝑹𝟐 
𝑲𝐀 (∆𝜺𝐢𝐧𝐝)  
for f-HSA 
WRF I (1.07 ± 0.23)× 105 2.58±0.13 308 (3.87 ± 0.19)× 10−1 (1.90 ± 0.15)× 10−3 0.9927 8.62 × 104 (1.84) 
DZP II (3.60±10.00)×107 −1.73 ± 0.06 316 (5.77 ± 0.21)× 10−1 (1.26 ± 1.72)× 10−4 0.9961 1.09 ×106 (−7.45) 
BLV III (3.36 ± 0.93)× 106 62.0 ± 1.4 385 (1.61 ± 0.04)× 10−2 (6.93 ± 0.88)× 10−5 0.9985 1.93 × 106 (62.1) 
 
The strong decrease of ∆𝜀ind observed for the DZP–(i-HSAUF) complex (Fig. 8) is consistent with a 
mechanism of direct binding competition between octanoate and DZP at site II: indeed, the 
presence of a high-affinity competitor (octanoate) in the i-HSAUF sample breaks one of the 
requirements of the Benesi-Hildebrand approach, i.e. the equimolar ratio between the ligand and the 
available binding sites. The saturation of the ICD signal for the DZP–HSA complex is therefore 
reached at a lower concentration, resulting in a significant overestimation of 𝐾A and a marked 
increase of the uncertainty for the values derived by linear regression analysis. 
 
Figure 8| Benesi-Hildebrand curves. Benesi Hildebrand curves for the ICD affinity studies on 1:1 mixtures of f-HSA 
(solid lines), i-HSAUF (dotted lines) and i-HSAdial (dashed lines) with site-specific ICD markers. (A) WRF (site I; 𝜆max 
= 308 nm). (B) DZP (site II; 𝜆max = 316 nm). (C) BLV (site III; 𝜆max = 385 nm). 𝑥 = √|∆𝐴ind| 𝑙⁄  ; 𝑦 = [𝑃]0 𝑥 ⁄ . 
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The binding capacity of i-HSA at site II is heavily influenced by the efficiency of the purification 
method used for the removal of stabilizers. CD measurements on i-HSAUF samples subjected to 8 




) than samples obtained after 20 UF 




). These results confirm that UF is only partially successful in 
depleting octanoate from i-HSA samples due to the high affinity of octanoate to HSA.  
The presence of octanoate influenced the binding properties of site I as well, although the 𝐾A and 
∆𝜀ind values of WRF–HSA complexes increased going from f-HSA to i-HSAUF (Fig. 8). Previous 
studies on the effect of stabilizers on the binding properties of HSA at site I reported a small 
reduction in the fluorescence emission of WRF bound to excess HSA in the presence of octanoate 
[13]. Considering the racemic nature of the marker, the behavior observed in the ICD affinity assay 
might be explained by a change in the binding enantioselectivity for the two enantiomers of WRF 
[26], resulting in a variation of the overall ICD signal of the mixture. The analysis of BLV–HSA 
complexes, on the other hand, showed minor differences between the binding properties of f-HSA 
and i-HSAUF (Fig. 8). Therefore, the presence of octanoate in i-HSAUF does not seem to interfere 
significantly with the binding capacity of site III. 
The results of ICD affinity assays strongly support the usefulness of site II-specific ICD markers to 
monitor the removal of octanoate from i-HSA and the recovery of its optimal binding capacity. Site 
II-specific ICD markers are ideal in this framework thanks to the strong stereospecificity observed 
at this site and the strong modulation of its binding properties displayed by octanoate. An additional 
proof of the usefulness of site II-specific ICD markers for this application was given by the 
observation that the binding of DZP to s-HSA (where octanoate is added to f-HSA) displays a 
similar reduction in the intensity of ICD response compared to i-HSAUF (Fig. 9A). 
 
Figure 9| ICD spectra for site-II specific markers. ICD spectra for the 1:1 mixtures (50 μM) of HSA samples with 
site II-specific ICD markers (solvent: PB 67 mM pH 7.4; cell pathlength: 1 cm). (A) DZP. (B) KPF. Solid: f-HSA. 
Dotted: i-HSAUF. Short-dashed: i-HSAdial. Long-dashed: s-HSA. Dash-dotted: s-HSAdial. 
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The binding impairment at HSA site II caused by the presence of octanoate was further investigated 
using an additional site II-specific ICD marker, i.e. KPF. An even more dramatic effect was 
observed: the presence of octanoate in i-HSAUF and s-HSA caused the complete disappearance of 
the peculiar negative ICD band of the complex at around 340 nm (Fig. 9B) [27]. The different 
extents of the binding impairment at site II triggered by octanoate can be explained by the 
differences in the binding modes of benzodiazepines and non-steroidal anti-inflammatory drugs 
[20,28]; the evidence of competition by octanoate for both classes of drugs gives additional strength 
to the choice of site-II specific ICD markers as excellent tools in the evaluation of the effect of 
stabilizers on the binding properties of i-HSA.  
 
4.3.3 Removal of stabilizers by dialysis 
The efficiency in the removal of stabilizers, quantified by HPLC-UV analysis (Fig. 1), revealed that 
ultrafiltration was ineffective in depleting octanoate (residual concentration 80 % after 20 cycles) 
due to its strong affinity with HSA [13,14]. Analogous results were obtained by means of adsorbent 
devices and common protocols of equilibrium dialysis, in which octanoate bound to the protein 
proved to be 27 ± 3 % and 17 ± 6 % of its starting concentration in i-HSA, respectively [16]. 
Aiming at improving the removal of octanoate, a more drastic and extensive protocol of dialysis 
was performed, which allowed to exploit the reversible unfolding of HSA as a function of pH [29].  
Dialysis was carried out on i-HSA and s-HSA. Initial steps were performed at pH 7.4 to eliminate 
excess of octanoate and NAT, similarly to UF. Then, the pH of dialysis buffer was decreased to 3.0, 
where HSA undergoes a reversible transition from its physiological fold (normal or N form; pH 8–
4.3) to a transiently unfolded conformation characterized by a larger solvent-accessible surface area 
and a partial loss of α-helical structure (fast-migrating or F form; pH 4.3–2.7) [2]. Moreover, 
octanoate is mostly protonated in this acidic environment (p𝐾𝑎 = 4.9), and the adsorption of 
octanoic acid by charcoal further promotes the dissociation of octanoate from HSA [30]. 
Subsequent dialysis steps carried out against buffer with increasing pH values enabled protein 
refolding to the N form. 
The initial HSA concentration submitted to dialysis proved to be crucial to obtain a successful 
removal of stabilizers: since the solubility of the F form is significantly lower than the N form [2], 
different concentrations were tested to avoid protein precipitation at pH 3.0, which hampered the 
efficient extraction of octanoic acid (data not shown). Based on this experimental evidence, i-HSA 
and s-HSA solutions were dialyzed at an initial concentration of 500 μM. At the end of the 
procedure, i-HSAdial and s-HSAdial were spectrophotometrically quantified and the final 
concentrations ranged from 80 to 85% (w/w) of the initial amount. 
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The secondary structure of i-HSAdial and s-HSAdial was investigated by CD spectroscopy to verify 
the recovery of the physiological conformation of HSA after dialysis; the excellent agreement of the 
recorded spectra with those of f-HSA and i-HSAUF (Fig. 10), which displayed the typical features of 
α-helix-rich proteins with negative bands centered at 208 and 222 nm [31], confirmed that the 
secondary structure of HSA was completely restored after dialysis. 
 
Figure 10| Secondary structure spectra. Far-UV CD spectra (in molar units per residue) of f-HSA (solid), i-HSAUF 
(short-dashed), i-HSAdial (dotted) and s-HSAdial (long-dashed). Solvent: PB 67 mM pH 7.4. Cell pathlength: 0.05 cm. 
The binding capacity for DZP and KPF at site II was analyzed to verify the total removal of 
stabilizers from dialyzed samples. The excellent overlapping of the ICD spectra obtained with i-
HSAdial, s-HSAdial and f-HSA (Fig. 9) proved the successful removal of octanoate. LC-UV analysis 
excluded the presence of octanoate at detectable concentrations. 
 
Table 4| Affinity constant (𝐾A), induced molar differential extinction coefficients (∆𝜀ind) and linear 
regression parameters of the Benesi-Hildebrand equations for the binding of site-specific ICD 
markers to i-HSAdial, as obtained by CD spectroscopic analysis (𝑛 = 2). 𝐾A and ∆𝜀ind values for f-
HSA are also listed for comparison. 











𝒎 𝒒 𝑹𝟐 
𝑲𝐀 (∆𝜺𝐢𝐧𝐝)  
for f-HSA 
WRF I (9.91 ± 1.24) × 104 1.89 ± 0.05 308 (5.29 ± 0.15) × 10−1 (2.31 ± 0.11) × 10−3 0.9975 8.62 × 104 (1.84) 
DZP II (1.71 ± 0.28) × 106 −7.02± 0.13 316 (1.42 ± 0.03) × 10−1 (2.88 ± 0.21) × 10−4 0.9991 1.09 × 106 (−7.45) 





Figure 11| ICD spectra of site-specific markers.  ICD spectra for the 1:1 mixtures of i-HSAdial with site-specific ICD 
markers, as measured using different cell pathlengths (solvent: PB 67 mM pH 7.4). (A) WRF, site I marker. Solid: 100 
μM (0.5 cm). Long-dashed: 50 μM (1 cm). Dash-dotted: 25 μM (2 cm). Short-dashed: 10 μM (5 cm). Dotted: 5 μM (10 
cm). (B) DZP, site II marker. Solid: 30 μM (0.5 cm). Long-dashed: 15 μM (1 cm). Dash-dotted: 7.5 μM (2 cm). Short-
dashed: 3 μM (5 cm). Dotted: 1.5 μM (10 cm). (C) BLV, site III marker. Solid: 30 μM (0.5 cm). Long-dashed: 15 μM 
(1 cm). Dash-dotted: 7.5 μM (2 cm). Short-dashed: 3 μM (5 cm). Dotted: 1.5 μM (10 cm).  
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4.4 Conclusions 
A full characterization of the ADMET profile of a drug requires a comprehensive study of plasma 
bioavailability, which is strongly affected by the binding to serum proteins. The presence of fatty 
acids or the addition of stabilizers in pharmaceutical formulations may compete with the binding of 
drugs to HSA, causing an impairment in the assessment of the binding capacity. Analytical 
approaches able to quantify binding parameters, detect concomitant interactions and provide a 
deeper insight on the availability of the binding sites offer clear advantages toward a better 
characterization of drugtarget interactions; the application of CD spectroscopy to binding affinity 
studies has an enormous potential in this respect. Indeed, the highly stereoselective responses of 
well-characterized ICD markers allow the direct assignment of the observed signal to a specific 
binding event, a feature that other biophysical techniques cannot provide.  
The comparison between the binding parameters (𝐾A, ∆𝜀ind) achieved for all site-specific ICD 
markers (warfarin, diazepam, biliverdin) and those obtained for fatty-acid-free HSA proved the 
inefficiency of ultrafiltration in removing octanoate, which affected the binding capacity at site II 
and, to a lesser extent, at site I. Conversely, the proposed dialysis protocol, that involves the 
reversible unfolding of the protein in acidic conditions, successfully granted both stabilizers 
depletion. The reversible conformational transition of HSA, from the N to the F form, proved to be 
necessary to remove octanoate strongly bound to HSA. The recovery of binding capacity of HSA 
was further verified for all site-specific ICD markers as a proof of the totally restored availability of 
the binding sites, enhancing previous results reported in the literature based on different purification 
methods such as marketed adsorbent devices or common protocols of equilibrium dialysis.  
The use of CD spectroscopy guaranteed a thorough site-specific assessment of the availability of 
the high-affinity binding sites, as well as to verify the recovery of the physiological conformation of 
HSA after removal of the stabilizers. The approach proposed proved to be trustworthy for studying 
drug–HSA interactions, when the modulation of the binding properties needs to be assessed. The 
clear competition displayed by octanoate at site II makes site-II specific ICD markers excellent 
tools in the evaluation of the effect of stabilizers on the binding properties of i-HSA, providing an 
easy method to monitor the depletion of stabilizers from pharmaceutical-grade HSA submitted to 
different purification methods. In the attempt to develop more efficient devices for the removal of 
stabilizers, the proposed ICD approach might be employed as a method to selectively monitor the 
full availability of the binding sites of HSA after purification, thus ensuring further progress in the 
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Characterization of the interaction between glycated HSA and the 




Due to RAGE role as pattern recognition receptor and its involvement in pathological setting of 
many chronic diseases, many efforts have been made to define structural requirements for RAGE 
binding and activation. The current lack of a clear picture is partially related to AGEs heterogeneity. 
Based on these premises, the current study aimed to investigate the interaction between the VC1, 
i.e. RAGE ectodomain, and a form of glycated albumin (HSAgly), recently released on the market, 
by a tailored multimethodological strategy able to provide affinity parameters along with structural 
features for VC1 recognition. Four sites of glycation, including glycation at K525, were identified 
by 2D-LC-ESI-MSMS while top down LC-MS approach allowed the definition of glycation extent. 
The ability of the HSAgly to interact with VC1 was confirmed by surface plasmon resonance (SPR) 
studies using a HSAgly sensing surface and affinity proteomics employing a purposely developed 
VC1 column. The related steady state dissociation constant (KD) highlighted a moderate affinity 
between the two interactants while displacement studies using chondroitin sulphate, a known 
RAGE binder, validated the VC1HSAgly interaction assessed by the SPR-based assay. The 
combination of epitope extraction method with LC-MSMS analysis allowed further insights into the 
region(s) of HSAgly involved in the binding. Specifically, preliminary outcomes of these analyses 
highlighted that glycation at K525 and subdomain IA may be important for VC1 biorecognition. 
The study is still in fieri. However, so far obtained outcomes showed that the proposed 
multimethodological strategy can be a suitable approach to shed light on requirements for VC1 
biorecognition and it may be further employed to investigate the interaction with different glycated 
interactants including AGEs.  
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5.1 Introduction  
Circulating glycated human serum albumin (HSA) is the result of the non-enzymatic glycation of 
the native protein by reducing sugars, mainly glucose, over the course of albumin life-time. The 
glycation process initially leads to the formation of chemically reversible Schiff bases and Amadori 
adducts, which are also known as early stage glycation products. Amadori adducts slowly undergo 
further irreversible rearrangements such as dehydration, oxidation, polymerization and intra/inter 
molecular crosslinking, which result in the formation of the so-called advanced glycation end 
products (AGEs), a generic name indicating the heterogeneous class of products resulting from this 
process. Early glycation products can also undergo oxidation, i.e. glycoxidation reaction, forming 
advanced glycoxidation products. In addition to this complex framework, AGEs can also directly 
derive from irreversible reactions between proteins and glucose-based reactive dicarbonyls (e.g. 
methylglyoxal) [1]. Protein glycation occurs at a limited extent in healthy subjects and glycation 
products accumulate with aging, contributing to the aging process itself. However, in specific 
pathological conditions, such as in diabetes, this process is accelerated [2]. Indeed, the main 
hallmark of diabetes is the dysregulation of plasma glucose levels, which strongly influences 
protein glycation rate and AGEs formation [3]. Since HSA is the most abundant circulating protein 
in plasma, accounting for more than 50 % of the total plasma protein content, and its primary 
structure contains aminoacid residues targeted by glycation, i.e. arginine and lysine residues, this 
protein is highly sensitive to glycation and albumin-derived AGEs are commonly found in human 
body [4].  
AGEs are considered as biomarkers of several diseases including kidney failure, arteriosclerosis, 
cancer or Alzheimer’s disease. Moreover, emerging data suggest that AGEs play a role in the onset 
of diabetic complications such as nephropathy, retinopathy and cardiomyopathy, acting as 
pathogenic factors and/or as damaging-intermediates [2,5]. In this scenario, structural 
characterization of the different AGEs, their quantification along with the elucidation of their role in 
pathological conditions constitute an emerging need of paramount importance [6].  
AGE accumulation-related damages arise from multiple pathological mechanisms including loss of 
proteins function, proteins dysregulation, aggregation and signaling mediated by the activation of 
receptors such as the receptor for advanced glycation end product (RAGE) [7,8]. RAGE is a 
transmembrane receptor which belongs to the immunoglobulin superfamily and plays a role in 
innate immunity and inflammatory response [9]. It consists of an extracellular region, which is 
composed by one ligand-binding V-type Ig domain and two Ig-like constant domains (C1 and C2), 
a transmembrane domain and a cytosolic signal-transducing tail. The V and C1 domains form an 
integrated structural unit (VC1) involved in the binding of the majority of RAGE ligands including 
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AGEs [10,11]. Recent studies have suggested that the activation of RAGE by AGEs plays a role in 
the pathogenesis of some chronic diabetes complications [7]. Despite the advances in the 
understanding of AGE–RAGE axis, the pathological role of specific AGEs as well as AGEs 
structural requirements for AGE-RAGE interaction and RAGE activation still mostly remain 
unclear. The lack of a clear picture is partially related to AGEs heterogeneity, their chemical and 
metabolic instability along with the negligible amounts of circulating AGEs and complexity of 
biological matrices from which they need to be isolated [7]. In vitro studies involving RAGE are 
most commonly performed using BSA- or HSA-derived AGEs as reference ligands. However, 
BSA-AGEs and HSA-AGEs are commonly prepared in house by in vitro glycation [11–14] and the 
obtained AGE mixtures are usually employed without any further characterization of the formed 
AGEs species. This lack of a detailed knowledge on the AGE species used for binding experiments 
dramatically hampers the comprehension of the biorecognition phenomenon, preventing the rational 
design of new RAGE antagonists. 
In this scenario, the use of structurally well characterized ligands seems to be compulsory. With this 
in mind, we decided to investigate glycated HSA–RAGE interaction in order to possibly highlight 
the structural features involved in such interaction. 
To achieve this goal the binding between VC1 from human RAGE, expressed by Degani et al.[15], 
and a form of glycated albumin, recently released on the market (HSAgly), was studied. LC-MS 
was employed to define glycation sites on the commercial product, a prerequisite for the 
comprehension of the observed recognition phenomenon. Taking advantages of peculiar features of 
SPR [16,17], a HSAgly-sensing surface was employed to estimate binding affinity towards VC1. A 
competition assay involving the reference RAGE binder chondroitin sulphate [18,19] was used to 
further validate the binding between VC1 and HSAgly. Affinity chromatography coupled with mass 
spectrometry (affinity-MS) approach [20] was further developed in order to highlight the region(s) 
of the protein scaffold involved in such interaction. The outcome of the current study is the 
development of a multimethodological strategy to characterize HSAgly–VC1 binding with the aim 
of getting to elucidate molecular basis of AGE–RAGE interactions.  
  
 59 
5.2 Experimental section 
5.2.1 Materials  
Glycated human serum albumin lyophilized powder (product code A8301) and trypsin from bovine 
pancreas were purchased from Sigma-Aldrich (Milan, Italy). Human recombinant RAGE 
ectodomain, i.e.VC1, was expressed in Pichia Pastoris and was kindly supplied by Prof. Popolo 
(University of Milan, Italy) [15].  
Analytical grade racemic warfarin sodium salt (rac-WRF), chondroitin sulphate sodium salt from 
shark cartilage (CND), N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), potassium 
dihydrogen phosphate (KH2PO4), disodium hydrogen phosphate (Na2HPO4), sodium chloride 
(NaCl), polyoxyethylenesorbitan monolaurate (p-20), formic acid (FA), trifluoroacetic acid (TFA), 
ammonium bicarbonate (AMBIC, NH4HCO3), sodium bicarbonate (NaHCO3), ammonium acetate 
(NH4OAc), sodium hydroxide (NaOH), sodium acetate (NaOAc), ethylenediaminetetracetic acid 
(EDTA), dithiothreitol (DTT) and iodoacetamide (IAA) were supplied by Sigma-Aldrich (Milan, 
Italy). HPLC-grade (≥ 99.9%) acetonitrile (ACN) was supplied by Honeywell (Milan, Italy). 
Research-grade CM5 sensor surface, N-ethyl-N-(3-dimethylaminopropyl)-carbodiimide (EDC), N-
hydroxysuccinimide (NHS), ethanolamine hydrochloride (pH 8.5, 1 M), CNBr-activated 
sepharose
TM
 4B were purchased from GE Healthcare Bio-Sciences (Uppsala, Sweden). 2,5-
Dihydroxybenzoic acid (DHB) and super 2,5-dihydroxybenzoic acid (SDHB) were supplied by 
Bruker Daltonics (Bremen, Germany). 
Amicon
®
 Ultra 0.5 mL centrifugal filters (50 kDa MWCO) were supplied by Millipore Merck 
(Darmstadt, Germany). 
Mobicol-Classic columns (cod.1002) and filter (small) 35 m pore size (cod. M513515) were 
purchased from MoBiTec GmbH (Göttingen, Germany).  
Deionized water was obtained by Milli-Q system (Millipore, Milford, MA, USA) and all aqueous 
solutions were filtered through 0.22 m membrane filters before use.  
 
5.2.2 Surface plasmon resonance-based analyses 
SPR measurements were carried out on a Biacore
TM 
X100 system (GE Healthcare Bio-Sciences, 
Uppsala, Sweden) provided with an in-line degasser and thermostated at 25°C. Data elaboration 
was performed using Biacore
TM
 X100 2.0 evaluation software and GraphPad Prism 6.0 software 





5.2.2.1 Preparation and validation of HSAgly-biosensing surface  
For the preparation of HSAgly-functionalized surface, HSAgly was solubilized in NaOAc buffer 
(0.01 M) at various pH (pH range 4.0–5.5) at a 30 g mL
-1 
concentration in order to test the 
electrostatic pre-concentration over the chip surface (pH scouting). Ligand pre-concentration was 
evaluated by injecting stock solutions at different pH values at 5 L min
-1
 for a contact time of 180 
s, using as running buffer phosphate buffered saline solution (PBS) (pH 7.4), which contains 
Na2HPO4 (10 mM), KH2PO4 (1.8 mM), KCl (2.7 mM) and NaCl (137 mM). After each injection, 
the baseline was restored injecting twice a NaOH solution (0.05 M) at the same flow rate and 
setting 20 s as contact time. The NaOAc (pH 4.5; 0.01 M) proved to be the best immobilization 
condition and was used for HSAgly immobilization. HSAgly was immobilized on a carboxymethyl 
dextran CM5 sensor chip through amine coupling reaction [21]. Briefly, the sensor surface was 
activated by flushing a freshly prepared mixture of EDC (0.4 M) and NHS (0.1 M) for 7 min at flow 
rate of 10 L min
-1
. Then, a solution of HSAgly 30 g mL
-1
 in NaOAc (pH 4.5; 0.01 M) was 
injected until the required amount of immobilized protein was obtained, i.e. 5500 response units 
(RUs). After the immobilization step, residual active esters were quenched by treating the surface 
with a solution of ethanolamine hydrochloride (1 M; pH 8.5) which was injected for 7 min at the 
same flow rate. Besides the flow cell with immobilized HSAgly (active flow cell), to account for 
non-specific binding events, a reference flow cell was prepared using the same protocol apart from 
HSAgly injection. Finally, sensor surface was allowed to stabilize overnight by flowing PBS buffer 
to obtain a steady baseline.  
Before further use, the functionality of the HSAgly-sensing surface was verified using rac-WRF as 
test compound. Analysis conditions were set as follow: PBS (pH 7.4) with the addition of p-20 0.05 
% (v/v) was used as running buffer, 75 L min
-1 
as flow rate and 45 s and 60 s as association and 
dissociation time, respectively. rac-WRF was dissolved directly in running buffer (600 M), diluted 
in three-fold serial dilutions (from 30.0 to 0.50 M) and injected over the surface. Data achieved 
were processed as described in Section 5.2.2.4. 
 
5.2.2.2 Analysis of VC1–HSAgly binding 
Affinity assays were carried out in multi-cycle kinetic (MCK) mode employing HEPES (0.02 M), 
NaCl (0.15 M), EDTA (50 M) and p-20 0.05 % (v/v) (pH 7.1), labeled HEPES buffered saline 
(HBS-E-T), as running buffer. HSAgly–VC1 affinity studies were performed setting the flow rate at 
20 L min
-1
. Stock solution of VC1 1.00 mg mL
-1
 in HEPES buffered saline (pH 7.1) without 
EDTA and p-20 (HBS) was diluted in running buffer by two-fold serial dilutions from 4.00 M to 
0.016 M and injected in ascending order over the sensing surface. The contact time and the 
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dissociation time were set at 300 s and 1300 s, respectively. At the end of each injection, NaOH 
(0.05 M) was injected twice (contact time = 20 s) in order to re-establish the baseline before starting 
a new cycle. In between VC1 cycles, blank injections of running buffer were made to monitor 
baseline stability and to enable double-reference subtraction [22]. VC1–HSAgly affinity studies 
were carried out in duplicate. Data achieved were processed as described in Section 5.2.2.4. 
 
5.2.2.3 SPR-based displacement assay using chondroitin  
A 1.0 mM stock solution of chondroitin sulphate from shark cartilage (CND) (Sigma-Aldrich) was 
prepared in running buffer (HBS-E-T, pH 7.1) while VC1 stock solution, which consisted of 1.00 
mg mL
-1
 in HBS (pH 7.1), was diluted at 2 M in HBS-E-T (pH 7.1). VC1-CND mixtures at 
increasing concentrations of CND (1M, 2 M, 5 M) and constant concentration (1 M) of VC1 
were also prepared in running buffer in order to obtain final [CND]/[VC1] molar ratios equal to 0/1, 
1/1, 2/1 and 5/1.  Moreover, in order to account for possible CND direct binding to HSAgly, a CND 
solution at the highest used concentration (5 M) was also prepared in running buffer (blank 
solution). Displacement experiments were performed injecting the CND/VC1 mixtures and the 
CND blank solution over the HSAgly-sensing surface in the following experimental conditions: 
flow rate 10 L min
-1
, contact time and dissociation time 240 s and 800 s, respectively. At the end 
of each injection, NaOH (0.05 M) was injected for 20 s in order to re-establish the baseline before 
the next cycle.  
 
5.2.2.4 SPR data analysis 
The binding capacity of immobilized HSAgly was questioned injecting rac-WRF as reference 
compound. The experimentally determined Rmax, which corresponds to the maximal response (RU) 




∗ RUimmobilized ∗ stoichiometry                                                                              (7) 
Sensorgrams dataset for both rac-WRF and VC1 binding to HSAgly were processed according to 
the same protocol. Firstly, SPR responses were double corrected for responses obtained from both 
reference channel and blank injections [22]. Then, responses recorded at the steady state were 
plotted against concentration. The equilibrium dissociation constant (KD) of the ligand–HSAgly 
complex was extrapolated assuming a 1:1 isotherm binding model, as defined in Eq. (8): 
Req = (Rmax ∗ c)/(KD + c) + Rbulk                                                                                                           (8) 
 62 
where c (M) is analyte concentration, Req and Rmax  (RU) correspond to SPR responses at the 
steady state and upon ligand saturation respectively and Rbulk  refers to the response resulting from 
the bulk contribution of analyte solutions (RU). 
VC1–HSAgly binding analysis was repeated in duplicate and each dataset was independently fitted 
in the theoretical binding model. Achieved 𝐾𝐷 values were averaged and reported with the 
corresponding standard deviation (±SD).  
 
5.2.3 HSAgly–VC1 interaction studies by affinity-MS approach 
5.2.3.1 HSAgly in solution tryptic digestion. 
Trypsin stock solution (1.0 mg mL
-1
) was prepared dissolving trypsin in HCl (2 mM). The solution 
was stored at -20°C until use. A 2.0 mg mL
-1
 stock solution of HSAgly was prepared by dissolving 
the lyophilized powder in ultrapure water. Working solution was prepared by diluting HSAgly 
stock solution 0.5 mg mL
-1
 in AMBIC (pH 8.5; 0.05 M). 800 µL of HSAgly working solution were 
treated with 40 L of DTT (0.1 M, in AMBIC pH 8.5; 0.05 M) and incubated at 56 °C for 30 min, 
under gentle shaking (600 rpm). Afterwards, 40 L of freshly prepared IAA solution (10 mg mL
-1 
in AMBIC pH 8.5; 0.05 M) were added and the solution was incubated for 40 min in the dark at 
room temperature. Lastly, 8 L of trypsin stock solution were added and the sample was incubated 
overnight at 37 °C, under shaking (600 rpm). Digestion was stopped by rapidly freezing the 
solution at -80°C. In the digested samples, the final concentration of each component resulted: 
HSAgly 0.45 mg mL
-1
, DTT 4.50 mM, iodoacetamide 0.45 mg mL
-1 





HSAgly/trypsin ratio (p/p) was 45:1.  
HSAgly peptides were analyzed by 2D-LC-ESI-MSMS (Section 5.2.4.3) and were used for affinity-
MS analysis (Section 5.2.3.3). 
 
5.2.3.2 Preparation and validation of immobilized VC1 affinity column 
VC1 stock solution (1.00 mg mL
-1
 in HBS) was ultrafiltered (UF) for buffer exchanging. HBS was 
replaced with sodium bicarbonate (0.2 M) and NaCl (0.5 M) (pH 8.3) (coupling buffer). UF was 
carried out with a Varifuge 3.0 R centrifuge (Heracus Sepatech, Hanau, Germany). 150 L of VC1 
stock solution were diluted up to 500 L with the coupling buffer and submitted to UF using 
Amicon Ultra centrifugal filters membranes. Four UF cycles were performed setting 6000xg for 15 
min at 25 °C. At the end of each cycle, an aliquot of 400 L of coupling buffer was added before 
resubmitting the solution to UF.  
VC1 immobilization onto sepharose beads was carried out via amine coupling following a previous 
developed protocol [23]. Briefly, 30 mg of dry CNBr-activated sepharose beads were transferred 
 63 
into an empty spin column (Mobicol-Classic, MoBiTec GmbH, Göttingen, Germany) with a 
volume of 800 L in which a small lower filter of 35 m was inserted to avoid bead leakage. The 
beads were pre-treated with 0.5 mL of HCl (0.1M) for 15 min, under shacking (450 rpm). Beads 
were washed ten times with 0.4 mL NaOAc (pH 4.0; 0.2 M) containing NaCl (0.5 M) (washing 
buffer) and ten times with 0.4 mL of coupling buffer (pH 8.3). At the end of the washes, coupling 
buffer was drained and 127.8 L of VC1 sample, now diluted in coupling buffer at 0.88 mg mL
-1
, 
was transferred into the column and incubated with activated beads for 3 h at room temperature, 
under gentle shacking (450 rpm). The ratio (w/w) VC1/beads was chosen according to previous 
developed protocols for which 3.75 g of target ligand were added for each mg of beads [23]. A 
blank column was also prepared following the same experimental procedure (except for VC1 
addition) in order to account for non-specific interactions. After immobilization, the coupling buffer 
was drained and columns (test column and blank column) were washed ten times with 0.4 mL of 
washing buffer and ten times with 0.4 mL of blocking buffer, i.e. ethanolamine (0.2 M) and NaCl 
(0.5 M) (pH 8.3) to remove the unbound receptor. Then, an aliquot of 0.4 mL of blocking buffer 
was added and columns were incubated 3 h at room temperature, under shacking, to quench residual 
active cyanate esters. Finally, columns were washed 20 times with 0.4 mL AMBIC (pH 8.5; 0.05 
M).  
To test VC1 functionality after immobilization, the binding to HSAgly was verified. To this aim, 30 
L of a 2 mg mL
-1 
HSAgly solution in AMBIC (pH 8.5; 0.05 M), corresponding to 60 g of 
HSAgly, was added to the VC1-beads and incubated overnight at room temperature, under gentle 
shacking. The theoretical ratio (w/w) HSAgly/VC1 was 0.5. Afterwards, the supernatant was 
drained, and the column was washed 40 times with 0.4 mL of ammonium acetate (pH 7.2; 0.05 M). 
Last wash was subjected to Matrix-Assisted Lased Desorption/Ionization Mass Spectrometry 
(MALDI-TOF MS) analysis to confirm the absence of unbound protein or other contaminants. 
Finally, the bound fraction was eluted with 0.3 mL of H2O:FA (99.9:0.1 v/v). and was analyzed by 
MALDI-TOF MS as described at Section 5.2.4.1. 
 
5.2.3.3 VC1–HSAgly binding studies by epitope extraction method 
The characterization of the interaction between HSAgly and VC1-based column was studied 
following the epitope extraction method [23,24]. Briefly, the column was washed ten times with 0.4 
mL of AMBIC (pH 8.5; 0.05 M), last wash was drained. 60 g of tryptic digested HSAgly [0.45 mg 
mL
-1 
in AMBIC (pH 8.5; 0.05 M)] (Section 5.2.3.1) were transferred into the VC1 column and 
incubated overnight at room temperature, under gentle shacking (450 rpm). The tryptic 
peptides/VC1 ratio (w/w) was 0.5. After overnight incubation, the supernatant containing unbound 
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peptides was collected and the column was washed 40 times with 0.4 mL of ammonium acetate (pH 
7.2; 0.05 M). Last wash was analyzed by MALDI-TOF MS to confirm the total clearance of 
unbound peptides. Bound peptides were eluted with 0.3 mL of H2O:FA (99.9:0.1 v/v). An identical 
experiment was performed on a blank column to account for non-specific interactions with 
sepharose beads. The protocol (Fig. 17-A) was repeated in duplicate for two freshly prepared VC1 
and blank columns. All collected fractions (unbound and bound) were analyzed by HPLC-ESI-
MSMS (Section 5.2.4.4) and data were processed as described in Section 5.2.4.5. 
Elution fractions were also resubmitted to trypsin digestion (Fig. 17-B). Briefly, both fractions were 
diluted 1:2 (v/v) in AMBIC (pH 8.5; 0.5M), treated with 10 L of DTT (0.1 M) in AMBIC (pH 8.5; 
0.5 M), incubated at 56 °C for 30 min, under agitation (600 rpm), further treated with 10 L of IAA 
[10 mg mL
-1
 in AMBIC (pH 8.5; 0.5 M)] and incubated 40 min in the dark at room temperature. 
Finally, 5 L of trypsin (1 mg mL
-1
) in HCl (2 mM) were added to each sample and they were 
incubated overnight at 37°C, under shacking (rpm 600). All digested fractions collected from VC1 
and blank columns were dried at room temperature by a SpeedVac vacuum concentrator, 
resolubilized in bidistilled water and analyzed by HPLC-ESI-MSMS (5.2.4.3). Data were processed 
as described in Section 5.2.4.4.  
 
5.2.4 MS-based analysis 
5.2.4.1 MALDI-TOF MS detection 
MALDI-TOF MS analyses were performed with a Brucker Autoflex Smartbeam linear TOF mass 
spectrometer (Bruker Daltonics, Bremen, Germany) equipped with external scout fully automated 
X-Y target stage MALDI pulsed collision gas. A nitrogen UV laser (max = 337 nm) was used and 
ions were generated by 10 laser shots for 0.5–1 s at 30 V and extracted at 15 V. MS spectra were 
recorded setting 10 laser shots for each scan and accumulating 30-60 scans. Mass range was set at 
0-70 kDa m/z for the detection of intact HSAgly (Section 5.2.3.2) and at 0-7 kDa when HSAgly 
tryptic peptides were analyzed (Section 5.2.3.3). A freshly prepared 50 mg mL
-1
 SDHB solution in 
ACN:H2O:TFA (50:49.9:0.1 v/v) was used as matrix solution for the MS analysis of intact HSAgly 
while a 20 mg mL
-1
 DHB in ACN:H2O:TFA (50:49.9:0.1 v/v) was used for the analysis of the 
digested peptides. In both cases, 0.5 L of matrix solution was mixed with 0.5 L of sample 
solution. The mixture was lodged on the MALDI target plate and the drop was allowed to dry at 
room temperature. MS analyses were performed using a 20 kV acceleration voltage and 1.5 kV 
detector voltage. Spectra were processed by Bruker Daltonic flexAnalysis software 3.3.80.0 and 
corresponding evaluation program was used for mass calculation, data calibration and processing. 
Spectra were re-elaborated by mMass software (version 5.5.0). Before measurements, external 
 65 
calibration was carried out using monoisotopic masses of the singly protonated ions of human 
angiotensin I, angiotensin II, neurotensin, bradykinin, bovin insulin -chain (oxidized) and bovin 
insulin.  
 
5.2.4.2 LC-ESI-MS characterization of HSAgly 
10 µL aliquots of HSAgly dissolved at 0.1 mg mL
-1 
in bidistilled water were analyzed by LC-MS 
approach using an Agilent 1200 HPLC system (Walbronn, Germany) and a monolithic CIMac C4 
Analytical column (5 mm × 5.3 mm I.D.; pores size 1.3 m). Mobile phases A 
[water/acetonitrile/FA (99:1:0.1, v/v/v)] and B [water/acetonitrile/FA (2:98:0.1, v/v/v)] were used 
to develop a gradient as follow: 30%–70% B, 10 min; 70%–20% B, 1 min; 20% B, 1 min. The 
column was re-equilibrated with the starting conditions of analysis for 3 min before the next 
injection. Flow rate was set at 0.4 mL min
-1
 and the injection volume was 3 µL. MS analyses were 
performed on a Q-TOF Micro quadrupole time-of-flight (Q-TOF) hybrid analyzer (Micromass, 
Manchester, UK) equipped with a Z-spray electrospray ion source (ESI). Analysis parameters were 
set as follow: source temperature 120°C, capillary voltage 3.5 kV, cone voltage 45 V. The scan time 
and the interscan time were set at 2.4 s and 0.1 s, respectively. The cone gas flow was set at 120 L/h 
and the desolvation gas at 500 L/h. Mass chromatograms were recorded in total ion current (TIC) 
within 1000-1700 m/z range. The HSA baseline-subtracted spectrum (m/z 1000–1500) was 
deconvoluted onto a true mass scale using the maximum entropy (MaxEnt1)-based software 
supplied with MassLynx 4.1 software. The abundance of single isoforms was calculated as the ratio  
between their fractional intensity and the sum of the intensities of all isoforms, expressed as 
percentage. Data were analyzed by Microsoft Excel software.  
 
5.2.4.3 2D-LC-ESI-MSMS analysis of HSAgly 
A 2D chromatographic approach was used to resolve the HSAgly peptides obtained from the tryptic 
digestion. The first dimension consisted of reverse phase liquid chromatography (RP-LC) analyses 
performed on Jasco PU-1585HPLC system (Jasco Corporation, Tokyo, Japan) equipped with a 
Rheodyne 7281 injection valve (50 µL sample loop). The peptide separation was carried out by 
using a Zorbax Extend-C18 RP column (5 μm, 250 mm × 4.6 mm I.D.; column porosity 100 Å). 
Mobile phases A [water/acetonitrile (98/2) (v/v), adjusted to pH 10.0 using ammonium hydroxide] 
and B [acetonitrile/water (98/2) (v/v), adjusted to pH 10.0 using ammonium hydroxide] were used 
for gradient development. The solvent gradient was set as follow: 2%–70% B, 20 min; 70% of B, 2 
min.  The column was equilibrated for 10 min before the next injection. The analysis flow rate was 
0.5 mL min
-1
. The chromatogram was monitored at 214 nm and the eluate was collected every 2 
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min into 1.5 mL Eppendorf tubes. Samples were dried under vacuum and reconstituted in 50 μL of 
water for subsequent second dimension analyses as describe in the Section 5.2.4.4. 
 
5.2.4.4 LC-ESI-MSMS analysis 
LC-ESI-MSMS analysis was carried out by using an Agilent 1200 Series (Walbronn, Germany) 
equipped with a CO-2067 Plus Jasco column oven and a G1329A Agilent autosampler. Analyses 
were performed on Aeris Peptide XB-C18 (3.6 µm; 150 x 2.1 mm I.D.; column porosity 100 Å) at 
40 °C. Mobile phases A [water/acetonitrile/FA (99:1:0.1) (v/v)] and B [acetonitrile/water/FA 
(99:1:0.1) (v/v)] were used to develop a gradient set as follow: 0–5% B, 1 min; 5–40% B, 59 min; 
40–70% B, 5 min. Column was re-equilibrated with the starting conditions for 12 min before the 
next injection. The injection volume was 50 μL.  
MS analyses were performed on a QTOF spectrometer (Micromass, Manchester, UK) equipped 
with a Z-spray ion source. The source temperature was set at 120 °C, the desolvation temperature at 
280 °C, the capillary voltage at 3.0 kV, and the cone voltage at 35 V. 
Peptides endowed with 2, 3 and 4 charges with m/z values within 600-1900 and an intensity higher 
than 10 counts/sec were selected for fragmentation and MSMS analyses. Scan time was 1 s for the 
parent ion and 1 s for the MSMS ions. Collision energy was selected using charge state recognition.  
 
5.2.4.5 Data processing 
Raw files from LC-ESI-MSMS analyses were processed using Mascot Distiller 2.5.1.0 (Matrix 
Science, London, UK), a software program that reduces MS raw data to high-quality peak lists for 
database searching. Data bank search was performed on the human SWISSPROT database 
(2018_10; 558590 sequences; 200544181 residues; http://www.uniprot.org) allowing five missed 
cleavages. The precursor and fragment ion tolerance were 0.5 and 0.3 Da, respectively. Cysteine 
carbamidomethylation was selected as fixed modification while methionine oxidation, cysteine 





5.3 Results and discussion 
5.3.1 Characterization of HSAgly by LC-ESI MS and 2D-LC-ESI-MSMS  
The lack of a clear picture concerning AGE-HSA–RAGE interaction is partially related to AGE-
HSA heterogeneity. Indeed, the use of not well-characterized albumin-AGEs in in vitro studies 
hampers the identification of structural requirements for interaction and RAGE activation. To 
partially overcome this problem, we focused our attention on a commercially available glycated 
HSA (HSAgly), which has been recently released on the market, as possible reference compound 
for interaction studies. Based on the vendor specifications, the commercial HSAgly was produced 
by reaction with glucose as reducing sugar. Hence, it is expected to present fructosyl-lysines in its 
structure. Nevertheless, no other information is available from the supplier and the glycation extent 
as well as the specific aminoacid residues involved in glycation were unknown. For this reason, 
before studying HSAgly–VC1 interaction, the structure of the commercial product was investigated 
by both top-down and bottom-up approaches. 
At first, the glycation extent of the protein was determined by analyzing the intact protein by LC-
ESI-MS. The protein was resolved by RP chromatography. From the multicharged mass spectrum 
acquired under the HSAgly chromatographic peak, the deconvoluted ESI-MS spectrum was 
derived, enabling the evaluation of protein micro-heterogeneity. Along with the native unmodified 
protein, other modified isoforms were detected and the most abundant were the cysteinylated and 
glycated forms. Focusing on the glycated isoforms, their relative abundance was calculated, as 
reported in Fig. 12. The overall albumin glycation was found to be 51.4 %.  
 
 
Figure 12| Representative deconvoluted ESI-MS spectrum for HSAgly. The HSAgly micro-heterogeneity was 
identified by LC-ESI-MS (see Section 5.2.4.2). In addition to the native HSA, isoforms displaying cysteinylation at the 
cysteine-34 residue (HSA+ Cys), glycation with different hexose molecules (HSA + nHex), and combination of both 
(HSA+ cys + nHex) were detected. The insert table lists the glycation state along with the relative abundance (%) 
calculated for the various glycated isoforms. 
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To identify sites of glycation, a two-dimensional liquid chromatography separation coupled with 
mass spectrometry detection (2D-LC-ESI-MSMS) was employed. 2D separation prior to MSMS 
analysis facilitates the resolution of complex mixtures, offering advantages in terms of sensitivity 
[25]. This method previously proved to be suitable for the analysis of the glycated proteome 
notwithstanding the complexity of clinical samples and the low abundance of in vivo glycated 
proteins [26]. Tryptic mixture was first resolved in basic conditions, eluates were collected every 2 
min, dried under vacuum, reconstituted in water and analyzed by ESI-MSMS in acidic conditions. 
The databank search confirmed a 75 % coverage of HSAgly sequence. The 2D-LC-MSMS 
approach allowed the identification of four glycated residues: K137, K414, K525, K574 (Table 5). 
No carboxymethyl/carboxyethyl lysines (CML/CEL), which are the most abundant AGEs in vivo 
[27], were detected by 2D-LC-ESI-MSMS analysis, pointing out the early glycation state of the 
commercial product. 
 
Table 5. Tryptic peptides of HSAgly, containing glycated residues on their sequence, identified by 
2D-LC-ESI-MSMS. The corresponding observed m/z value, molecular weight (MW), retention time 
(RT) and sequence with the glycated residues involved along with Mascot search score are reported. 
Peptide Observed m/z Peptide MW tR (min) Score
a
 Sequence 
137-144 609,57 1217,13 19.48 42 K.KYLYEIAR.R + [+162.1256 at N-term] 
413-428 867.39 1801.73 24.53 50 K.KVPQVSTPTLVEVSR.N [+162.1256 at K2] 
525-534 646,19 1290,36 20.53 43 K.KQTALVELVK.H + [+162.0528 at N-term] 
574-585 652,86 1303,70 26.66 41 K.KLVAASQAALGL.+ [+162.0528 at N-term] 
a
tR stands for retention time. 
b
Score is derived from Mascot database and is based on the calculated probability, 
P, that the observed match between the experimental data and the database sequence is a random event. Score 
greatest than 35 indicates high probability of identity.  
 
Among the found glycated residues, K525, which is the most common glycated lysine residue of 
albumin both in in vitro glycation and in clinical samples, was detected [2]. In particular, clinical 
studies showed that glycation at K525 accounts for 33% of the total glycated HSA in patients with 
unstable blood glucose and that K137, K414, K574 are common glycation sites, frequently detected 
in HSA from diabetic patients [2,26,28]. The similarity between the glycation pattern observed in 
the commercial HSAgly and diabetic patients makes the former a good reference compound to 
correlate the role of early glycated albumin with RAGE activation in diabetes.  
 
5.3.2 Biosensing surface preparation and validation 
HSAgly sensing surface was prepared via amine coupling reaction. The covalent binding between 
the amine groups of lysines on the surface of target molecule and the carboxymethyl dextran layer 
is the most commonly used approach for target immobilization on sensor chips. Indeed, thanks to 
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the high stability and high surface density, this strategy has been previously exploited to investigate 
binding parameters of small molecules to HSA [29–31].  
To assess the best immobilization conditions, a pH scouting procedure was carried out by diluting 
HSAgly in several immobilization solutions at different pH. To obtain an adequate pre-
concentration of the protein over the surface, immobilization buffer requires a pH above the 
isoelectric point (pI) of the dextran layer and below pI of the protein. pH scouting evaluation 
showed that the NaOAc (pH 4.5; 0.01 M) solution granted the best conditions for immobilization, 
providing a stable, high and time-dependent pre-concentration of the protein over the surface (data 
not shown). 
For HSAgly immobilization the surface was activated by treatment with EDC/NHS mixture prior 
injection of a HSAgly solution to reach an immobilization level of 5500 RUs (Fig. 13). According 
to classic amine coupling protocol, residual active esters were quenched by flushing a solution of 
ethanolamine hydrochloride (pH 8.5; 1 M) [22] and the sensing surface was stabilized overnight in 
PBS. The overnight stabilization is required to stabilize the baseline and remove the residual 
HSAgly not covalently bound to the surface. Final immobilization level resulted 5000 RUs, 
approximatively corresponding to a surface density of 5.0 ng mm
-2
 [21].  
 
  
Figure 13| Sensorgram of HSAgly immobilization to a CM5 sensor chip. HSAgly was immobilized according to 
amine coupling procedure which involves (1) activation of the sensor surface by EDC/NHS mixture, (2) injections of a 
HSAgly solution in NaOAc (pH 4.5; 0.01 M), (3) quenching of residual activated esters by treatment with an 
ethanolamine solution. After overnight stabilization the surface density was estimated to be about 5.0 ng mm -2.  


























After covalent immobilization, the validation of the sensing surface is required to assess if the 
covalent anchorage to the surface has preserved target binding properties. To evaluate HSAgly 
functionality, rac-WRF, which is one of the mostly used markers to assess HSA binding capacity at 
binding site I [31], was used as test compound. The measured KD value (11.5 × 10
-6 
M) resulted in 
agreement with previously reported SPR analysis of the interaction of rac-WRF and HSA [31]. 
Altogether, the comparison between the experimental Rmax value with the theoretical maximal 
response and the affinity for rac-WRF confirmed that the functionality of the surface was 
maintained.  
It is worth to note that commercial HSAgly is in an early stage of glycation (see Section 5.3.1). This 
fact may explain the comparable binding capacity of HSAgly and native protein. The obtained KD 
resulted in agreement with affinity values reported by Joseph K.S et al. [32] for WRF–HSAgly  and 
WRF–HSA, quantified by high performance affinity chromatography (HPAC).  
 
5.3.3 Characterization of VC1HSAgly binding by SPR 
SPR biosensing is the gold standard method to real time monitor biorecognition phenomena. This 
highly informative technique allows easy access to affinity and kinetic data on complex 
formation/disruption [33]. Despite the great interest on RAGE–AGE interaction, a limited amount 
of SPR-based studies are available in the literature [13,14,34]. In the current work, SPR biosensor 
was used to investigate HSAgly binding to the ectodomain VC1 of RAGE. HSAgly was chosen as 
immobilized target instead of VC1 because of the lack of commercially well-characterized AGE-
albumin binders to validate the VC1-sensing surface after immobilization. Conversely, using the 
opposite system (immobilization of HSAgly) the resulting sensing surface could be validated (see 
Section 5.3.2).  
VC1 (MW= 28 kDa measured by ESI-MS) was firstly diluted in HBS-E-T at 1 M and injected 
over HSAgly sensing surface. The obtained double-reference corrected sensorgram resulted well 
discernable from background noise confirming the interaction between the two biomolecules. To 
our knowledge, this is the first time that the interaction between VC1 and this form of commercially 
glycated albumin was analyzed and, as consequence, no data are available regarding the affinity of 
the complex and the range of concentrations for VC1-HSAgly affinity studies. The higher tested 
concentration was 4.00 M, because responses recoded at higher concentrations resulted 
compromised, making unreliable the sensorgrams related to the binding event. Possible explanation 
of that may be high steric hindrance, crowding and possible aggregation at the functionalized 
surface when high concentrations were used [22].  
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VC1–HSAgly affinity analysis were carried out diluting VC1 in HBS-E-T in two-fold serial 
dilutions from 4.00M to 0.016 M. All measured interactions reached the steady-state condition 
within the selected injection and dissociation time, i.e. 300 s and 1300 s, respectively (Fig. 14-A). 
Two injections of regeneration solution (NaOH, 0.05 M) were required to re-establish the baseline 
condition. Responses recorded at equilibrium were plotted against concentration and the 
equilibrium dissociation constant (KD) was calculated applying a 1:1 binding model (Fig. 14-B) 
resulting in the averaged value of (6.05 ± 0.96) ×10
-7
 M (n= 2).  
Moreover, preliminary evaluation of association and dissociation events suggested a slow 
interaction, which required a long VC1 injection (300 s) before reaching the steady state as well as 
a long dissociation time (1300 s) to allow the disruption event.  
 
Figure 14| SPR sensorgrams and corresponding 1:1 isotherm for VC1–HSAgly interaction. A) Different VC1 
concentrations (0.016–4.00 M) were injected in ascending order over the sensing surface. Increasing concentrations 
(0.016, 0.031, 0.063, 0.125, 0.250, 0.500, 1.00, 2.00, 4.00) are denoted by different shade of blue (from light to dark). 
KD value for VC1–HSAgly complex was extrapolated by plotting the double-reference corrected responses (RUs) 
recorded at the equilibrium as function of VC1 concentration. A simple 1:1 binding model, which fitted the 
experimental data, was applied, according to Eq. (8). 
 
To our knowledge, no affinity datum is available from literature regarding the interaction of VC1 
with this form of glycated albumin. Hence, to further validate the VC1HSAgly binding, a SPR-
based displacement assay was performed using CND, a selective RAGE binder, as displacing agent. 
Affinity for the CNDRAGE interaction has been previously assessed by Mizumoto S. et al. by a 
SPR-based approach, which highlighted a KD value of (3.06  1.63) x 10
-7 
M [18,19]. On the other 
hand, CND is not a HSAgly binder, as proved by our studies. Indeed, injection of CND over the 
HSAgly-sensing surface did not result in any significant interaction. This finding makes CND a 
suitable agent for displacement studies. 
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Displacement study was carried out monitoring VC1HSAgly binding as a function of increasing 
concentrations of CND (Fig. 15). A concentration-dependent competition of CND towards HSAgly-
VC1 binding was observed, inferring a specific interaction involving overlapped binding sites. 
Indeed, solutions of [CND]/[VC1] molar ratios of 1/1, 2/1, 5/1 reduced SPR response of the 
VC1HSAgly complex recorded in the absence of CND ([CND]/[VC1] = 0/1) by 15.1 %, 31.8 %, 
66.7 %, respectively (Fig. 15). 
 
 
Figure 15| SPR-based displacement assay for the VC1HSAgly interaction. Competition assay was carried out 
injecting CND/VC1 mixtures at increasing stoichiometry molar ratios. Reference SPR response in the absence of CND 
is depicted as black line while signals recorded at increasing [CDN]/[VC1] ratios are depicted as green lines of 
decreasing shades as detailed in the graph. 
 
Results proved VC1HSAgly interaction is specific and can be hampered by a VC1 known RAGE 
binder.  
Commercial glycated albumin is an early stage glycation product as compared to AGEs and, as 
consequence, it is unrepresentative of advanced glycation end products which may form in vivo in 
severe hyperglycemia. Nevertheless, preliminary data obtained by the SPR-based assay allowed to 
make some considerations on the binding of this early stage product with VC1, thus laying the basis 
for subsequent investigations on AGE–RAGE interaction. 
 
5.3.4 HSAgly–VC1 interaction studies by affinity-MS approach 
The immobilization strategy chosen for affinity-MS approach envisaged VC1 covalent 
immobilization onto CNBr-activated sepharose beads pre-packed into a microcolumn. Moreover, 
the strategy enabled to reduce VC1 consumption, usually higher when the receptor is selected as 
analyte instead of as immobilized target. Covalent immobilization of VC1 onto CNBr-activated 























sepharose beads through amine coupling [23]  granted VC1 stability, enabling the reusability of the 
VC1-based column for multiples analyses. The effectiveness of immobilization procedure was 
confirmed by affinity-MS approach (Fig.16) [20]. 
 
 
Figure 16| Schematic representation affinity-MS approach used to test VC1 column functionality. The method 
briefly consisted of incubation of the intact HSAgly, the removal of unretained protein (or peptides) as well as washing 
steps to remove not specifically bound analytes, the disruption of the binding complex by acidic conditions, the 
collection of the bound fraction and the analysis by MALDI-TOF MS.  
 
In order to validate the VC1 column, the interaction with HSAgly was studied. In the preliminary 
set up of the method, the effectiveness of washing steps was confirmed by analyzing washings by 
MALDI-TOF MS and confirming the absence of any protein in the last wash (Fig. 17-B). In the 
optimized procedure, HSAgly was added to the VC1 column and incubated overnight, unbound 
fraction was washed and, finally, HSAgly–VC1 binding was disrupted in acidic condition. The 
eluted fraction was collected and analyzed by MALDI-TOF MS (Fig. 17-A).  
 
 
Figure 17| Comparison of MALDI-TOF MS spectra obtained by Affinity-MS approach for VC1 column 
validation. A) Elution of bound fraction was analyzed by MALDI-TOF MS and HSAgly intact protein was recorded 
(black spectrum). Monocharged ion [M+H] + = 66925.4 Da, doubly charged ion [M+2H]2+ = 33480.4 Da and triply 
charged ion [M+3H] 3+ = 22369.3 Da were detected, validating VC1 column. B) The flip spectrum (blue) corresponds to 
the analysis of the last washing step. The absence of any residual unbound protein or contaminant confirmed that 
washing protocol was efficient in removing any unbound analyte from the column before elution. 
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The detection of the intact protein in the bound fraction confirmed the binding of HSAgly with 
immobilized VC1, supporting the results achieved by SPR-based assay. Most importantly, the 
retained binding capacity of VC1 towards HSAgly confirmed that VC1 was functional after 
immobilization. A blank column was also prepared following the same procedure and was used as 





Figure 18| Schematic representation of the tailored epitope extraction method described in Section 5.2.3.3. 
Epitope extraction method was exploited to isolate tryptic peptides of HSAgly involved in the binding with VC1. A) 
Supernatant (unbound) and elution (bound) were directly analyzed by LC-ESI-MSMS. B) Supernatant (unbound) and 
elution (bound) were re-digested with trypsin before analysis by LC-ESI-MSMS.  
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Once assessed the functionality of immobilized VC1, the column could be applied to further 
studies, in particular to the determination of the protein region involved in HSAgly–VC1 
recognition. To this purpose, the so-called epitope extraction method was applied [23,35]. This 
approach has been set up to identify the epitope involved in antigen-antibody interaction. Briefly, 
the method consists of target (i.e., antibody) immobilization onto a microcolumn packed with 
sepharose beads, the incubation of the peptide mixture derived from proteolytic digestion of the 
ligand protein, the isolation of the bound peptides, their elution and the identification of the epitope 
sequence by MS analysis of the eluates [23,24,35,36]. Herein, a slightly modified set up was used to 
identify the surface region of HSAgly involved in the binding with VC1 receptor to shed light on 
protein structural requirements necessary for HSAgly–VC1 recognition.  
In Figure 18 the tailored experimental workflow for epitope extraction method is reported. In detail, 
the peptide mixture obtained by tryptic digestion of HSAgly was overnight incubated on VC1 and 
blank columns. The unbound peptides were collected and the columns were washed. Before eluting 
the bound peptides, the effectiveness of washing procedure was assessed by MALDI-TOF MS 
analysis of the last washing. Finally, the bound fraction was eluted in acidic conditions and 
analyzed by LC-ESI-MSMS. Figure 19 shows the chromatographic profile of the bound fraction 
collected from the VC1 column in comparison with the bound fraction collected from the blank 
column. The absence of significant signals in the bound fraction of the blank column highlighted 
negligible non-specific interactions between HSAgly peptides and sepharose beads. 
 
 
Figure 19| LC-ESI-MSMS total ion chromatogram of the bound fractions eluted from VC1 and blank columns.  
Bound fractions eluted from A) VC1 and B) blank column were analyzed. Retention time values are displayed on 
relative peak apexes. The peak at 42.80 min was identified as peptide [287-311]. High MW peptides, for which further 
studies were required, were eluted at higher retention time and their corresponding peaks are pointed out. Analysis 
conditions are reported in Section 5.2.4.4.  
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The LC-MSMS analysis of the bound fraction and the following MASCOT database search allowed 
the identification of only one peptide, namely peptide [287-311] eluting at 42.8 min (Table 6). The 
good score ensured the peptide identification. 
Bound fraction also contained high MW (HMW) peptides, which eluted with longer retention times, 
which were not selected from further fragmentation. The experimental set-up, indeed, involves the 
fragmentation of [M+2H]2+, [M+3H]3+ and [M+4H]4+ ions (Section 5.2.4.4) while these HMW 
peptides are characterized by a higher charge state. As example, Fig 20-A shows the multicharged 
mass spectrum acquired under the peek apex eluting at 52.77 min and the corresponding 
deconvolution spectrum (Fig. 20-B). 
 
Table 6. Characteristics of the peptide [287-313] identified by the epitope extraction method as 
interactant with VC1. Mascot search score is also reported. 
 
Peptide Observed m/z  Peptide MW tR (min) Score
a
 Sequence 
287-313 992.2 2973.33 42.7 63 K.SHCIAEVENDEMPADLPSLAADFVESK.D 
a
tR stands for retention time. 
b
Score is derived from Mascot database and is based on the calculated probability, P, 
that the observed match between the experimental data and the database sequence is a random event. Score 




Figure 20| ESI-MS analysis of high MW peptide eluted at 52.77 min and found in bound fraction. A) Multi-
charged mass spectrum, acquired on peak apex eluting at 52.77 min, and B) corresponding deconvoluted ESI-MS 
spectrum. For analyses condition see Section 5.2.4.4.  
 
In order to identify these HMW peptides, the bound fraction was re-digested to get peptides with 
lower MW and facilitated their identification by subsequent LC-ESI-MSMS analysis (Fig. 18-B). 
This approach led to the identification of a number of peptides which are summarized in Figure 21.  
Among glycated peptides identified by 2D-LC-MSMS, only the one containing K525, the most 
common lysine residue involved in glycation reaction of albumin [1], was identified in the bound 
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fraction. This suggest that this residue (and region of the protein around this region) is the most 
likely involved in the interaction with VC1.  
It should be also mentioned that tryptic digestion makes available for the interaction also peptides 
otherwise not exposed on the protein surface. This explains the identification of a number of 
peptides which are not located at the protein surface. Although they clearly cannot play a role in the 
biorecognition of VC1 when the protein if correctly folded, it cannot be excluded at this stage of the 
study that these peptides may be involved in the stabilization of the interaction between AGE-
albumins which are characterized by an extensive alteration of the native structure including 
dimerization, oligomerization and misfolding. Furthermore, interaction of VC1 with these 
embedded peptides also opens the possibility of identifying structure requirements for binding to 
VC1. 
Finally, among HSA domains, the subdomain IA is that with the higher degree of identified amino 
acid sequence (63%). This observation suggests this region may be the most likely involved in the 
interaction with VC1.  
 
 
Figure 21| Aminoacidic sequence and tridimensional structure of the HSAgly highlighting bound peptides 
identified by epitope extraction procedure. A) Aminoacidic sequence of HSAgly. The peptides identified by LC-ESI-
MSMS after the re-digestion of the bound fraction are depicted in bold (red). B) HSAgly tridimensional structure in 
which regions corresponding to peptides identified in the bound fraction are highlighted in red. The glycated peptide 
corresponding to sequence [525-534], detected in the bound fraction, is depicted in light green. Identified peptides from 
bound fraction cover 63% of aminoacidic sequence of subdomain IA.   
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5.4 Conclusions and perspectives 
In the current study we set up a multimethodological strategy to investigate the binding between the 
ectodomain of human RAGE, i.e. VC1, expressed in Pichia Pastoris by Degani et al. [15], and a 
glycated albumin recently released on the market. The interest on such ligand arises from its 
commercial availability and its similarity in terms of glycation pattern and glycation degree with the 
average glycated HSA forms found in diabetic patients. Indeed, 2D-LC-ESI-MSMS analysis 
allowed the identification of four site of glycation, among which the residue K525, i.e. the most 
commonly glycated lysine residue detected in glycated albumins both obtained by in vitro glycation 
and found in diabetic patients. 
Although HSAgly is not an advanced glycation end product, SPR-biosensing studies using a 
HSAgly-sensing surface highlighted HSAgly can interact with VC1 with a moderate affinity (KD = 
6.05x10
-7
) and with a slow association and dissociation rate. Observed interaction was confirmed to 
be specific as proved by displacement studies with a well-known RAGE binder, i.e. chondroitin. 
Application of affinity-proteomics, involving the use of a purposely developed VC1-affinity 
column and subsequent MS analysis of the retained protein or peptides, allowed further insights into 
HSAgly–VC1 biorecognition. In details, the study identified the glycated peptide [525-534], with 
glycation at residue K525, as the only glycated peptide of HSAgly able to interact with VC1. 
Furthermore, and quite interestingly, preliminary results also highlighted a possible involvement of 
the area including subdomain IA in VC1 biorecognition (63% coverage of the subdomain). This 
area does not contain glycated lysine residues. This observation, if confirmed by further studies, 
may open new considerations on a possible more complex biorecognition pattern. 
The identification of peptides normally embedded into the protein as possible interactants of VC1 
arises from the exposure of these peptides upon protein denaturation prior to tryptic digestion. 
Although interesting information on the structural requirements for VC1 binding may be obtained 
from the analysis of these peptides, they obviously cannot contribute to VC1 recognition by native 
HSAgly. Therefore, to overcome the latter limitation, further experiments, which will include 
analysis of peptides obtained from HSAgly digestion in non-denaturing conditions, will be carried 
out.  
As general consideration, the outcomes of this study showed that combination of VC1-affinity 
column for interactants isolation, HPLC-ESI-MSMS for the identification of the binding region(s) 
along with SPR technology for affinity quantification of the binding complex, may be a useful 
strategy to elucidate structural requirements for VC1 binding. In particular, the proposed approach 
may be further employed to investigate the interaction between VC1 and in vitro albumin-AGEs 
formed at different stages of glycation, including the forms more representative of diabetes 
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conditions. Finally, the availability of increasing information on biorecognition mechanisms 
involving RAGE, or its ectodomain VC1, although partial, are useful to start fulfilling the gap 
between circulating glycated species (either early glycation products or end products) and the 
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6.1 General remarks 
Cholinesterase (ChE) is a generic name for a family of enzymes implicated in the hydrolysis of the 
neurotransmitter acetylcholine (ACh) both in the central and in the peripheral nervous system. 
These serine hydrolases play a key role in the catalysis of ACh into choline and acetic acid, thus 
promoting the termination of the neurotransmission at cholinergic synapses and the restoration of 
the resting state [1] (Fig. 22).  
 
 
Figure 22 Graphical representation of biological mechanisms involved in ACh neurotransmission. After the 
synthesis of ACh in the cytosol of pre-synaptic cholinergic neurons, the neurotransmitter is incorporated into synaptic 
vesicles. Due to depolarization induced by calcium ions, ACh exocytosis releases ACh into synaptic cleft. The 
neurotransmitter can bind two different receptors, namely nicotinic and muscarinic receptor, thus promoting ACh-based 
cascade response. The role of AChE grants ACh hydrolysis with the subsequent reuptake of acetate and choline into the 
pre-synaptic neurons. Reprinted with permission from [1]. 
 
Cholinesterase includes two types of enzymes, namely acetylcholinesterase (AChE) and 
butyrylcholinesterase (BuChE), which are located ubiquitously through human body regulating 
different functions. The former, which is the most abundant enzyme belonging to this family, is 
located both in central and peripheral neurons. [2]. BuChE, also known as plasma cholinesterase, is 
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predominantly located in liver, blood plasma and central nervous system where it is associated with 
glial cells. In the nervous system, it directly acts as co-regulator of ACh levels in brain, although to 
a lesser extent compared with AChE [3]. Since ACh plays a key role in cognitive process, 
impairment of the cholinergic system is considered an important hallmark in dementia including 
Alzheimer’s disease (AD).  
AD is a progressive age-related neurological syndrome, marked by a gradual memory loss. 
Pathological hallmarks of AD include neuronal death, decrease of ACh levels with consequent 
impairment of the central cholinergic tone and accumulation of plaques in the brain (especially 
amyloid-beta aggregates).  
Inhibitors of AChE (AChEIs) represent the major class of compounds released on the market and 
approved to treat AD with the aim of increasing ACh levels by reducing AChE hydrolysis rate. 
Nevertheless, current marketed inhibitors can only temporally reduce cognitive deficits, thus 
enhancing the quality of life [4]. Recently, the possibility of hitting BuChE instead of/or 
simultaneously with AChE for the treatment of AD and related dementias has been highlighted. 
Compounds with risen selectivity for BuChE, e.g. cymserine-like molecules, or dual inhibitors 
towards both ChEs, e.g. rivastigmine, revealed potential beneficial effects in AD treatment and 
related dementias. Therefore, efforts in the design of new dual inhibitors towards AChE and BuChE 
are increasing with the purpose of developing new and more efficient treatment options [3].  
Despite the continuous progress in the comprehension of the multiple networks involved in AD, this 
form of dementia represents one of the major public health concerns [5]. Indeed, the increasing 
number of patients and the lack of effective treatment for cure challenge medicinal chemists to 
design new chemical scaffolds. Several hypotheses have been suggested to rationalize clinical 
failure. Among these, the multifactorial nature of AD along with the various molecular targets 
involved have been proposed as reasons for clinical withdrawn of drug candidates [6]. This 
knowledge has laid the foundation of a novel design strategy, the so-called multi-target-directed 
ligands (MTDLs). This rational strategy aims to synthesize heterogeneous class of compounds 
which are able to simultaneously target more than a single molecular target in the pursuit of the 
development of new molecules endowed with better pharmacological effect [7–9]. Advantages in 
using multipotent drugs with respect to the administration of a combination of drugs are also 
ascribed to the decrease of drug–drug interactions and the simplification of ADMET studies.  
In this scenario, continuous efforts in developing chemical entities are paralleled by the efforts in 
developing analytical strategies able to better assess drug–target interaction. Concerning the 
identification of new ChE inhibitor in the early phase of the drug discovery process, in solution 
assays to assess the half-maximal inhibitory concentration (IC50) and the binding mode (reversible 
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or pseudo-irreversible; competitive, non-competitive or mixed type) are the most common 
approaches [10]. In particular, IC50 is the classical parameter which is quantified to rank inhibitors 
during first screening and SAR studies. Recently, the interest in the development of highly-
informative screening methodology is rising. In particular the availability of robust methodologies 
which can provide kinetic information on drug binding events, thus providing additional 
information which may better predict the in vivo duration of action may help the correct 
prioritization of favorite chemical scaffolds to be further developed, thus reducing the attrition rate 
in the first phased of the drug discovery process.  
 
6.2 Structure and catalytic function of AChE  
The main biological function of AChE is the termination of impulse transmission by the rapid 
hydrolysis of ACh (into choline and acetate) at cholinergic synapses (Fig. 23). In physiological 
conditions, its role as serine hydrolase is marked by highly significant activity, getting closer to the 
limit of diffusion-controlled reaction. Indeed, almost 25000 molecules of ACh neurotransmitter are 
hydrolyzed per second by each enzyme [11]. 
AChE secondary structure is formed by 14  helices which centrally encircle 12 stuck parallel and 
antiparallel  sheets, thus conferring to the molecule a ellipsoid-like form [12]. Typical feature of 
AChE structure is a narrow and ~20 Å deep gorge which extends for half the enzyme length and 
widens near the base. The wall of the gorge is lined by 14 aromatic residues, highly conserved 
across the species [12].  
Early kinetic studies showed that AChE active site is formed by two main subsites, namely esteratic 
and anionic subsites. The esteratic subsite acts as catalytic machinery and contains three amino 
acids which forms the so-called catalytic triad: serine at position 200 (Ser200), histidine at position 
440 (His440) and glutamate at position 327 (Glu327) of AChE backbone (the amino acid 
numbering in this section, if not otherwise specified, refers to AChE from Torpedo californica, as 
first form of AChE to have been crystallized) [13]. Corresponding amino acids forming the catalytic 
triad in human AChE are Ser203, His447 and Glu334 [14].  
Substrate hydrolysis starts with the nucleophilic substitution promoted by the serine residue towards 
the ACh carbonyl group, forming the so-called tetrahedral intermediate which has the oxygen of the 
carbonyl group of the neurotransmitter negatively charged. This intermediate further undergoes the 
breakup between acetyl- and choline moieties, thus resulting in the release of choline. Finally, the 
hydrolysis of the acyl-based intermediate with AChE grants the displacement of acetic acid, thus 
restoring the resting state of AChE (Fig. 23). The proximity of His440 increases the nucleophilicity 
of serine residue, thus enhancing the reaction. Instead, Glu327 grants the stabilization of the 
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transition through hydrogen bond. Similarly, His440 favors the nucleophilic attack by water 
molecule due to its acid-base catalyst function (Fig. 23) [15,16].  
 
 
Figure 23 Mechanism of ACh degradation promoted by the so-called catalytic triad. Reprinted with permission 
from [4].  
 
The anionic subsite, also known as choline-binding pocket, is an uncharged lipophilic portion able 
to interact with choline via the charged quaternary nitrogen moiety. Among amino acidic residues 
which constitute this site, tryptophan at position 84 (Trp84) plays a key role in the choline binding. 
Experimental evidence has also proved that its replacement with an alanine residue decreases the 
activity rate of more than three thousand times [17–19]. Moreover, the permanent dipole displayed 
by AChE is aligned with the active-site gorge, suggesting that the electrostatic field facilitates the 
substrate guidance down the aromatic gorge to the active site [20]. This mechanism may also 
explain the fast interaction between AChE and cationic molecules.  
In addition to the catalytic center, AChE holds an additional binding site, the so-called peripheral 
anionic site  (PAS) [21]. PAS is involved in the binding with ACh as well as with other ligands 
which can modulate AChE activity in an allosteric way. Binding of the natural substrate (at high 
concentration) to PAS also determine AChE activity inhibition [22,23]. 
ACh substrate is larger than the narrowest part of gorge. For this reason, fluctuations of gorge wall 
are required to allow substrate guidance down this portion and subsequent interaction with the 
active site. Since the early 1990s, molecular dynamics simulations and X-ray crystallography 
studies indicated the presence of the so-called backdoor, a channel located at the thin part of the 
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gorge, adjacent to the active site, probably involved in the transit of substrate, solvent and products 
by its constant fluctuation between opening and shutting state. This evidence may explain the high 
turnover of AChE [24–26].  
Despite AChE is encoded from a single gene, it exists in several polymorphism of quaternary 
structures as consequence of different mRNA splicing and diverse subunits combination. Catalytic 
subunits, which can also differ in glycosylation extent, can oligomerize thus forming dimmer- or 
tetramer-based globular structures, namely G1, G2 and G4. These structures can be further divided 
depending on their amphiphilicity [27,28]. In the brain of healthy subjects, the G4 quaternary 
structure is the most abundant. However, in elderly people and especially AD patients, G4 form 
progressively decreases while G1 form seems to have growing importance both in ACh hydrolysis 
at cholinergic neurons and disease progression [29]. 
 
6.3 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most frequent form of neurodegenerative disorder. This incurable 
age-related dementia is usually diagnosed in people over 65 years of age even if, in case of early-
onset AD, it arises much earlier [30]. Due to aging increase in the world population, AD is 
becoming significantly much more common. It is estimated that in 2050 AD will affect 1 in every 
85 people [5].  
Since its discovery, three main hallmarks have been underlined: (i) the neurodegeneration of the 
central nervous system which particularly affects the cholinergic tone, (ii) the extracellular deposits 
of protein aggregates of human beta-amyloid (Aβ) peptides, i.e. senile plaques, (iii) the intracellular 
formation of protein deposits, i.e. neurofibrillary tangles. Over the years, different theories have 
been postulated, e.g. the amyloid cascade hypothesis, the cholinergic hypothesis and the 
hyperphosphorylation hypothesis [31–34]. Recently, the understanding that not only a single theory 
but combinations of multifactorial events contribute in disease etiology is widely accepted. Indeed, 
many factors are thought to play a role in the pathogenesis of the disease including inflammation, 
overproduction of free radicals induced by oxidative stress, mitochondrial failure, metal 
dyshomeostasis, cholesterol-based lipid rafts [35]. The consciousness that further potential targets 
are engaged in the progression of AD shows that polypharmacological treatment is likely a more 
promising strategy to be pursued for drug research. Nowadays, only palliative drugs aimed at 
alleviating AD symptoms and countering memory loss have been released on the market. 
Nevertheless, drug development for AD therapies is steadily increasing and several potential 




Figure 24 Chemical compounds in clinical trials for AD therapy in 2018. Currently 112 agents are under 
investigation in clinical trials: 26 agents in phase III, 65 agents in phase II, 23 agents in phase I. Reprinted with 
permission from [5].  
 
6.3.1 AD treatment: targeting AChE 
In terms of clinical therapy, the rational design which has so far generated the majority of drugs 
released on the market is based on the cholinergic hypothesis, postulated over 20 years ago [32]. 
The hypothesis is based on the evidence that AD patients, compared with healthy elderly subjects, 
have a significant decrease of the enzyme responsible for ACh synthesis, namely choline 
acetyltransferase (ChAT) and of the corresponding neurotransmitter. Indeed, these reductions have 
been observed in AD brain, especially in the cholinergic forebrain area and their projections to the 
cerebral cortex, as a result of a significant loss of cholinergic neurons [36]. Coupled with the latter, 
a decrease of AChE levels, in particular the G4 form, occurs and it is partially due to the overall 
loss of cholinergic activity. The formation of plaques and tangles as well as the progression of the 
disease correlate with these losses [37]. Moreover, it has been reported that AChE may act as 
molecular chaperone promoting the aggregation of beta-amyloid (A peptides. In particular, the 
recognition site for A seems to be PAS [38,39]. Although the cholinergic impairment only 
partially accounts for some clinical aspects of the pathology, cholinergic hypothesis has promoted 
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the research and the development of drugs targeting the cholinergic system. In this scenario, 
compounds which target muscarinic or nicotinic receptors as well as compounds which indirectly 
increase ACh levels in the synaptic cleft by inhibiting the activity of AChE have been widely 
studied and are still under investigation [1].  
Inhibitors of AChE (AChEIs) were the first class of drugs successfully released on the market for 
treating AD symptoms (Fig. 25). Currently, four AChEIs have been approved by the U.S. Food and 
Drug Administration (FDA) for pharmacologic therapy, namely tacrine, donepezil, rivastigmine and 
galantamine [4]. All these inhibitors are involved in the centrally inhibition of AChE, thus 
increasing ACh availability in the brain. From a symptomatic point of view, they can temporally 
improve memory and cognitive performance in subjects with mild to moderate AD, enhancing their 
quality of life. Despite they belong to the same drug class, i.e. inhibitors of AChE, they differ in 
many aspects, from adverse effects to inhibition modes (reversible or pseudo-irreversible; 
competitive, non-competitive or mixed type). A different pharmacological response induced by 
these inhibitors is usually observed across AD patients, thus requiring case-by-case custom dosing 
and treatment.  
 
 
Figure 25 Chemical structures of AChE inhibitors approved for AD treatment.  
 
Tacrine (Fig. 25) is a reversible inhibitor towards both AChE and BuChE. Tacrine hydrochloride 
(Cognex
®
, Park-Davis) was the first drug approved (in 1993) for treating AD. Nowadays, its 
administration has been abandoned due to hepatotoxicity (~50 % of patients) and gastrointestinal 
side effects [40]. Nevertheless, tacrine has been employed as reference compound in the 
development of further AChEIs and many tacrine analogues are involved in preclinical and clinical 
trials [41]. In recent years, tacrine-based structures are also used in the rational design of hybrids 




, Eisai-Pfizer) was the second marketed drug for treating AD. 
Donepezil (Fig. 25) is a reversible inhibitor highly selective for AChE beyond BuChE: indeed, the 
affinity to the former target is almost one thousand greater. This inhibitor binds both the catalytic 
and the peripheral anionic site exerting a mixed type inhibition towards AChE. Moreover, it seems 
involved in the delaying of amyloid plaques accumulation [45,46]. Although donepezil is usually 
prescribed to patients with mild/moderate AD, clinical evidence has shown that it can ameliorate 
cognition also in patients affected by severe AD [47]. Donepezil has long duration of action and a 
long half-life time (~70 h), thus allowing once-daily dose. Side effects are much less severe 
compared to tacrine and include nausea, diarrhea, abdominal pain and bradycardia [4]. Currently, 
the drug is on the market as oral tablets (5 or 10 mg) and transdermal patches [48]. For a long time, 
donepezil has been the most administered drug for AD treatment. Nowadays, the treatment with 
other FDA-approved drugs is growing. Moreover, donepezil-based hybrids have been recently 
developed according to the MTDLs approach [49,50]. An example is also presented in chapter 8.  
Rivastigmine (Exelon
®
, Novartis) is a pseudo-irreversible inhibitor, acting at the central nervous 
system, that displays activity towards both AChE and BuChE (Fig. 25). In particular, the inhibition 
of central BuChE is thought to contribute the efficacy of AD treatment [51]. Interestingly, it 
exhibits selectivity for the G1 form versus G4 of both ChE. Rivastigmine belongs to carbamate-
based AChEI class of inhibitors. The inhibition mode consists of the carbamoylation of Ser200 
within the catalytic triad [4] leading to the formation of a carbamoylated adduct. Although covalent, 
inhibition by rivastigmine is reversible, owning a short half-life time (~1.5 h) [52]. Its efficiency is 
comparable with that of donepezil even if it results less tolerated when administered at high doses 
[51]. Adverse reactions are typically those common for all cholinergic drugs such as diarrhea, 
nausea, anorexia. Rivastigmine is marketed in oral formulations or transdermal patches [53]. The 
administration regimen requires a gradual dosing increase: usually from 1.5 mg twice a day to 6.0 
mg twice a day in case of severe AD. A remarkable feature is its different metabolism, which is not 
relied on hepatic isoenzymes, but granted by cholinesterase hydrolysis. As consequence, in case of 
liver or kidney failure, no adjustment of the dosing is required. Furthermore, rivastigmine 
constitutes one of the pharmacologic approaches for Parkinson’s disease and Lewy bodies [51].  
Galantamine (Reminyl
®
, Janssen) is a natural compound isolated from Galanthus woronowii plant 
(Fig. 25). It is a tertiary alkaloid able to interact with both the anionic subsite and the aromatic 
residues along the gorge, resulting in a reversible competition, selective for AChE [54]. 
Galantamine is proposed for treating mild to moderate AD. Besides, this inhibitor acts as allosteric 
modulator for nicotinic receptors of cholinergic neurons. Indeed, it binds a different site compared 
to those of ACh and nicotinic agonists, enhancing the activity of nicotinic receptors when ACh is 
 91 
bound. This dual mechanism grants additional benefits for AD treatment since a loss of nicotinic 
receptors also occurs in severe AD [55]. Galantamine shows about ~8h of half-life time in plasma 
and high bioavailability. It is administered twice/day and the treatment usually starts from 4 mg up 
to 12 mg. The positive symptomatic effects in terms of cognition, memory and behavior seem to be 
retained for 3-6 months. Instead, adverse effects include gastrointestinal symptoms [55].  
Besides these ChE inhibitors, it is worth mentioning that also a non-competitive antagonist for N-
methyl-D-aspartate receptor (NMDA), namely memantine, was approved by FDA for treating 
moderate to severe AD [56].  
Despite it is not related to the aim of the present dissertation, it is worth mentioning that other 
design strategies based on cholinergic hypothesis have been explored to overcome clinical failure. 
In particular agonists for M1 muscarinic and nicotinic receptors, located on membranes of post-
synaptic neurons, along with antagonists for M2 receptors, located on membranes of pre-synaptic 
neurons have been widely investigated. The rationale relies on the importance of finding other 
strategies to enhance cholinergic tone, by prolonging receptors activation in the former case or, in 
the latter, by increasing synaptic levels of ACh [57,58]. Indeed, AChE inhibition grants the 
prolonging of ACh life-time, only for a short period [1]. Furthermore, attempts to promote ACh 
synthesis have been achieved by dosing ACh precursors, e.g. choline [59]. Despite many limits 
have been reported so far for all these compounds, such as low bioavailability, limited efficacy and 
several side effects, the pursuit of non-inhibitor AChE molecules constitutes an important area of 
investigation.  
 
6.3.2 AD treatment: the role of BuChE 
Butyrylcholinesterase (BuChE) is the sister enzyme of AChE, with whom shares 65% of homology. 
It is a non-specific cholinesterase able to hydrolyze different choline esters besides ACh. Moreover, 
compared to AChE it has different topology in terms of kinetic, location and activity. It 
ubiquitously exists throughout the human body even if it is predominantly situated in human liver, 
pancreas, blood and central nervous system. In the brain it is mainly detected in glial and 
endothelial cells [3,60]. It is able to catalyze butyrylcholine faster compared to ACh substrate, 
hence the name. Currently, BuChE role still remains unclear since butyrylcholine is not a 
physiological constituent of the brain and since subjects which have a silent form of this enzyme 
show analogues functions compared to healthy people.  
In healthy people the 90% of ACh hydrolysis depends on the activity of AChE, mainly located in 
neurons. BuChE has a lower concentration than AChE also displaying a more restricted distribution 
in the central nervous system. Nevertheless, it has been shown that the 10-15% from all cholinergic 
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neurons in amygdala and hippocampus contain BuChE instead of AChE as synaptic enzyme 
involved in ACh metabolism. BuChE has proved to compensate AChE functions in case of AChE 
failures. In particular, it shows a remarkable activity at high substrate concentrations, interesting 
fact since these two ChEs have different kinetic responses as function of ACh concentrations. 
Indeed, AChE decreases its efficiency in case of neurotransmitter excess, while BuChE becomes 
highly efficient, thus supporting AChE activity. Similar to its ‘‘sister’’, BuChE exists in different 
isoforms and, among them, the G4 form is the most abundant in the brain of healthy people whereas 
the G1 form becomes more important in AD [61].  
Owing to its low expression in the central nervous system, the importance of central BuChE has not 
been considered at first. However, different studies confirmed its remarkable role in the brain, in 
particular regarding the co-regulation of ACh levels in AD. Indeed, if the abundance ratio of 
BuChE to AChE is almost 0.3 in normal conditions, in the case of AD this value increases to 11 in 
cortical areas [60]. With AD progression, AChE activity is reduced of almost 55%–65%. In these 
conditions, ACh hydrolysis is almost exclusively carried out by BuChE which becomes of 
functional importance. The alteration in AChE/BuChE ratio affects ACh metabolism, thus 
contributing to cholinergic failure [60]. The association of BuChE to AD has been investigated in 
several ethnic groups. Outcomes of these studies have underlined how this enzyme may promote 
the risk of late-AD onset, both alone or in synergic association with a variant form (i.e. K variant), 
in particular in humans who carry the apolipoprotein E4 allele (ApoE4) [62,63]. Moreover, BuChE 
co-localizes with amyloid plaques, dystrophic neurons and neurofibrillary tangles, which constitute 
the main hallmarks of AD. Moreover, studies carried out comparing the brains (temporal cortex) of 
demented and normal subjects demonstrated that Apeptides found in patients had a BuChE-based 
reactivity 6 times higher compared to non-demented individuals [64]. However, controversial in 
vitro and in vivo studies have been reported regarding BuChE role in promoting or inhibiting 
amyloid fibril formations [65]. 
Due to BuChE central activity in the hydrolysis of ACh as well as its involvement in the disorder 
progression, this enzyme has been proposed as a viable therapeutic target for treating AD. In 
particular, according to cholinergic hypothesis, inhibitors of BuChE should prolong ACh activity at 
synaptic clefs, thus ameliorating AD-related symptoms, with particular beneficial effect in patients 
with moderate-to-severe forms of AD-type dementia [66]. Among drugs approved by FDA for AD 
treatment, already discussed in the previous paragraph, rivastigmine acts as dual inhibitor for both 
ChEs. Moreover, its inhibition role towards BuChE seems to have an additional role in protecting 
the formation of A plaques [51]. As consequence, the clinical therapy with rivastigmine provides 
long-term symptomatic effects in the treatment of subjects with AD-related dementia.  
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In this scenario, various selective BuChE inhibitors have been recently developed as potential 
candidates for AD treatment [65]. Nevertheless, the interest in designing selective inhibitors for 
BuChE seem a viable and promising strategy. 
 
6.3.3 AD treatment: multi-target-directed ligands (MTDLs) 
Over the years, the accumulating insights into the pathogenesis and the progression of AD have 
highlighted the multifactorial nature of this disorder, promoted by several elements such as genetic, 
environmental and endogenous factors. The multiple etiologies include protein misfolding and 
aggregation, formation of free radicals induced by oxidative stress, neuroinflammatory processes, 
mitochondrial anomalies, cholesterol-based lipid rafts, calcium dyshomeostasis [35]. The 
complexity of the picture has been proposed as one of the possible reasons why the currently 
available drugs have turned out to be palliative instead of healing. In this scenario, alongside drug 
development focuses on agents able to specifically counteract amyloid and tau aggregation, a 
rational approach based on the ‘‘one molecule multiple targets’’ concept has increasingly attracted 
the attention of medicinal chemists. The rational design to obtaining ligands towards multiple 
targets, is usually based on the synthesis of new compounds by combining distinct known 
pharmacophores selective for different targets. This approach, which should lead to the 
identification of the so-called multi-target-directed ligands (MTDLs), can be considered closely 
related to the known multiple-medication therapy (MMT), well-accepted in clinical [67]. Indeed, 
the use of MMT to treat AD, i.e. memantine (NMDA antagonist) in combination with AChEI, has 
already shown additional benefits with respect to the use of single drugs, ameliorating tolerance and 
effectiveness of the treatment [68]. MTDLs strategy may thus provide advantages over the MMT 
approach. Indeed, the administration of a single drug, which possesses multiple biological 
properties, may limit drug–drug interaction, facilitate ADMET studies and simplify therapeutic 
regimen.  
In this scenario, MTDLs have emerged as an intriguing drug discovery avenue to treat AD and 
several MTDLs have been recently developed [69]. So far, the most common strategy has been 
based on the synthesis of compounds endowed with inhibitory potency towards ChE in combination 
with different activities towards one of the multiple targets involved in AD etiology.  
In the MTDLs rational design context, the first strategy has been focused on the synthesis of the so-
called dual binding sites AChEIs, aimed at simultaneously interacting with AChE catalytic and the 
peripheral site [69]. These AChEIs might mitigate cognitive impairment by restoring cholinergic 
activity and, most importantly, might reduce A aggregation, important mechanism involved in 
AD, through the interaction with PAS. In this class of compounds, AP2238 was the first developed 
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dual inhibitor towards AChE which successfully displayed inhibitory potency along with the 
capacity of countering Aprotein misfolding and aggregation [70]. Since then, a variety of dual 
inhibitors has been synthesized [69]. Nevertheless, it is worth to remark that compound capacity to 
bind both CAS and PAS is a not sufficient condition to call them MTDLs. Dual site inhibitors, 
however, can be considered MTDLs if their peripheral binding allows slowing and countering A 
assembly.  
Thenceforth, hybrids able to simultaneously interact with different targets involved in AD etiology 
have been developed. Among these, active molecules towards other neurotransmitter systems, 
besides the cholinergic one, have been considered. Indeed, the neuropsychiatric abnormalities 
observed in AD patients are not related only to the huge loss of cholinergic neurons but also to 
impairment in the serotoninergic, noradrenergic and glutamatergic systems. For instance, AD-
related serotoninergic failures steam from raphe atrophy and lead to depression and psychosis. AD-
related noradrenergic failures is related to locus ceruleus atrophy and lead to depression [71,72]. In 
this context, rational design strategies aiming at combining inhibitors of AChE with: (i) inhibitors 
of monoamine oxidase (MAO), namely dual AChE/MAO inhibitors, (ii) inhibitors of serotonin 
transporter (SERT), i.e. AChE/SERT, (iii) agonists or antagonists exerting a modulation on the 
serotoninergic or histaminergic pathways, have been widely investigated [73]. 
Another widely investigated class of MTDLs is constituted by multifunctional compounds endowed 
with anti-AChE activity and antioxidant properties. Indeed, molecules able to contrast oxidative 
damage and, in the meantime, enhance cholinergic tone have emerged as promising multipotent 
compounds [74]. An example of donepezil-lipoic acid hybrids is presented in chapter 8.  
One of the major class of MTDLs designed for AD treatment is represented by AChEIs endowed 
with the capacity of regulating calcium homeostasis. Indeed, since the connection between calcium 
dyshomeostasis and AD etiology is well-supported [75], different AChE inhibitors also possessing 
a moderate ability to block calcium channels have been developed [73]. An example of hybrids 
synthetized with this dual goal is presented in chapter 9.  
However, the mentioned class of multifunctional compounds only account for a small part of all 
MTDLs strategies investigated over recent years. Indeed, it is worth to mention that several other 
MTDLs designed to hit different targets such as amyloid peptide production and aggregation, tau 
hyperphosphorylation and aggregation, metal dyshomeostasis, neuroinflammation and 
mitochondrial disfunction have been developed. Further details can be retrieved in some recent 
reviews [69,73,76,77].  
Regardless of the rationale which promotes design strategies, synthesis of new lead compounds 
requires, in parallel, the development of analytical methods to assess drug–target interaction. To 
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rank AChE/BuChE inhibitors, definition of the inhibitory potency by classic in solution assay 
(Ellman’s assay)  [78] is the mostly used approach. Recently, accessing kinetic information on drug 
binding events at initial stages of the drug discovery process is gaining increasing interest among 
pharmaceutical chemists. The possibility of counting on additional information which may better 
predict the in vivo duration of action (e.g. kinetic constants and residence time), indeed, facilitates 
the prioritization process and the selection of favorite chemical scaffolds. 
With this regard, following chapters include different studies carried out during my PhD program 
and based on the characterization of different AChE/BuChE inhibitors. In particular, classical in 
solution assay and a developed SPR-based assay, which proved to be a suitable approach for nicely 
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Combination of human acetylcholinesterase and serum albumin 
sensing surfaces as highly informative analytical tool for inhibitor 
screening  
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In the continuous research for potential drug lead candidates, the availability of highly informative 
screening methodologies may constitute a decisive element in the selection of best-in-class 
compounds. In the present study, a surface plasmon resonance (SPR)-based assay was developed 
and employed to investigate interactions between human recombinant AChE (hAChE) and four 
known ligands: galantamine, tacrine, donepezil and edrophonium. To this aim, a sensor chip was 
functionalized with hAChE using mild immobilization conditions to best preserve enzyme integrity. 
Binding affinities and, for the first time, kinetic rate constants for all drug–hAChE complexes 
formation/disruption were determined. Inhibitors were classified in two groups: slow-reversible and 
fast-reversible binders according to respective target residence time. Combining data obtained on 
drug–target residence time with data obtained on serum albumin binding levels, a good correlation 
with potency, plasma protein binding in vivo, and administration regimen was found. The outcomes 
of this work demonstrated that the developed SPR-based assay is suitable for the screening, the 
binding affinity ranking and the kinetic evaluation of hAChE inhibitors. The method proposed 
ensures a simpler and cost-effective assay to quantify kinetic rate constants for inhibitor–hAChE 
interaction as compared with other proposed and published methods. Eventually, the determination 
of residence time in combination with preliminary ADME studies might constitute a better tool to 
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7.1 Introduction 
Acetylcholinesterase (AChE) is the most abundant cholinesterase in the human body. Via fast 
hydrolysis of the neurotransmitter acetylcholine (ACh), it plays a crucial role in terminating 
cholinergic neurotransmission both in the central and in the peripheral nervous system [2]. Since 
ACh is directly involved in cognitive processes, alteration of cholinergic system is encountered as 
upstream or downstream hallmark in many neurodegenerative disorders, including Alzheimer’s 
disease (AD), a progressive age-related pathology characterized by a progressive memory loss 
which parallels a decrease of the central cholinergic tone, neuronal death and deposition of 
aggregated proteins inside and outside neurons [3]. Thus, according to the cholinergic hypothesis 
inhibition of centrally active AChE has been studied as the first avenue to contrast cognitive 
impairment [4].  
AChE inhibitors (AChEI) constitute the largest class of marketed drugs approved for AD treatment 
and are one of the largest neurological drug class in terms of overall retail spending in several West 
Countries [5]. Although current marketed drugs mainly exert a symptomatic effect [6], numerous 
new inhibitors, which combine primary anti-cholinesterase activity with a secondary 
pharmacological activity (inhibition of amyloid peptide aggregation) are under investigation to find 
effective disease-modifying agents [7]. Besides application in AD, peripherally active AChEI are 
used to increase neuromuscular transmission in the treatment of myasthenia gravis. Quaternary-
ammonium derivatives such as pyridostigmine and neostigmine are orally administered to 
ameliorate muscular weakness while edrophonium, a short acting AChEI, is used as diagnostic tool 
[8].  
In vitro drug efficacy is classically quantified in terms of equilibrium dissociation constant (KD) and 
half-maximal inhibitory concentration (IC50); parameters usually determined in closed systems with 
invariant concentrations of both ligand and target. However, in living organisms, the target is 
exposed to continuous fluctuation of ligand concentration, and pharmacological effects are rather 
dependent on the stability of complexes that the drug forms with primary and secondary targets 
along with its metabolic stability and serum protein binding [9,10]. In this scenario, characterization 
of binding mechanisms and determination of kinetic parameters are key elements. Especially, 
quantification of dissociation rate constant (koff) for drug–target complexes allows to estimate 
residence time (τ = 1/koff), which has recently emerged as critical feature of many best-in-class 
compounds [11]. τ has been proposed as a better means to correlate in vitro affinities to in vivo 
activities with respect to classical approach [9]. Therefore, accessing kinetic information on drug 
binding events at initial stages of the drug discovery process is gaining increasing interest among 
medicinal chemists [12]. 
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Among methods used for kinetic evaluations, surface plasmon resonance (SPR) biosensing has now 
assumed a central role. Fast, high-throughput and highly-informative assays can be developed to 
monitor interaction between unlabeled interactants in real-time [13]. When SPR biosensing assays 
are properly designed and trained operators are on the task, technology can be used at many stages 
of the drug discovery route, from fragment-based screening campaigns to hit-to-lead optimization 
[14,15].  
Considering the huge amount of research conducted in the AD field, kinetic studies on inhibitor–
AChE interaction are quite scarce and overlooked. Limited examples presented in the literature 
employ AChE from mouse [16] or Torpedo Californica [17] because of the high cost of the human 
recombinant isoform; however, species-related differences in bindings are well known and such 
studies are of limited applicability. Moreover, other proposed methods exploit web tools and 
mathematical treatment of enzymes kinetic to obtain indirect quantification of molecular binding 
events [18].  
In the present study, human recombinant AChE was for the first time tethered to a commercially-
available sensing surface and the SPR-based assay was exploited to measure kinetic rate constants 
of binding events with the marketed reversible AD drugs donepezil, galantamine and tacrine. 
Former two are rapidly reversible drugs approved by the U.S. Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA); while the latter was the first AChEI approved 
for AD treatment now withdrawn from the market [19–21]. To enlarge the screening window 
edrophonium, a peripherally active competitive AChEI characterized by an inhibitory potency in 
the micromolar range and fragment-like molecular weight (166 g/mol) was also considered. 
Compounds were selected to span inhibitory potencies over three orders of magnitude and differ in 
their mode of action (competitive and mixed type inhibitors) to ensure a case-insensitive evaluation 
system. Binding affinities, determined by SPR approach, were compared with IC50 values 
determined by classical in solution assay (Ellman’s assay) [22]. Additionally, taking advantage of a 
fast and previously validated screening methodology, SPR platform was employed to estimate 
binding affinity toward human serum albumin (HSA) for the selected inhibitors. HSA constitutes 
approximately 50 % of total serum protein content and markedly influences the pharmacokinetic 
(PK) profile of a compound entering human body [23]. The small time consumed to asses this 
parameter might be rewarding in the further stages of the drug development process, where poor PK 
still constitutes an important attrition factor [23–26]  
The method proposed here has the advantage of accessing kinetic parameters of AChEI–AChE 
interactions quickly and easily with respect to other proposed strategies. Moreover, the screening 
methods can be implemented at early stages of drug discovery where, traditionally, only inhibition 
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potency is determined. Outcomes from this study aim to constitute a proof of concept of the high 
information content achieved when target-based and HSA-based SPR-biosensing assays are 
combined.  
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7.2 Experimental section 
7.2.1 Materials 
Human recombinant acetylcholinesterase (hAChE) (EC 3.1.1.7) lyophilized powder, fatty-acid free 
human serum albumin (HSA) A3782 lyophilized powder, S-acetylthiocholine iodide (ACTh), 5,5’-
dithio-bis(2-nitrobenzoic acid) (DTNB; Ellman’s reagent), tacrine hydrochloride, donepezil 
hydrochloride, edrophonium chloride, (S)-warfarin and Triton X-100 were purchased from Sigma-
Aldrich (Milan, Italy). Galantamine hydrobromide was obtained from Tocris Cookson (UK). 
Research-grade CM5 sensor chip, N-ethyl-N-(3-dimethylaminopropyl)-carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) were purchased from GE Healthcare Bio-Sciences (Uppsala, Sweden). 
N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), ethylenediaminetetraacetic acid 
(EDTA), sodium chloride, potassium dihydrogenphosphate, dipotassium hydrogenphosphate 
trihydrate, polyoxyethylenesorbitan monolaurate (p-20), Tris(hydroxymethyl)aminomethane 
(TRIS), sodium acetate were also purchased from Sigma-Aldrich (Milan, Italy). Deionized water 
was obtained by Milli-Q system (Millipore, Milford, MA, USA). All solutions were filtered with 
0.22 µm membrane filters (Millipore, Milford, MA, USA) before use. 
 
7.2.2 Buffer preparation 
For enzymatic activity assay, potassium phosphate buffer (0.1M, pH 8.0)—PB was employed. 
Running buffer used for hAChE immobilization had the following composition: HEPES (0.01M) 
NaCl (0.15 M) EDTA (0.003 M) (pH 7.4)—HBS. Running buffer used to study inhibitor–hAChE 
interactions had the following composition: KH2PO4 (0.1M) K2HPO4 (0.1M) with the addition of p-
20 0.025% (v/v) (pH 8.0)—PB-T. For HSA immobilization and inhibitors binding analysis the 
following buffer was employed: Na2HPO4 (3.2 mM) KH2PO4 (0.5 mM) KCl (1.3 mM) NaCl (135 
mM) with 0.05% (v/v) p-20 (pH 7.4)—PBS-T.  
 
7.2.3 Sample preparation 
hAChE stock solution was prepared dissolving hAChE lyophilized powder in PB (pH 8.0; 0.1 M) 
with the addition of Triton X-100 1% (v/v). To test hAChE activity and the inhibition capacity of 
the selected compounds, the stock solution was further diluted in PB (pH 8.0; 0.1 M) containing 
0.1% (v/v) Triton X-100. For SPR immobilization, hAChE stock solution was diluted in phosphate 
buffer (pH 5.0; 0.1 M) containing 0.33% (v/v) Triton X-100. Stock solutions of edrophonium (6 
mM), tacrine (4 mM), galantamine (3 mM) and donepezil (3 mM) were prepared in bidistilled 
water. (S)-warfarin was dissolved in PBS-T in order to obtain a stock solution of 600 M. 
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7.2.4 In solution enzymatic activity assay  
Enzymatic assays were carried out on a Jasco V-530 double beam spectrophotometer equipped with 
a HAAKE DC30 thermostating system (Thermo Haake, Germany) and data were processed with 
GraphPad Prism 4.03 software (GraphPad Software Inc.).  
Enzymatic activity in the absence and in the presence of inhibitor were spectrophotometrically 
assessed using the Ellman’s method [22]. Assay solution (1 mL) consisted in: PB (pH 8.0; 0.1 M), 
0.02 unit/mL hAChE, 550 M substrate (ATCh) and 340 M DTNB. Solutions were incubated at 
37°C for 20 min before the addition of the substrate. Hydrolysis rate was quantified by measuring 
changes in the absorbance at 412 nm for 3 min at 37°C.  
In the case of inhibition studies, five increasing concentrations of tested inhibitor were assayed 
(n=3) to obtain percent inhibition in the range of 20-80%. Blank solutions containing all 
components except hAChE were prepared in parallel to account for the non-enzymatic hydrolysis of 
the substrate. IC50 values for selected inhibitors were determined by plotting the percentage of 
inhibition as function of the decimal log of the tested inhibitor concentration.  
 
7.2.5 Surface plasmon resonance-based analyses  
SPR analyses were performed using Biacore™ X100 system (GE Healthcare Bio-Sciences, 
Uppsala, Sweden) equipped with an in-line degasser and thermostated at 25 °C. SPR data reduction 
and processing were performed with Biacore™ X100 2.0 evaluation software or Scrubber2 
BioLogitech® 2008 software.  
 
7.2.5.1 hAChE immobilization and binding analysis  
For preparation of hAChE-functionalized surface, enzyme stock solution was diluted to 53.3 
units/mL in potassium phosphate buffer (0.1 M) at various pH values (pH range 4.0–6.0) and 
percentage of Triton X-100 (0.33–1% v/v). Each sample was injected at 10 L/min for 30 s, and 
electrostatic pre-concentration at the surface was evaluated. hAChE sample diluted in potassium 
phosphate buffer (pH 5.0; 0.1 M) containing 0.33% (v/v) Triton X-100 was immobilized through 
amine-coupling procedure, employing HBS as running buffer [27]. Briefly, sensor surface was 
activated with a 7-min injection (10 µL/min) of EDC (0.4 M)-NHS (0.1 M) (1:1 v/v) mixture and 
enzyme was injected until an adequate immobilization level of 7000 Response Units (RU) was 
obtained. Then, quenching of residual active esters on the surface was performed by overnight 
flowing of TRIS buffer saline: TRIS (0.05 M)-NaCl (0.1 M) (pH 8.0). A reference channel was 
prepared employing the same protocol apart from enzyme injection. Apparent surface binding 
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capacity after immobilization process was estimated employing donepezil as test compound 
according to Eq. (9) (see Section 7.2.5.3). 
Binding studies were carried out in multi-cycle kinetic (MCK) mode employing 75 µL/min as flow 
rate. Injections of running buffer were interspersed among inhibitor injections and used as ‘blank’ 
for double-referencing purposes [28]. InhibitorhAChE interactions were monitored using PB-T 
(pH 8.0; 0.1 M) as running buffer. Stock solutions of the selected drugs were directly diluted in 
running buffer to obtain a series of dilutions centered around the reported Ki values [29]. In details, 
edrophonium 60.0-0.6 µM; donepezil 600-3 nM; galantamine 30.0-0.3 µM; tacrine 8.0 µM-0.1 µM. 
For edrophonium and donepezil contact time and dissociation time were set at 60 s and 180 s, 
respectively. For galantamine and tacrine a 60s-association and a 120s-dissociation steps were set. 
Each interaction was analyzed at least in duplicate. 
 
7.2.5.2 HSA surface preparation and binding analysis 
HSA-functionalized surface was prepared according to previously published protocols [26,30–32]. 
Briefly, HSA was diluted at 30 g/mL in sodium acetate buffer (0.01 M; pH 5.0) and was 
immobilized onto CM5 sensor surface exploiting amine-coupling chemistry and employing PBS-T 
as running buffer. At the end of the immobilization protocol, the functionalized surface was allowed 
to stabilize overnight. After stabilization, an immobilization level of 7000 RU was obtained.  
(S)-warfarin was used as reference compound in order to test surface functionality. (S)-warfarin 
stock solution was prepared directly in running buffer and injected in a three-fold dilution series 
from 30 to 0.4 µM. Inhibitor-HSA interaction was monitored in PBS-T, injecting each compound in 
a three-fold dilution series (from 100 µM to 1.2 µM). Binding studies for drug-HSA complexes 
were carried out setting association and dissociation time to 45 s, with a flow rate of 75 µL/min.  
 
7.2.5.3 Data evaluation 
Apparent surface binding capacity after immobilization was estimated according Eq. (9): 
   / * *max analyte ligand immobilizedR MW MW RU stoichiometry   (9) 
Each set of sensorgrams was processed according to the same procedure. SPR responses obtained in 
the active channel were corrected for the response obtained in the reference channel and 
subsequently subtracted of the responses from blanks in order to obtain double-referenced 
sensorgrams [28]. Corrected responses recorded at steady-state were plotted against the 
concentration injected and non-linear regression analysis was used to extrapolate the equilibrium 
dissociation constant (KD). For inhibitor–hAChE interaction, a model accounting for one binding 
site (i=1), defined by Eq. (10) was employed:  
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R (C / K )
R =
1+C / K
    (10) 
where c (M) is the inhibitor concentration, Req (RU) is the response at the steady-state and Rmax 
(RU) is the maximal response. 
For inhibitor–HSA interactions Eq. (10) was also employed, posing i=2. Inclusion of a secondary 
binding site accounts for the unspecific binding to HSA likely happening at the high inhibitor 
concentration employed for the study. Primary KD extrapolated by this approach was then converted 
into percentage of drug bound to HSA according to the procedure reported in [31]. 
For kinetic analysis, sensorgrams were globally fitted to a theoretic model describing a simple, 
reversible 1:1 binding event (Eq. (11)). Association (kon) and dissociation (koff) rate constants for 
inhibitor–hAChE reaction were extrapolated according to the integrated rate Eq. (12): 
 
      (11) 
  
          
-(kon[B]+koff)t
eq[AB] = [AB] (1- e )    (12) 




and koff is expressed in s
−1
.  
According to 1:1 binding model, the KD value is equal to the ratio between off- and on-rate 
constants, as shown in Eq. (13). 
      KD = koff/kon                                                            (13)  
On the basis of the applied theoretical model, target residence time (τ), expressed in s, is defined as 
the inverse of dissociation rate constant [12] as described in Eq. (14): 
      τ = 1/koff   (14) 
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7.3 Results and discussion 
7.3.1 Optimization of immobilization and SPR analysis conditions 
Amine-coupling can be considered as the first choice for ligand immobilization when protein–small 
molecules interactions want to be investigated by SPR sensing approach. Stable and high-density 
surfaces can be generated, and reliable data can be produced even for low molecular weight 
analytes. However, it is crucial that ligand binding properties are unaltered upon anchorage to 
dextran matrix. Coupling condition, which envisage acidic, low-ionic-strength solutions, might 
result too harsh when an intrinsically unstable enzyme like hAChE is engaged. Thus, for this study 
a series of tailor-made immobilization conditions were explored. Each coupling solution was 
evaluated both for its pre-concentration efficiency through pH-scouting procedure and for its 
residual enzymatic activity after incubation in each coupling buffer. This latter step is essential to 
verify whether hAChE retains most of its catalytic activity upon exposure to the coupling condition, 
thus being immobilized in its active form. 
Supplementing coupling solution with a non-ionic detergent might reduce reaction efficiency but 
resulted essential to maintain enzyme stability. Indeed, dilution in phosphate buffer without Triton 
X-100 determined a significant and fast loss of enzyme activity over short time (data not shown). P-
20, a common non-ionic detergent routinely supplemented in SPR running buffer, resulted less 
efficient than Triton X-100 in stabilizing hAChE (p-20 supplemented solution lost 90% of activity 
within an hour). Based on these results addition of Triton X-100 to AChE solutions was considered 
essential to maintain enzyme functionality and consequently produce a functional sensing surface. 
Concerning pHs, AChE optimum working and storage pH is 7.4–8 or above, depending on the 
enzyme source; pH values lower than 6.5 seem to reduce not only enzyme activity but also enzyme 
stability [33]. Nonetheless, covalent immobilization at pH 5.0 of hAChE monolithic supports for 
enzymatic studies was previously achieved with good results [34]. Hence, hAChE stock solution 
was diluted either in 10 mM sodium acetate buffer or in phosphate buffer (0.1 M) at various pH 
values (pH range 4.0–6.0). 
Each sample was injected at 10 L/min for 30 s and electrostatic pre-concentration at the surface 
was evaluated. To assess the activity loss upon dilution in the immobilization buffer, hAChE 
solutions used for the pH scouting procedure were further diluted in the activity assay buffer (PB 
pH 8.0; 0.1 M) and residual activity was evaluated by Ellman’s assay [22] . Buffer type resulted to 
affect enzyme activity with PB performing slightly better than acetate buffer at the same pH value 
(15% difference in activity). When hAChE was dissolved in PB (pH 5.0; 0.1 M) supplemented with 
0.33 % (v/v) Triton X-100, highest residual activity was observed and the enzyme could be 
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efficiently pre-concentrated. Consequently, this condition was chosen to carry out the 
immobilization procedure on SPR platform.  
hAChE stock solution (1716 U/mL) was diluted into the former buffer (53.3 U/mL) and 25 units of 
active enzyme were injected over the activated surface until an immobilization level of 7000 RUs 
was achieved. Then, deactivation was attained switching running buffer to TBS. Primary amine of 
TRIS (0.05 M) provided a milder means to quench residual active esters with respect to classical 
injection of ethanolamine (pH 8.0; 1 M). After an overnight stabilization in TBS, 5500 RUs, 
corresponding to a surface density of 5.0 ng/mm
2 
[27], were stably coupled to the surface (minimal 
baseline drift was observed, i.e., <0.3 RU/min). Surface binding capacity was estimated to be 
approximately 20 % of theoretical Rmax Eq. (9). Despite this might seem a low value, expected Rmax 
after amine-coupling is usually around 50 % of theoretical. Due to the random orientation of ligand 
on the surface, binding site accessibility might be hampered when covalent bond formation occurs 
in their immediate proximity [27]. Moreover, apparent activity showed by our sensing surface is 
comparable to data presented in the literature where AChE from other species was tethered to 
dextran matrices [17,35] or others solid supports [29,34]. 
 
7.3.2 Determination of thermodynamic and kinetic parameters of inhibitor–hAChE 
interaction 
Having established hAChE could endure coupling condition, a series of well characterized hAChE 
inhibitors (Fig. 26) were employed to test binding performances of the immobilized enzyme.  
Selected compounds are all drugs used either in AD treatment or myasthenia gravis diagnosis for 
which bioavailability data and administration regimens are available, so that our results can be 
compared to well-established parameters.  
 
 
Figure 26| Structure of the selected hAChE inhibitors. Molecular weights are reported under the corresponding 
compound. 
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Concerning the mechanism of action, tacrine and donepezil are mixed-mode competitors, i.e., they 
are reported to bind both the hAChE catalytic site and the peripheral anionic binding site (at high 
concentration) while galantamine and edrophonium are substrate-competitive inhibitor. 
Edrophonium is also characterized by a low molecular weight (166 g/mol). Overall, molecular 
weights range from 166 g/mol to 379 g/mol and inhibitory potencies span over four orders of 
magnitude. 
To assess whether the hAChE sensing surface was suitable to discriminate among the different 
inhibitors, stock solutions were diluted in running buffer and presented to the hAChE-
functionalized surface. Resulting sensorgrams were discernible from background noise for all 
employed concentrations and useful data could always be retrieved (Fig. 27). Binding affinities 
were compared with inhibitory potencies (IC50 values) determined by a classical in solution assay 
[22] and employing the same hAChE used for hAChE immobilization and inhibitor solutions used 
for SPR interaction analysis.  
 
 
Figure 27| Affinity and kinetic studies of the four selected inhibitors binding to immobilized hAChE chip surface. 
Double-referenced sensorgrams (main) and equilibrium responses (inset) of inhibitors–hAChE interactions. The 
injected inhibitor concentrations were: 3.0, 15.0, 30.0, 60.0, 300.0 and 600.0 nM for donepezil (A); 0.1, 0.4, 2.0, 4.0 and 
8.0 μM for tacrine (B); 0.3, 1.0, 3.0, 6.0 and 30.0 μM for galantamine (C); 0.6, 1.8, 3.0, 6.0, 12.0, 30.0 and 60.0 μM for 
edrophonium (D). Kinetic rate constants were extrapolated applying a theoretic reversible 1:1 binding model (light) to 
experimental data (dark). KD for each inhibitor–hAChE complex, was extrapolated plotting corrected responses (RU) at 
steady-state against concentration and fitting experimental data to Eq. (10).  
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The measured inhibition potencies (Table 7) were in good agreement with those reported in the 
literature as well as with previously determined inhibition constant (Ki), which were calculated 
under the same experimental conditions [29,34]. 
 
Table 7| Half-maximal inhibitory concentrations (IC50) determined by in solution assay, 
equilibrium dissociation constants (KD), kinetic rate constants (kon, koff), dissociation constants 
measured via kinetic analysis (koff/kon) and residence time (τ) determined by SPR analysis on 
hAChE-inhibitor complexes. The reported values are the mean of at least two independent 
measurements. Data are reported with corresponding standard deviation ( SD). Inhibition 
constants (Ki) are also reported for comparison purposes. 
a
 Inhibition constants (Ki) reported in literature and calculated using the same experimental conditions [29]. 
b
 n.d., not determined.  
 
All monitored interactions (Fig. 27) reached steady-state conditions within the chosen injection time 
and equilibrium dissociation constant (KD) could be extrapolated. In agreement with the Ki values 
for the enzyme in solution [29] (Table 7), the strongest binder was identified in donepezil, which 
showed a KD = (4.34 ± 2.68) • 10
−8 
M; the weakest binder was identified in edrophonium whose KD 
was (2.28 ± 1.07) • 10
−6
 M. The latter value also agrees with recent published data obtained by in 
solution isothermal titration calorimetry (ITC) studies (edrophonium KD = 1.4 ± 0.4 µM), strongly 
suggesting immobilization did not hamper hAChE binding activity [36].  
Concerning reactions profiles, complexes of edrophonium–hAChE and tacrine–hAChE both 
showed rapid on-/off-rates resulting in squared-shaped sensorgrams, while complexes of 
galantamine–hAChE and donepezil–hAChE displayed significantly slower dissociation events. 
Sensorgrams quality allowed applying a global kinetic fitting procedure to each data set. All 
monitored interactions were analyzed employing a simple, reversible, 1:1 binding model (Eq. (10)) 
that gave in return reasonable numerical values. Association and dissociation rate constants values 
for edrophonium and tacrine (Table 7) were in good agreement with those reported in literature and 
Inhibitor IC50 (M) Ki (M) 
a






) koff/kon (M) τ (s) 
Edrophonium (7.300.35)•10-6 (1.630.23)•10−6 (2.281.07)•10-6 (1.07±0.54)•10
5 (2.52±1.37)•10–1 (2.390.78)•10-6 3.96 
Tacrine (4.010.10)•10-7 (1.510.16)•10−7 (3.612.92)•10-7 (1.46±0.56)•10
6 (3.58±0.71)•10–1 (2.550.49)•10-7 2.79 
Donepezil (2.030.13)•10-8 (2.050.33)•10−8 (4.342.68)•10-8 (1.81±0.08)•10
6 (4.97±1.49)•10–2 (2.740.70)•10-8 20.12 
Galantamine (2.000.23)•10-6 n.d.
b (3.940.61)•10-7 (9.46±0.92)•10
4 (2.48±0.53)•10–2 (2.610.30)•10-7 40.32 
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achieved by stopped-flow fluorescence titration in which both compounds showed rapid kinetics 
[37]. The slight differences in kon and affinity values with respect to those obtained by fluorescence 
titration might be ascribed to the different enzyme origin (mouse vs human).  
Because of the limited number of tested compounds and different chemical structures 
structure/kinetic relationships cannot be derived. The lower off-rates displayed by galantamine and 
donepezil (slower dissociation) may be partially ascribed to the high stability and 
thermodynamically favorite conformations resulting from their binding to hAChE, as recently 
rationalized by molecular dynamic studies [38,39]. 
 
 
Figure 28| Kinetic chart for tested inhibitors. Plot of association (kon) rate constants as function of dissociation rate 
constants (koff) of hAChE inhibitors. Dotted lines (iso-affinity line) refer to KD values calculated from kinetic analysis 
(koff/kon). 
 
Dissecting KD values in their individual on-/off-rate constants provides further insight into the 
different inhibitor–AChE interactions (Fig. 28). For instance, galantamine and tacrine show rather 
similar thermodynamic KD and they lay on extremely close iso-affinity lines; however, the stability 
of the two inhibitor–hAChE complexes diverges, with respective koff values differing more than one 
order of magnitude. This is not surprising, since chemical entities with similar affinities for the 
target molecule in vitro can show large difference in both kon and koff values. Such differences might 
reflect differences in binding modes, thereby also differences in their in vivo efficacy. Resolving 
kinetic rate constants make possible to differentiate otherwise undistinguishable compounds 
providing an additional layer of discrimination when chemical series are tested. Moreover, desired 
therapeutic effect (short or long action) might be better correlated to fast or slow interaction 
profiles, so that a good balance between therapeutic and adverse effects can be achieved [9].  
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The possibility of relating kinetic aspects (KD=koff/kon) with experimental thermodynamic 





) [40], provides a deeper characterization of biomolecular equilibria. However, the amount of 
AChE required for in vitro thermodynamic studies, among which ITC is the most commonly used 
approach [41], is not compatible with the extremely high cost of recombinant hAChE. As 
consequence, experimental thermodynamic data available from literature have been obtained using 
less expensive non-human AChE isoforms, such as AChE from Electric eel or Torpedo Californica. 
Specifically, thermodynamic parameters for the same set of inhibitors object of this study were 
assessed by Draczkowski et al. (2016) using ITC and AChE from Electric eel [42]. However, as 
stated by the authors [42], ITC thermodynamic data did not well correlate with the experimental 
inhibition constants as they were compromised by a low Wiseman factor c [43], which flatted the 
experimental Gs (range from 39.5 to 42.9 kJ/mol), and, consequently, the related KD values.  
 
7.3.3 Drug–target residence time and early pharmacokinetic estimation 
Binding affinities values measured via kinetic analysis (KD = koff/kon) were in excellent agreement 
with affinity constants determined via equilibrium studies. Moreover, maximal responses (Rmax), 
refractive index corrections (RI) and residual plots inspection all indicates goodness of fit by our 
kinetic model. Based on these premises, dissociation rate constants were used to calculate residence 
time. The four drugs showed different τ (Table 7) and could be ranked in two main groups: (i) fast-
reversible binders with residence time lower than 5 s, i.e tacrine (2.79 s) and edrophonium (3.96 s) 
and (ii) slow-reversible binders, i.e. donepezil (20.12 s) and galantamine (40.32 s). As first  
approximation, all molecules showed quite rapid escape from their respective binding site(s) on 
hAChE. This could be expected when an enzyme that assumes a crucial role as terminator of signal 
transduction is targeted for inhibition and adverse effects can arise if inhibitory effect prolongs 
extensively [44,45].  
Looking at duration of action for the selected drugs in vivo, a good correlation with target residence 
time was found. Edrophonium action only lasts 1.2–2.3 min after i.v. administration [46] and 
tacrine, among anti-AD drugs, has the shortest duration of action (administration: 4 times/day), in 
agreement with the kinetic classification. On the other hand, galantamine (twice per day) and 
donepezil (once daily), both have a lower frequency of suggested administration to AD patients, in 
agreement with their longer residence time. However, pharmacologic effect and length of action for 
administrated drugs arise from the combination of binding kinetic to the primary target and 
adsorption, distribution, metabolism and excretion (ADME) profile. Binding to serum proteins 
represents an important aspect in determining ADME profile of a molecule entering human body. 
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HSA is the most abundant among circulating protein and plays a central role as transporter of many 
endogenous and exogenous poorly soluble compounds [23].  
Thus, as a proof of concept that combination of residence time and HSA binding might represent a 
better predictive parameter, the propensity of the four selected drugs to interact with immobilized 
HSA was estimated through SPR technology. Binding to HSA was rapid and reversible (Fig. 29), as 
expected when transport proteins are involved in complex formation; additionally, interactions 
exceeded 1:1 stoichiometric ratio and a binding model accounting for two independent binding sites 
was employed. This is not surprising since the same molecule can occupy multiple binding sites on 
HSA, namely at low concentrations binding sites with high affinity and low capacity, at higher 
concentration binding sites with lower affinity but higher capacity [31,32,47]. Primary affinity 
measured for the different compounds was converted into bound percentage assuming physiological 
concentration of the protein (680 µM) and 10 µM of compounds.  
 
 
Figure 29| Drugs–human serum albumin (HSA) interaction studies. Double-referenced sensorgrams (upper panel) 
and equilibrium responses (lower panel) for inhibitor–HSA interactions. All compounds are tested in a three-fold 
dilution series: (S)-warfarin 30 µM to 0.4 µM; inhibitors from 100 µM to 1.2 µM. Corrected responses (RU) at steady-




Interestingly, results (Table 8) showed that galantamine did not significantly interact with HSA, 
while the other inhibitors showed high affinity toward the immobilized plasma protein. Bound 
percentage for donepezil and galantamine were also comparable to pharmacokinetic data obtained 
in clinical studies [48]. Galantamine is reported to have ~18 % plasma protein binding percentage 
and serum half-life of 7h; on the other hand, donepezil has a plasma protein binding percentage of 
~96 % and serum half-life of 70 h [48]. Likely, the significant binding of donepezil to HSA, may 
preserve it from enzymatic and non-enzymatic degradation and excretion enhancing its plasma 
stability and duration of action. This good correlation further indicates that measuring binding 
affinity towards immobilized HSA constitutes a good approximation of in vivo inhibitor binding to 
the human serum proteins and may offer a good estimation of its fate after adsorption. 
 
Table 8| Primary equilibrium dissociation constants (KD) determined for drug–HSA complexes by 
SPR analysis. Results are listed with corresponding standard error ( SE). Percentage bound values 
(% bound) to HSA were obtained according to the procedure described in [31]. 
Drug KD (M) % Bound  
Edrophonium 4.23  2.07 94.4 
Tacrine 4.40  1.08 94.2 
Donepezil 2.00  0.22 97.2 
Galantamine n.d.a n.d.a 
(S)-Warfarin 1.40  0.34 98.0 




When enzymes are targeted for inhibition, drug discovery campaigns are usually conducted 
employing functional assays, where the main focus is on increasing inhibition potency. However, 
within the same chemical series is not unusual to have compounds with comparable IC50 values and 
same inhibition mode, for which a clear prioritization criterion is hard to identify. In this context, 
having additional elements to discriminate between chemical entities becomes a clear advantage. 
Dissociation rate constant (koff), or its reciprocal term residence time (𝜏) of inhibitor–enzyme 
complexes, might provide further insight on target-inhibitor interactions, thus aiding the selection 
process. Moreover, 𝜏 is a valid parameter in systems where drug concentration fluctuates over time, 
as in in-vivo settings. At present day there is no simple and cost-effective method to resolve kinetic 
interactions of hAChE inhibitors with their target.  
In the present study, an SPR-based biosensing assays has been developed to quantify binding 
affinities and kinetic rates constant for hAChE–inhibitors binding events. The use of a custom 
coupling solution ensured immobilization of the enzyme in its active form and resulting sensing 
surface was amenable to measure binding affinities ranging over three orders of magnitude. As test 





 M) inhibition mode (competitive or mixed mode) and molecular weight (from 166 to 379 
g/mol) were employed. Thermodynamic and kinetic parameters were accurately extrapolated even 
for edrophonium (fragment-like molecular weight), suggesting the suitability of the method even 
for fragment-based drug discovery campaigns. Determination of the kinetic rate constants under 
same experimental conditions for all marketed anti-AChE drugs used in AD constitutes a first of its 
kind study and provide a better comparison of their kinetic behavior, which allowed their 
classification into two main classes: slow-dissociating and fast-dissociating reversible inhibitors. 
Moreover, SPR technology was employed to determine binding level toward immobilized HSA in 
an easy and fast fashion with the aim of roughly predicting the pharmacokinetic behavior. 
Combination of data on the primary target with data on HSA found good correlation with drug 
potency and administration regimens in therapeutic routine. 
Application of the proposed method offers a solution to implement inhibition data, traditionally 
obtained when new hAChE inhibitors are tested, with deeper information on the intrinsic drug–
target interaction and preliminary pharmacokinetic data. Parameters such as koff and bound 
percentage to serum proteins can be easily obtained, and favorite chemical scaffolds can be 
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Abstract  
Alzheimer disease (AD) is a complex disease related to multiple pathogenic mechanisms. A 
strategy to develop effective drugs is based on the so-called multi-target-directed ligands (MTDL) 
by using hybrid compounds. So, in the present study, we analyzed two hybrids, containing the 
indanone-piperidine moiety of donepezil, a drug approved for the treatment of AD, and the lipoic 
acid scaffold, an antioxidant compound endowed with neuroprotective effects. The latter hybrid 
displayed moderate inhibitory activity against human AChE and greater activity against human 
BuChE. The selectivity for BuChE was further rationalized by theoretical study. Importantly, 
studies carried out by other groups involved in the project showed that the second hybrid had a 
good antioxidant activity, exhibiting better ability in scavenging 2,2-diphenyl-1-picrylhydrazyl 
(DPPH) radicals than lipoic acid.  
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8.1 Introduction  
In the continuous research of more efficient drugs for treating Alzheimer disease (AD), the so-
called multi-target-directed ligands (MTDLs) approach represents an intriguing strategy [2]. This 
method builds on the development of a single drug that can simultaneously interact with different 
targets. The advantages of this polypharmacological strategy, when compared with the 
administration of a combination of multiple drugs, are the reduction of the risk of drug-drug 
interactions and a simplification of the pharmacokinetic and pharmacodynamic studies. Moreover, 
the success rate of the treatment of a complex disease of the elderly, as AD, should be higher [3]. In 
this context, MTDLs design approach may offer advantages in drug discovery due to multiple 
targets involved in AD etiology. Near the formation of amyloid plaques, neurofibrillary tangles and 
the decrease of cholinergic tone and ACh levels, an extensive oxidative stress has been observed 
which is a result of an altered balance of formation of reactive oxygen species (ROS) versus 
scavenging activity [4,5]. The production of ROS is also related to calcium homeostasis; the 
misbalance of calcium influx affects the mitochondrial enzymes and ROS production is a normal 
part of the electron transport chain. However, excessive levels of these species damage proteins, 
lipids and nucleic acids [6].  
Donepezil, a palliative drug approved in 1996, is indicated for the treatment of mild and moderate 
forms of AD [7]. Its structure represents an attractive starting point for the rational design of new 
MTDLs that can inhibit acetyl-(AChE) and butyryl-(BuChE) cholinesterases and, at the same time, 
interact with other targets involved in AD onset and progression [8]. Many prototypes for new 
drugs based on the hybridization strategy have been developed starting from donepezil fragments, 
i.e. indanone-piperidine moiety or piperidine-benzyl fragment [9]. Furthermore, donepezil hybrids 
with tacrine [10,11], diaminobenzyl group, ferulic acid [12], coumarin [13] among others have been 
prepared. Hybrids containing the piperidine-benzyl moiety of donepezil and lipoic acid (LA) (Fig. 
30) were described by several groups [14,15]. The hybrids showed activity against cholinesterase 
(ChE) enzymes, antagonism toward σ1 receptors, β-secretase inhibition and antioxidant activity.  
LA is a natural disulfide compound present in almost all foods from animal and vegetable sources. 
LA and its reduced form, dihydrolipoic acid (DHLA) (Fig. 30), play an important role in 
pathological conditions characterized by oxidative stress such as: (i) scavenger of ROS, (ii) capacity 
to increase the level of reduced glutathione and other antioxidant enzymes, (iii) downregulation of 
the inflammatory processes, (iv) scavenging of lipid peroxidation products, (v) redox active 
transition metal chelation, (vi) increase of ACh production by activation of choline acetyltransferase 
[16,17]. On the basis of such activities, LA can exert beneficial effects in AD, possibly stabilizing 
cognitive functions [18]. Thus, LA is a good prototype to design new hybrids to combat AD, and 
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previously developed LA hybrids maintained the antioxidant activity and showed other beneficial 




Figure 30| Chemical structures of lipoic acid (LA) and of dihydrolipoic acid (DHLA).  
 
In 2005, Rosini et al. [18] reported the synthesis of lipocrine, an LA-tacrine hybrid, which further 





methoxy-benzyl)-hexane-1,6-diamine moiety or with rivastigmine. Although there are works 
involving the hybridization of the benzyl-piperidine moiety of donepezil with LA, to our 
knowledge, there is no report on the hybridization of the indanone-piperidine moiety with LA.  
In this context, two hybrids containing the indanone-piperidine moiety of donepezil and the LA 
scaffold were designed and synthesized by the research group of Ângelo de Fátima with the aim of 
achieving new MTDLs for the treatment of AD [1]. The newly synthesized hybrids were 
investigated by us in terms of anticholinesterases activity towards both human AChE (hAChE) and 
BuChE (hBuChE), using classic in solution approach [21]. The purpose of inhibition studies was 
the quantification of hybrids inhibition potency as well as the assessment of retained inhibition 
capacity of these compounds when the pharmacophore of donepezil was combined with LA.  
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8.2 Experimental section 
8.2.1 Materials  
Human recombinant acetylcholinesterase (hAChE) (EC 3.1.1.7) lyophilized powder, 
butyrylcholinesterase (E.C. 3.1.1.8) from human serum (hBuChE), S-acetylthiocholine iodide 
(ACTh), butyrylthiocholine iodide (BTCh), respectively). 5,5’-dithio-bis(2-nitrobenzoic acid) 
(DTNB; Ellman’s reagent), donepezil hydrochloride, dipotassium hydrogenphosphate trihydrate, 
potassium dihydrogenphosphate and Triton X-100 were purchased from Sigma-Aldrich (Milan, 
Italy). HPLC grade methanol (MeOH) was supplied by Honeywell (Milan, Italy). Plasma from 
human prepared from pooled human blood was purchased from Sigma-Aldrich (Milan, Italy). 
Deionized water was obtained by Milli-Q system (Millipore, Milford, MA, USA). All solutions 
were filtered with 0.22 µm membrane filters (Millipore, Milford, MA, USA) before use.  
All compounds (Fig. 31) (compound 1 and 2) and lipoic acid were synthesized by Bruna Terra 




C NMR, IR 
and ESI-MS [1].  
 
 
Figure 31| Chemical structures of hybrids 1 and 2. Schematic design strategy for the synthesis of compound 1 and 2 
performed by Terra et al. 
 
8.2.2 Determination of inhibitory effect on AChE and BuChE activity 
The capacity of hybrids and donepezil to inhibit AChE activity was assessed using the Ellman’s 
method [21]. Initial rate assays were performed at 37 °C with a Jasco V-530 double beam 
Spectrophotometer by following the rate of increase in the absorbance at 412 nm for 3 min. AChE 
stock solution was prepared by dissolving hAChE in phosphate buffer (0.1 M; pH = 8.0) containing 
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Triton X-100 0.1%. Stock solution of BuChE was prepared by dissolving the lyophilized powder in 
an aqueous solution of gelatine 0.1%. The final assay solution consisted of a phosphate buffer (pH 
= 8.0; 0.1 M), with the addition of 340 M DTNB, 0.02 unit/mL of hAChE or hBuChE and 550 M 
of substrate ATCh or BTCh, respectively. Stock solutions of hybrid 2 were prepared in methanol 
and diluted in methanol, while donepezil was solubilized in water and dilutions were prepared in 
water. Five different concentrations of inhibitor were selected in order to obtain inhibition of the 
enzymatic activity comprised between 20 and 80%. 50 L aliquots of increasing concentration of 
inhibitor were added to the assay solution and pre-incubated for 20 min at 37 °C with the enzyme 
before the addition of the substrate. Assays were carried out with a blank containing all components 
except AChE or BuChE in order to account for the non-enzymatic reaction. The reaction rates were 
compared and the percent inhibition due to the presence of inhibitor was calculated. Each 
concentration was analyzed in duplicate, and IC50 values were determined graphically from log 
concentration–% inhibition curves (GraphPad Prism 4.03 software, GraphPad Software Inc.). 
 
8.2.3 Evaluation of the formation of LA- and hybrid 2-albumin adducts by LC-MS 
The reactivity of synthesized compounds to form mixed disulfides with proteins was tested by 
assessing the capacity of LA and hybrid 2 to form covalent adducts with albumin, which is the most 
abundant protein in plasma. 10 mM LA and hybrid 2 stock solutions were prepared in methanol. 
Aliquots of stock solutions were added to pooled human plasma to reach a final concentration of 
180 M. Plasma with the addition of an equal amount of solvent was used as blank sample. All 
solutions were incubated for 3 h at 37 °C, under gentle shaking (400 rpm) using a Thermomixer 
(Eppendorf, Milan, Italy). Afterwards, they were diluted in deionized water (1:100) and analyzed by 




8.3 Results and discussion 
To determine the potential interest of the new donepezil-LA hybrids for the treatment of AD, the 
inhibitory potency toward hAChE and hBuChE was assessed by Ellman’s method [21]. Results, 
expressed as half maximal inhibitory concentration (IC50) values, i.e. the IC50 that reduces the 
cholinesterase activity by 50%, are listed in Table 9. In particular, anti-BuChE activity has recently 
raised interest because it was shown that with AD progression, BuChE activity in specific brain 
regions increases while AChE activity is greatly reduced [23]. Conversely to donepezil, which is an 
AChE selective inhibitor, hybrid 2 showed to be a selective BuChE inhibitor. Hybrid 1 was scarcely 
soluble in the assay conditions. At the highest tested concentration (50 mM) hybrid 1 did not 
significantly inhibit ChE enzymes.  
 




















2 171  10 62.9  5.4 0.37 
Donepezil 0.0203  0.0013 7.13 0.19 351 
a
IC50: inhibitory concentration; 
b
SEM stands for standard error of the mean; 
c
n.a. stands for not active 
(% inhibition <10%) at the highest concentration achievable (50 M) in the assay conditions. 
 
In order to prove the rationale of these compounds, their antioxidant activity was tested by other 
coauthors by means of 2,2-diphenyl-1-picrylhydrazyl (DPPH) antioxidant assay [42]. LA, selected 
as reference compound, confirmed its weak DPPH radical scavenging activity compared to the 
corresponding reduced form, i.e. dihydrolipoic acid (DHLA), in agreement with data reported in 
literature (half maximal effective concentration, EC50 >> 100 M [24], EC50 > 500 M [25,26]). 
Compound 1 displayed a similarly weak antioxidant profile of LA, exhibiting a scavenging activity 
lower than 50% at the maximum tested concentration. Conversely, compound 2 showed a 
concentration-dependent DPPH scavenging activity with an EC50 of 300 M. Notwithstanding the 
still weak scavenging activity of 2, since the antioxidant property of LA and related hybrids is 
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granted by the 1,2-dithiolane moiety, which is maintained in all tested compounds, other studies 
need to be performed to better understand the observed trend, e.g. by assessing any chemical 
instability in the assay conditions.  
The reactivity of synthesized compounds to form mixed disulfides with proteins was evaluated by 
assessing the possible formation of covalent adducts between the dithiolane ring of both LA and 
hybrid 2 with albumin, which was selected as reference protein as the most abundant protein in 
plasma [22]. LC-MS analysis showed that no structural modification of albumin (no adduct was 
formed) occurred upon 3h-incubation at 37°C (data not shown) when concentrations equals to the 
IC50 value of 2 were used. These data are in agreement with the high administration dosage 
suggested for LA (300-600 mg) and the absence of any record on immunogenicity at the 
recommended dosages [27,28].  
Docking studies on these novel hybrids with both hAChE and hBuChE were also performed by 
coauthors and provided further insights into their binding mode and their potential binding sites. For 
complete results and discussion of these sections as well as for hybrids synthesis details, please 
refer to the original article [1].  
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8.4 Conclusions 
In this work, two donepezil-LA hybrids containing the indanone-piperidine moiety of donepezil, 
namely compound 1 and compound 2, were designed and synthesized by the group of Ângelo de 
Fátima with global yields of 42% and 19%, respectively. Anticholinesterase studies performed by 
us highlighted that hybrid 2 was a selective BuChE inhibitor even if less potent than donepezil. 
Moreover, integration of these results with antioxidant activity and docking studies carried out by 
the other research groups involved in the project provided further insights into the behavior of these 
compounds. Indeed, combination of inhibitory studies with molecular modeling investigation 
highlighted hybrids binding mode and their binding site on ChE. In particular, the lower activity 
observed was ascribed to the loss of the interaction with Trp86A, an amino acid of the AChE 
catalytic site, when the benzyl moiety of donepezil was replaced by LA. Moreover, the selectivity 
of 2 toward hBuChE may be explained by the larger gorge of this enzyme, which can better 
accommodate hybrid 2. Finally, and quite interestingly, hybrid 2 showed better scavenging ability 
toward DPPH radicals than LA. The combined anti-ChE and antioxidant properties exhibited by the 
hybrid 2 confirmed its potential as anti-AD agent also suggesting further studies on donepezil-LA 
hybrids.   
 128 
References 
[1] B.S. Terra, P.H.C. Da Silva, A. Tramarin, L.L. Franco, E.F.F. Da Cunha, F. Macedo, T.C. Ramalho, M. 
Bartolini, M.L. Bolognesi, Â. De Fátima, Two novel donepezil-lipoic acid hybrids: synthesis, anticholinesterase 
and antioxidant activities and theoretical studies, J. Braz. Chem. Soc. 29 (2018) 738–747.  
[2] A. Cavalli, M.L. Bolognesi, A. Mìnarini, M. Rosini, V. Tumiatti, M. Recanatini, C. Melchiorre, Multi-target-
directed ligands to combat neurodegenerative diseases, J. Med. Chem. 51 (2008) 347–372.  
[3] M.L. Bolognesi, Polypharmacology in a single drug: multitarget drugs, Curr. Med. Chem. 20 (2013) 1639–45. 
[4] D. Praticò, Peripheral biomarkers of oxidative damage in Alzheimer’s disease: the road ahead, Neurobiol. 
Aging. 26 (2005) 581–3.  
[5] C. Behl, B. Moosmann, Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic 
approach, Free Radic. Biol. Med. 33 (2002) 182–91. 
[6] G.E. Gibson, Interactions of oxidative stress with cellular calcium dynamics and glucose metabolism in 
Alzheimer’s disease, Free Radic. Biol. Med. 32 (2002) 1061–70. 
[7] L.H. Opie, Donepezil for severe Alzheimer’s disease, Lancet. 368 (2006) 361–362. 
[8] L. Ismaili, B. Refouvelet, M. Benchekroun, S. Brogi, M. Brindisi, S. Gemma, G. Campiani, S. Filipic, D. 
Agbaba, G. Esteban, M. Unzeta, K. Nikolic, S. Butini, J. Marco-Contelles, Multitarget compounds bearing 
tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer’s disease, 
Prog. Neurobiol. 151 (2017) 4–34.  
[9] M.C. Rodrigues Simões, F.P. Dias Viegas, M.S. Moreira, M. de Freitas Silva, M.M. Riquiel, P.M. da Rosa, 
M.R. Castelli, M.H. dos Santos, M.G. Soares, C. Viegas, Donepezil: an important prototype to the design of 
new drug candidates for Alzheimer’s disease, Mini Rev. Med. Chem. 14 (2014) 2–19. 
[10] P. Camps, X. Formosa, C. Galdeano, T. Gómez, D. Muñoz-Torrero, M. Scarpellini, E. Viayna, A. Badia, M.V. 
Clos, A. Camins, M. Pallàs, M. Bartolini, F. Mancini, V. Andrisano, J. Estelrich, M. Lizondo, A. Bidon-Chanal, 
F.J. Luque, Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-
induced beta-amyloid aggregation, J. Med. Chem. 51 (2008) 3588–98.  
[11] D. Alonso, I. Dorronsoro, L. Rubio, P. Muñoz, E. García-Palomero, M. Del Monte, A. Bidon-Chanal, M. 
Orozco, F.J. Luque, A. Castro, M. Medina, A. Martínez, Donepezil–tacrine hybrid related derivatives as new 
dual binding site inhibitors of AChE, Bioorg. Med. Chem. 13 (2005) 6588–6597.  
[12] Y. Zhu, K. Xiao, L. Ma, B. Xiong, Y. Fu, H. Yu, W. Wang, X. Wang, D. Hu, H. Peng, J. Li, Q. Gong, Q. Chai, 
X. Tang, H. Zhang, J. Li, J. Shen, Design, synthesis and biological evaluation of novel dual inhibitors of 
acetylcholinesterase and β-secretase, Bioorg. Med. Chem. 17 (2009) 1600–1613.  
[13] M. Catto, L. Pisani, F. Leonetti, O. Nicolotti, P. Pesce, A. Stefanachi, S. Cellamare, A. Carotti, Design, 
synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors 
of acetylcholinesterase, Bioorg. Med. Chem. 21 (2013) 146–52.  
[14] O. Prezzavento, E. Arena, C. Parenti, L. Pasquinucci, G. Aricò, G.M. Scoto, S. Grancara, A. Toninello, S. 
Ronsisvalle, Design and synthesis of new bifunctional sigma-1 selective ligands with antioxidant activity, J. 
Med. Chem. 56 (2013) 2447–2455.  
[15] M. Estrada, C. Pérez, E. Soriano, E. Laurini, M. Romano, S. Pricl, J.A. Morales-García, A. Pérez-Castillo, M.I. 
Rodríguez-Franco, New neurogenic lipoic-based hybrids as innovative Alzheimer’s drugs with σ-1 agonism and 
β-secretase inhibition, Future Med. Chem. 8 (2016) 1191–1207.  
[16] L. Holmquist, G. Stuchbury, K. Berbaum, S. Muscat, S. Young, K. Hager, J. Engel, G. Münch, Lipoic acid as a 
novel treatment for Alzheimer’s disease and related dementias, Pharmacol. Ther. 113 (2007) 154–164.  
[17] A.I. Durrani, H. Schwartz, M. Nagl, G. Sontag, Determination of free α-lipoic acid in foodstuffs by HPLC 
coupled with CEAD and ESI-MS, Food Chem. 120 (2010) 1143–1148. 
[18] M. Rosini, E. Simoni, M. Bartolini, A. Tarozzi, R. Matera, A. Milelli, P. Hrelia, V. Andrisano, M.L. Bolognesi, 
C. Melchiorre, Exploiting the lipoic acid structure in the search for novel multitarget ligands against 
Alzheimer’s disease, Eur. J. Med. Chem. 46 (2011) 5435–42.  
[19] M. Koufaki, A. Detsi, C. Kiziridi, Multifunctional lipoic acid conjugates, Curr. Med. Chem. 16 (2009) 4728–
42. 
[20] M.L. Bolognesi, A. Minarini, V. Tumiatti, C. Melchiorre, Lipoic acid, a lead structure for multi-target-directed 
 129 
drugs for neurodegeneration, Mini Rev. Med. Chem. 6 (2006) 1269–74. 
[21] G.L. Ellman, K.D. Courtney, V. Andres, R.M. Featherstone, A new and rapid colorimetric determination of 
acetylcholinesterase activity, Biochem. Pharmacol. 7 (1961) 88–95.  
[22] M. Naldi, F.A. Giannone, M. Baldassarre, M. Domenicali, P. Caraceni, M. Bernardi, C. Bertucci, A fast and 
validated mass spectrometry method for the evaluation of human serum albumin structural modifications in the 
clinical field, Eur. J. Mass Spectrom. 19 (2013) 491–496.  
[23] N.H. Greig, T. Utsuki, Q. Yu, X. Zhu, H.W. Holloway, T. Perry, B. Lee, D.K. Ingram, D.K. Lahiri, A new 
therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase, Curr. Med. Res. Opin. 17 
(2001) 159–165.  
[24] M.L. Bolognesi, C. Bergamini, R. Fato, J. Oiry, J.-J. Vasseur, M. Smietana, Synthesis of new lipoic acid 
conjugates and evaluation of their free radical scavenging and neuroprotective activities, Chem. Biol. Drug Des. 
83 (2014) 688–696. 
[25] S.R.P. Madawala, R.E. Andersson, J.A. Jastrebova, M. Almeida, P.C. Dutta, Novel conjugates of 1,3-
diacylglycerol and lipoic acid: synthesis, DPPH assay, and RP-LC-MS-APCI analysis, J. Lipids. 2011 (2011) 
419809.  
[26] G. Melagraki, A. Afantitis, O. Igglessi-Markopoulou, A. Detsi, M. Koufaki, C. Kontogiorgis, D.J. Hadjipavlou-
Litina, Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-
aminoamides and their alpha-lipoic acid adducts, Eur. J. Med. Chem. 44 (2009) 3020–3026.  
[27] T.S. Foster, Efficacy and safety of α-Lipoic acid supplementation in the treatment of symptomatic diabetic 
neuropathy, Diabetes Educ. 33 (2007) 111–117. 
[28] D.R. Cremer, R. Rabeler, A. Roberts, B. Lynch, Safety evaluation of α-lipoic acid (ALA), Regul. Toxicol. 





Multi-target-directed ligands for AD treatment: inhibitory potency 
evaluation of tacrine-dihydropyrimidine hybrids 
 
This chapter is adapted from:  
Mourad Chioua, Eleonora Buzzi, Ignatio Moraleda, Isabel Iriepa, Maciej Maj, Artur Wnorowski, 
Catia Giovannini, Anna Tramarin, Federica Portali, Lhassane Ismaili, Pilar Lóperz-Alvarado, 
Maria Laura Bolognesi, Krzysztof Jóźviak, J. Carlos Menéndez, José Marco-Contelles, Manuela 
Bartolini. Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed 
ligands for Alzheimer's disease. European Journal of Medicinal Chemistry (2018), 155: 839-846. 
Doi 10.1016/j.ejmech.2018.06.044. [1]. 
 
Abstract  
Notwithstanding combination of cholinesterase (ChE) inhibition and calcium channel blockade 
within a multitarget therapeutic approach is envisaged as potentially beneficial to confront 
Alzheimer’s disease (AD), this strategy has been scarcely investigated. To explore this promising 
line, a series of 5-amino-4-aryl-3,4,6,7,8,9-hexahydropyrimido[4,5-b]quinoline-2(1H)-thiones 
(tacripyrimidines) were designed by juxtaposition of tacrine, a ChE inhibitor (ChEI), and 3,4-
dihydropyrimidin-2(1H)-thiones, as efficient calcium channel blockers (CCBs). In agreement with 
their design, all tacripyrimidines, except the unsubstituted parent compound and its p-methoxy-
derivative, acted as moderate to potent CCBs with activities generally similar or higher than the 
reference CCB drug nimodipine and were modest-to-good ChE inhibitors. Most interestingly, the 
3’-methoxy-derivative emerged as the first well balanced ChEI/CCB inhibitor, acting as low 
micromolar hChE inhibitor (3.05 µM and 3.19 µM on hAChE and hBuChE, respectively) and 
moderate CCB (30.4 % at 1 µM) with no significant hepatotoxicity toward HepG2 cells and good 
predicted oral absorption and blood brain barrier permeability. 
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9.1 Introduction  
Alzheimer's disease (AD) is a devastating, age-related neurodegenerative disorder [2] which has 
become a major and rising public health concern because of the high costs related to the 
management of the increasing number of AD patients, who have no effective treatment for cure. 
Clinical failure has been partially ascribed to the complexity of AD pathology, which features a 
multifaceted interplay of several factors, whose exact role is not yet fully understood [3]. This 
observation has laid down the basis for the current interest in the so-called Multitarget Directed 
Ligands (MTDLs), a heterogeneous class of compounds that are designed to simultaneously address 
more than one pathological event [4,5]. Based on this strategy, a number of MTDLs have been 
developed by modification of commercial drugs and active scaffolds [4-12]. Among those, tacrine-
based multitarget derivatives have been shown to be able to hit several key targets involved in AD 
and exert multiple beneficial activities both in vitro and in vivo. Indeed, the high ligand efficiency 
has made tacrine scaffold an ideal starting point for designing and achieving highly active MTDLs 
[9-11].  
Based on these considerations, some years ago José Marco-Contelles et al.  designed a class of 
MTDs called tacripyrines (I Fig. 32) by juxtaposition of tacrine and nimodipine, as reference 
molecules endowed with anticholinesterase and calcium antagonism profile, respectively, for the 
treatment of AD [13,14]. The most interesting tacripyrine, i.e., (±)-p-methoxytacripyrine (Fig. 32), 
showed high selectivity toward AChE, moderate inhibition of calcium intake after potassium 
stimulation in SHSY5 cells, weak inhibition of the pro-aggregating action of hAChE on A peptide, 
and moderate inhibition of A self-aggregation (34.9 %) [14,15]. Interest on calcium channel 
blockers (CCBs) is based on the fact that calcium levels regulate neuronal plasticity underlying 
learning and memory and neuronal survival. Dysregulation of the intracellular calcium homeostasis 
in AD is thought to play a role in neuron degeneration and death [16,17]. Consequently, blocking 
the entrance of Ca
2+
 through L-type voltage-gated calcium channels is considered a valuable 
strategy to prevent neuronal damage in AD [18,19]. Furthermore, CCBs have been shown to 
improve cerebrovascular perfusion and attenuate amyloid-β-induced neuronal decline and 
neurotoxicity, improve cell survival in the presence of Aβ in vitro, and exert neuroprotective effects 
in animal models [20-22]. These beneficial effects have been confirmed in clinical trials for the 
CCBs nimodipine and nilvadipine, which have reached phase III (ClinicalTrials.gov identifier 
NCT02017340). 
With these premises in mind and in the attempt of balancing the anticholinesterase and Ca-
antagonism activities by increasing CCB activity, MTDs tacripyrimidines (II, Figure 32) were 
designed by Contelles and coworkers by focusing again on tacrine scaffold as a template for 
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cholinesterase (ChE) inhibition and on the well-known capacity of 3,4-dihydropyrimidin-2(1H)-
thiones (III, Figure 32) to act as efficient calcium channel blockers [23,24]. Furthermore, very 
promisingly, dihydropyirimidine-thiones were recently shown to exert neuroprotective activity 
toward A-induced toxicity in a yeast model for proteinopathies, likely by attenuating the metal-
mediated toxicity of A [25].  
In this context, the newly synthesized tacripyrimidines were investigated by us in terms of 
inhibitory activity toward both human ChE enzymes. Moreover, for the most interesting derivatives 




Figure 32| Structure of tacripyrines (I), ()-p-methoxytacripyrine, and retrosynthetic analysis of the synthesis of 
tacripyrimidines (II).  
  
 133 
9.2 Experimental section 
9.2.1 Materials  
Human recombinant acetylcholinesterase (hAChE) (EC 3.1.1.7) lyophilized powder, 
butyrylcholinesterase (E.C. 3.1.1.8) from human serum (hBuChE), S-acetylthiocholine iodide 
(ACTh), butyrylthiocholine iodide (BTCh), 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB; Ellman’s 
reagent), tacrine hydrochloride, dipotassium hydrogenphosphate trihydrate, potassium 
dihydrogenphosphate and Triton X-100 were purchased from Sigma-Aldrich (Milan, Italy). 
Deionized water was obtained by Milli-Q system (Millipore, Milford, MA, USA). All solutions 
were filtered with 0.22 µm membrane filters (Millipore, Milford, MA, USA) before use. 
All compounds (Fig. 33) were synthetized by Contelles and coworkers and were characterized by 
1
H NMR and 
13
C NMR [1].  
 
 
Figure 33| Synthesis of tacripyrimidines 4a-l. For synthesis procedure, 1H NMR and 13C NMR please refer to original 
article [1]. 
 
9.2.2 Inhibition of human AChE and BuChE activities 
The capacity of tested compounds to inhibit hAChE and hBuChE activity was assessed using the 
Ellman’s method [26]. Initial rate assays were performed at 37 °C with a Jasco V-530 double beam 
Spectrophotometer: the rate of increase in the absorbance at 412 nm was followed for 3 min. 
hAChE stock solution was prepared by dissolving human recombinant AChE lyophilized powder in 
0.1 M phosphate buffer (pH = 8.0) containing Triton X-100 0.1 %. Stock solution of BuChE from 
human serum was prepared by dissolving the lyophilized powder in an aqueous solution of gelatine 
0.1 %. Stock solutions of inhibitors (1 or 2 mM) were prepared in methanol. Five increasing 
concentrations of the inhibitor were used, able to give an inhibition of the enzymatic activity in the 
range of 20-80 %. The assay solution consisted of a 0.1 M phosphate buffer (pH = 8.0), with the 
addition of 340 mM DTNB, 0.02 unit/mL of hAChE or hBChE and 550 µM of substrate (ATCh or 
BTCh, respectively). 50 µL aliquots of increasing concentration of the tested compound were added 
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to the assay solution and preincubated for 20 min at 37°C with the enzyme, followed by the 
addition of substrate. Assays were carried out with a blank containing all components except 
enzymes in order to account for the non-enzymatic reaction. The reaction rates were compared and 
the percent inhibition due to the presence of tested inhibitor at increasing concentration was 
calculated. Each concentration was analysed in triplicate, and IC50 values were determined 
graphically from log concentration–inhibition curves (GraphPad Prism 4.03 software, GraphPad 
Software Inc.). Each IC50 value was determined from at least two independent experiments. 
 
9.2.3 Kinetic studies for inhibition of human AChE activity by compounds 4k and 4e 
The mode of inhibition of compounds 4k and 4e and the corresponded was assessed by building 
Lineweaver-Burk double reciprocal plots at relatively low concentration of substrate (0.11-0.55 
mM) and using the same experimental conditions used to assess hAChE activity see Section 9.2.2). 
The plots were assessed by a weighted least square analysis that assumed the variance of v to be a 
constant percentage of v for the entire data set. Data analysis was performed with GraphPad Prism 
4.03 software (GraphPad Software Inc.). To confirm the mode of inhibition, Dixon plots were 
obtained by plotting 1/v versus inhibitor concentration [27]. 
K’i (dissociation constant for the enzyme-substrate-inhibitor complex) value was determined by 
plotting the apparent 1/vmax, app versus inhibitor concentration [27,28].  
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9.3 Results and discussion 
9.3.1 Inhibition of cholinesterases 
With compounds 4a-l in hand, we first addressed their hChE inhibition capacity, following 
Ellman’s protocol [28]. As shown in Table 10, most of tacripyrimidines 4a-l are hAChEI with IC50 
values ranging from 3.05 M (4e) to 31.0 M (4i), with the exception of tacripyrimidine 4k 
(hAChE: IC50= 0.0373 M), the most selective and potent hAChEI within the series. On the basis 
of the inhibitory potencies, some structure–activity relationship (SAR) could be drawn. 
Tacripyrimidines bearing strong electron-donor (4’-NMe2 for 4h; 2’-OMe for 4f) or electron-
withdrawing (4’-NO2 for 4l) substituents, and moderate electron-donor (4’-Me for 4b) or electron-
withdrawing (4’-F for 4i) substituents, regardless of their location at the aromatic ring, were the 
weakest hAChEIs. Among tacripyrimidines bearing a methoxy group, the most potent was 
compound 4e, followed by 4d and 4f, position C3’ being clearly preferred to C2’ and C4’. This 
observation is also confirmed by the comparison of compound 4b (4’-Me) and 4c (3’-Me). Not 
surprisingly, the three most potent hAChEIs were the 5-amino-4-(3-bromophenyl)-3,4,6,7,8,9-
hexahydropyrimido[4,5-b]quinoline-2(1H)-thione (4k), bearing a moderate electron-withdrawing 
substituent (Br) at C’3, followed by compound 4e (3’-OMe), which was 81.8-fold less potent, and 
tacripyrimidine 4j (C’4-Cl). Interestingly, compound 4k was a 9.4-fold more potent inhibitor than 
tacrine.  
By comparing the inhibition rate of the compounds belonging to the tacripyrimidine series to 
reference compounds, it can be concluded that 4k, the most potent AChEI in the tacripyrimidine 
series, is 10-fold more potent than tacrine in inhibiting hAChE, and it is also about 35 folds more 
potent than the best tacripyrine (p-methoxytacripyrine - p-MT, Table 10).  
Concerning inhibition of hBuChE, tacripyrimidines 4a-l showed significant selectivity for hBuChE, 
with the exception of compounds 4g, 4h, and 4k (which showed a reverse trend), with IC50 values 
spanning more than four orders of magnitude, i.e., varying from 0.372 M (4j, the most potent 
hBuChEI within the series) to 154 M (4h). Compound 4e (3’-OMe) exerted a balanced inhibition 
of both ChEs, in the micromolar range. Regarding the SAR for BuChE inhibition, almost similar 
trends were observed. Indeed, the most potent electron-donor substituents (4’NMe2 in 4h; 3’,4’-
OCH2O- in 4g, and 2’-OMe in 4f) afforded the poorest hBuChEIs, C’3 being a preferred position 
for a better hBuChE inhibition (compare compounds 4b and 4c for the Me group), although 
location at C’4 is also favored (compare compounds 4d-e for the OMe motif). Compared with 




Table 10| IC50 (M) for the inhibition of hAChE and hBuChE by tacripyrimidines 4a-l and tacrine. 
Calcium intake blockade induced by tacripyrimidines 4a-l and nimodipine was tested by coworkers 







IC50 (M) ± SEM 
hBuChE
 a 
IC50 (M) ± SEM 
calcium intake blockade 
(%) ± SEM
b 
4a H 10.8 ± 0.9 5.68 ± 0.38 10.58 ± 1.78
n/s 
4b 4’-Me 23.8 ± 1.4 3.47 ± 0.15 14.69 ± 3.77 
4c 3’-Me 10.1 ± 1.1 2.65 ± 0.25 40.01 ± 4.45 
4d 4’-OMe 7.64 ± 0.43 1.75 ± 0.14 23.58 ± 2.31 
4e 3’-OMe 3.05 ± 0.28 3.19 ± 0.11 30.40 ± 2.61 
4f 2’-OMe 31.2 ± 1.5 11.7 ± 0.6 32.18 ± 2.92 
4g 3’,4’-OCH2O- 8.18 ± 0.97 37.5 ± 2.4 36.76 ± 3.57 
4h 4’-NMe2 24.1 ± 3.1 154 ± 23 59.01 ± 1.69 
4i 4’-F 31.0 ± 1.2 10.0 ± 0.7 23.31 ± 2.96 
4j 4’-Cl 5.28 ± 0.19 0.372 ± 0.021 38.00 ± 3.36 
4k 3’-Br 0.0373 ± 0.0082 1.27 ± 0.10 42.23 ± 3.85 
4l 3’-NO2 29.8 ± 1.7 2.68 ± 0.15 66.79 ± 2.41 
p-MT
b
 - 0.105 ± 0.015 >100 32.75 ± 2.50 
Tacrine - 0.374 ± 0.053 0.0442 ± 0.0017 nd 
Nimodipine - nd nd 49.62 ± 1.24 
a Results are expressed as the mean of at least two experiments in which each datum was obtained in triplicate; b p-MT 
stands for p-methoxytacripyrine; data from [14]. SEM stands for standard error of the mean; nd stands for not 
determined. 
 
It is interesting to note that tacripyrimidines showed a distinctly different behaviour concerning 
BuChE inhibition in comparison with the previously developed tacripyridines, which were selective 
AChE inhibitors with no significant activity toward human BuChE [14]. Increasing evidence has 
shown that inhibition of CNS BuChE activity may be beneficial for the treatment of moderate to 
severe forms of AD as highlighted by the increasing interest on BuChE as a therapeutic target in 
AD drug discovery [29] and by the design of BuChE-selective inhibitors [30,31]. In fact, 
progressive elucidation of the role of BuChE in AD brain has highlighted that, with the progression 
of the disease, the role played by AChE in the hydrolysis of the neurotransmitter acetylcholine 
(ACh) decreases. Conversely, BuChE levels and activity in certain regions of AD brain have been 
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shown to increase [29]. Therefore, selective BuChE inhibitors could be more effective in patients 
with moderate to severe forms of this disease, although this tentative conclusion has not yet been 
clinically verified. Indeed, to date, no large-scale clinical trials of selective BuChE inhibitors have 
been performed in patients with AD. Studies on mild to moderate AD patients, that is the 
population of patients enrolled in most clinical trials on cholinesterase inhibitors, is unlikely to be 
able to highlight the benefits of selective BuChE inhibition. In the light of these observations, the p-
chloro tacripyrimidine 4j, which was a 14.2-fold more potent hBuChE inhibitor, is worth further 
investigation. As a perfectly balanced micromolar ChE inhibitor, 3’-methoxy-tacripyrimidine 4e is 
also worth to be considered. 
 
9.3.2 Binding mode evaluation for the most promising AChE inhibitors by in solution assay 
To achieve a deeper understanding of the mode of interaction of our derivatives, tacripyrimidines 4e 
and 4k, the two most potent hAChE inhibitors, were further investigated. Lineweaver-Burk plots 
for both compounds showed increasing slopes (lower vmax) but unaltered intercept (unvaried Km 
value) with increasing inhibitor concentration, indicating a non-competitive type of inhibition (Fig. 
34). This type of inhibition was further confirmed by data reprocessing according to the Dixon 
method (1/v vs [I]). The K'i constant, i.e., the dissociation constant of the enzyme-substrate-inhibitor 
complex, has been calculated and found to be 3.88 ± 0.30 M for 4e and 0.147 ± 0.011 M for 4k, 
respectively. Importantly, the interaction of these compounds with the enzyme’s PAS could be 






Figure 34| Kinetic study on the mechanism of hAChE inhibition by 4e (A) and 4k (B). Overlaid Lineweaver–Burk 
reciprocal plots of AChE initial velocity (v) at increasing substrate concentration in the absence and in the presence of 
inhibitor.  
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Based on the IC50 values and selectivity profile, binding of selected tacripyrimidines 4k and 4j, the 
most potent and selective AChEI and BuChEI, respectively, was investigated by an in silico 
approach (Prof. Iriepa Universidad de Alcalá, Spain) on hAChE and hBuChE. The same analysis 
was also carried out for tacripyrimidine 4e, the derivative showing no selectivity.  
Concerning 4k, in agreement with the experimentally confirmed non-competitive mechanism of 
action of (±)-4k, molecular modeling studies indicated that both (R)-4k and (S)-4k interact with 
residues at the PAS and not with those at CAS and highlighted the key interactions involved in the 
binding (see original article for details). On the other hand, concerning inhibition of hBuChE by 4k, 
the best-ranked docking solutions revealed that (i) BuChE can effectively accommodate both 
enantiomers inside the active site gorge and (ii) both enantiomers have similar binding modes. 
In general, the sets of interactions highlighted by docking studies on both ChEs (see full article for a 
detailed discussion) pointed out that the primary amino group and the halogen atoms are the 
features which mostly contribute to the inhibitory activities of compounds 4j and 4k toward hAChE 
and hBuChE. The position of the halogen atom also contributes to compound selectivity toward a 
specific ChE by establishing a network of interactions. 
Furthermore, the effectiveness of the MTDLs rational design was verified by investigating the Ca2+ 
influx induced by K
+
-depolarization in SH-SY5Y neuroblastoma cells, previously loaded with the 
fluorescent dye Fluo-4AM. The study was carried out by the research group of Prof. Jozwiak 
(Medical University of Lublin, Poland) (Table 10).  
In details, Fluo-4-loaded cells were incubated in the presence of tacripyrimidines 4a-l (1 μM) for 10 





 of 90 mM and 5 mM, respectively. Fluorescence emission intensity before stimulation and 
after stimulation was recorded at 535 nm (exc = 485 nm). DMSO (0.01%) was used as a vehicle 






All tacripyrimidines, except the unsubstituted derivative 4a, significantly inhibited Ca
2+
 influx 
(Table 10) although to different extents. Interestingly, tacripyrimidines 4h (bearing a 
dimethylamino substituent at position 4’) and 4l (bearing a nitro-group at position 3’) were more 
potent CCBs than the reference drug nimodipine (59.01% vs 49.62% and 66.79% vs 49.62%, 
respectively). Furthermore, 4c and 4k showed a very good blockade activity (>40% inhibition) 
which was not significantly different (n.s., P > 0.05) from that of nimodipine. Finally, from a 
statistical point of view, the encountered slightly lower CCB activity of derivatives 4g and 4e was 
scarcely significantly different to that of nimodipine (*P > 0.05). 
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The calcium channel blockade activity of tacripyrimidines seemed unrelated to the electronic nature 
of the substituents at the aromatic ring. Indeed, the two most active compounds within this series, 
i.e., 4h and 4l, bore an electron-donor (4’-NMe2) and an electron-withdrawing (3’-NO2) group, 
respectively. If a homogeneous set of substitution is considered, as in the case of methoxy- or 
methyl-tacripyrimidines, the 4’-position seems the least favorable one (compare 4b with 4c and 4d 
with 4e and 4f). 
For the sake of completeness, it is important to underline that further studies were carried out to 
assess physico-chemical properties, safety towards hepatoma cells and activity towards amyloid-
beta peptide. For full results and their extensive discussions, please refer to the original article [1].  
Briefly, the three most interesting tacripyrimidines, namely derivatives 4e, 4j and 4k, were 
investigated for their antiaggregating activity against Aβ42 self-aggregation by Prof. Bartolini. The 
tested tacripyrimidines exhibited poor inhibitory potency, with a % inhibition of about 10%. 
Furthermore, because of the hepatotoxicity displayed by tacrine in human body, all tacrine-based 
hybrids were assayed on human hepatoma cells (HepG2) to assess their safety. This study was 
performed by Dr. Giovannini (S.Orsola-Malpighi Hospital, CRBA, Bologna, Italy) using tacrine as 
positive control. Compounds were assayed in the concentration range 10-300 µM.  Cell viability at 
24 h was determined by quantifying ATP as an indicator of metabolically active cells, using a 
luminescence-based assay (CellTiter-Glo
®
 Assay, Promega). Among tacripyrimidines, only 
derivatives 4b (4’-Me derivative) and 4j (4’-Cl) showed higher hepatic cell toxicity than tacrine, 
while most tacripyrimidines were found to be similarly or slightly less toxic than tacrine. Quite 
promisingly, 4e emerged as the safest tacripyrimidine, with no toxic effect on HepG2 cells even at 
the highest tested concentration. Although to a lower extent, 4l also turned out to be safer than 
tacrine with a reduction of only 17% of the cell viability at the highest dose (300 µM). 
Finally, in-silico calculation of ADME parameters, carried out by Prof. Iriepa and coworkers, 
allowed assessing the ability of these compounds to be absorbed after oral administration, to cross 




The development of new drug candidates for an effective treatment of AD is a challenging task for 
medicinal chemists, and also a research area with a potentially tremendous impact in society. In this 
scenario, the contribution of the academic research to the definition of an effective therapeutic 
intervention is destined to increase as a consequence of the recent cut of AD focused research 
programs by some pharmaceutical companies. Having this in mind, new 5-amino-4-aryl-3,4,6,7,8,9-
hexahydropyrimido[4,5-b]quinoline-2(1H)-thione MTDLs able to modulate both cholinesterase 
activity and calcium influx mediated by voltage-dependent calcium channels have been studied. 
Indeed, in vitro inhibition studies performed by us, combined with in silico studies, showed that 
activity toward the two selected targets is modulated by the substituent attached to the aromatic ring 
at position C4. Derivatives bearing halogens (Br, Cl) at C3’ and/or C4’ position showed the highest 
inhibitory potencies toward hChEs. Moreover, combination of CCB studies performed by coauthors 
showed that the introduction of a dimethylamino group at position 4’ or a nitro group at position 3’ 
afforded the best calcium channel blockers, with potencies higher than that of the reference CCB 
drug nimodipine.  
Considering the overall biological profile of tacripyrimidines, including predicted ADME 
parameters and hepatotoxicity, tacripyrimidine 4e emerged as the first well balanced inhibitor of 
ChEs and calcium channel, endowed with no significant hepatotoxicity toward HepG2 cells and 
excellent predicted oral absorption and BBB permeability [1]. 
Not less importantly, in the light of the role of BuChE as prevalent ACh degradating enzyme in 
moderate-to-advanced forms of AD and considering the potential role of BuChE in the etiology and 
progression of AD, the 3’-nitro-tacripyrimidine 4l, which acts as moderately selective micromolar 
hBuChE inhibitor (AChE/BuChE = 10, IC50(BuChE) = 2.68 µM) and potent CCB with a significantly 
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Conclusions and future perspectives 
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Studying molecular biorecognition phenomena is pivotal to rationally interpret the complex 
network of communications which regulates physiological and pathological events. To be effective, 
this investigation requires advanced methodologies and analytical strategies to profile the binding 
partners and detail the structural features involved in such interaction. Several analytical techniques 
have been developed and applied over the years to clarify different aspects of the biorecognition 
processes and, depending on the analytical issue to be addressed, the most suitable (and available) 
strategy has been adopted. In this context, combination of different analytical techniques including 
circular dichroism spectroscopy (CD), surface plasmon resonance (SPR) and high-performance 
liquid chromatography coupled with mass spectrometry (HPLC-ESI-MSMS), among others, can 
facilitate the understanding of complex systems and multifaced biorecognition phenomena. Based 
on these considerations such approach has been pursued to investigate two targets of 
pharmaceutical interest, namely human serum albumin (HSA) and human cholinesterases (ChEs).  
In particular, interest on HSA structural modifications and their involvement in affecting HSA 
binding properties arose from the importance of altered forms of HSA as circulating biomarkers as 
well as prognostic factors and possible mediator of pathological events such as activation of the 
human receptor for advanced glycation end products (RAGE) upon advanced glycation in 
hyperglycemic conditions.  
Due to the strict connection between HSA binding properties and protein integrity, the assessment 
of HSA binding capacity is of relevance in clinical research as well as in the early stages of drug 
discovery. In the first work proposed, CD spectroscopy proved to be a trustworthy technique when 
the drug–HSA interactions are investigated, especially when possible competitors need to be 
considered. The proposed method enabled to clarify the role of N-acetyltryptophan and sodium 
octanoate in the impairment of HSA binding capacity when they are added as stabilizers in 
pharmaceutical formulations containing HSA (i-HSA). In particular, site-II ICD markers showed to 
be efficient tools in the evaluation of the effect of stabilizers on i-HSA binding properties and the 
CD-based assay enabled monitoring effective stabilizers clearance and recovery of binding 
properties within the development of more efficient removal strategies. 
Affinity chromatography, MS and SPR, instead, resulted highly informative to investigate 
biorecognition phenomena when used in combination. In particular, this multimethodological 
strategy was employed to obtain further insights into the interaction of glycated HSA (HSAgly) and 
the extracellular region (VC1) of RAGE. This modified form of circulating HSA, formed at higher 
amount in pathological conditions such as diabetes, may trigger inflammation and sustain chronic 
complications through RAGE activation. For this reason, the characterization of such interaction 
represents an emerging aspect to be elucidated. The herein proposed strategy enabled the 
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quantification of HSAgly-VC1 complex affinity and allowed to draw some preliminary hypotheses 
on the HSA region involved in the binding. Indeed, the majority of HSA peptides, identified by 
combining affinity chromatography and MS, revealed a possible involvement of subdomain IA (63 
% of peptides being retained onto the VC1 affinity column), as well as residue K525 as key 
glycated residue in the interaction with the receptor. In analytical terms, the outcomes of this study 
showed that combination of all these techniques may be a useful strategy to shed light on complex 
interacting ligands. 
In drug discovery, targeting ChEs has constituted and still constitutes an important strategy for 
Alzheimer’s disease (AD) treatment, especially in the light of new strategies based on multi-target 
compounds. In this context, classical in solution assays can be paralleled to new highly informative 
approaches, providing important elements for aiding the selection of favorite chemical scaffolds. 
Herein, in solution assays were performed for the evaluation of biological activity and the binding 
mode of new hybrid inhibitors, i.e. donepezil and tacrine hybrids, designed on the basis of the so-
called multi-target-directed ligand (MTDL) strategy. Data achieved enabled to elucidate some 
structure-activity relationships for ChEs inhibition and, in combination with in vitro and in silico 
studies carried out by other groups involved in the projects, allowed to identify some promising 
new MTDLs which could be further developed. In particular, most interesting results were achieved 
with the so-called tacripyrimidine derivatives which combine anticholinesterase activity with CCB 
properties. Furthermore, since a better prioritization of new chemical entities may reduce attrition 
rate in the drug discovery process, a human acetylcholinesterase (hAChE)-based SPR platform was 
developed. The SPR-based assay was employed to define kinetic rates constants and 
thermodynamic parameters for the inhibitors–hAChE binding events. Indeed, the definition of 
residence time and kinetic parameters by SPR technology besides the assessment of potency and 
inhibition profile might result useful powerful strategy in the early drug discovery phase. 
As conclusive remark, all analytical strategies summarized in this dissertation share the common 
purpose to elucidate biorecognition events and/or uncover alterations of such mechanisms which 
may result in pathological events. The final goal is to provide pivotal information which can help 



































Non sei partito per conoscerti meglio,  
o conoscere meglio i tuoi amici.  
Volevi disconoscerti, se mai. Dimenticare il tuo nome  
e restare nudo con la fatica e la gioia. 
Vicino a qualcuno di cui potevi fidarti 
 e alle cose essenziali che conoscevi da sempre. 















Alla Prof.ssa Bartolini e al Prof. Bertucci 
Perché la loro supervisione, il loro supporto e i consigli mai mancati mi hanno permesso di 
imparare e di crescere ‘‘puntando sempre un po’ più in là’’.  
A Edo, Thomas, Daniele e Marina 
Perché l’aver trovato amici con cui lavorare e condividere questo percorso ha colorato e reso piene 
di bei ricordi persino le più lunghe giornate in laboratorio. 
A Samuele 
Perché qualunque sia il futuro, è stato la mia costante e la mia squadra in tutte le fasi che mi hanno 
portato fino a qui.    
 
